


Lehne's Pharmacology for Nursing Care 12th Edition PDF

Visit the link below to download the full version of the ebook

[DOWNLOAD NOW](#)



Scan to Download
or Type the Link

ebook.ac/lehne12e

TWELFTH EDITION

JACQUELINE ROSENJACK BURCHUM
LAURA D. ROSENTHAL

LEHNE'S PHARMACOLOGY

for Nursing Care



Evolve®


Student Resources on Evolve
Access Code Inside

Evolve®

YOU'VE JUST PURCHASED MORE THAN A TEXTBOOK!

Enhance your learning with Evolve Student Resources.

These online study tools and exercises can help deepen your understanding of textbook content so you can be more prepared for class, perform better on exams, and succeed in your course.



Activate the complete learning experience that comes with each NEW textbook purchase by registering with your scratch-off access code at

<http://evolve.elsevier.com/Lehne/>

If your school uses its own Learning Management System, your resources may be delivered on that platform. Consult with your instructor.

If you rented or purchased a used book and the scratch-off code at right has already been revealed, the code may have been used and cannot be re-used for registration. To purchase a new code to access these valuable study resources, simply follow the link above.

Place
Sticker
Here

REGISTER TODAY!



You can now purchase Elsevier products on Evolve!
Go to evolve.elsevier.com/shop to search and browse for products.

A tailored education experience — *Sherpath* book-organized collections



Sherpath book-organized collections offer:



Objective-based, digital lessons, mapped chapter-by-chapter to the textbook, that make it easy to find applicable digital assignment content.



Adaptive quizzing with personalized questions that correlate directly to textbook content.



Teaching materials that align to the text and are organized by chapter for quick and easy access to invaluable class activities and resources.



Elsevier ebooks that provide convenient access to textbook content, even offline.


Sherpath is the digital teaching and learning technology designed specifically for healthcare education.

VISIT
myevolve.us/sherpath
today to learn more!



Set a course for success with individualized quizzing

Elsevier Adaptive Quizzing (EAQ) offers a bank of high-quality practice questions that allows students to advance at their own pace — based on their performance — through multiple mastery levels for each chapter, topic, or concept. EAQ integrates seamlessly into the curriculum to help students of all skill levels focus their study time and effectively prepare for class, course exams, and summative exams.



- **Elsevier’s trusted, market-leading content** serves as the foundation for all questions, which are written, reviewed, and leveled by experienced educators, item writers, and authors.
- **Detailed rationales for each question and essential test-taking tips and strategies** help students learn how to successfully dissect and tackle different question types and improve test-taking skills for both course exams and summative exams.
- **A robust performance dashboard** highlights usage and performance summaries and areas of strength and weakness tied to topics.



Find out how EAQ can help improve learning and program outcomes!

VISIT
myevolve.us/EAQ

LEHNE'S
PHARMACOLOGY
for Nursing Care

TWELFTH EDITION

LEHNE'S PHARMACOLOGY


for Nursing Care

**JACQUELINE ROSENJACK BURCHUM,
DNSc, FNP-BC, CNE**

Associate Professor
College of Nursing
Department of Advanced Practice and Doctoral Studies
University of Tennessee Health Science Center
Memphis, Tennessee

**LAURA D. ROSENTHAL,
DNP, RN, ACNP-BC, FAANP**

Associate Professor
Assistant Dean for DNP Programs
College of Nursing
University of Colorado, Anschutz Medical Campus
Aurora, Colorado



Elsevier
3251 Riverport Lane
St. Louis, Missouri 63043

LEHNE'S PHARMACOLOGY FOR NURSING CARE, TWELFTH EDITION
Copyright © 2025 by Elsevier, Inc. All rights reserved.

ISBN: 978-0-443-10710-8

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notice

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by Elsevier, authors, editors or contributors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.


Portions of these materials are taken from The Essentials: Core Competencies for Nursing Education ("The Essentials"), which is owned by the American Association of Colleges of Nursing ("AACN"). A full copy of The Essentials and the terms and conditions for downloading can be found at <https://www.aacnnursing.org/Essentials/Download-Order>. Except as otherwise provided in the AACN downloading terms and conditions, The Essentials may not be distributed in whole or in part to any third parties without express written permission from AACN. Any licensing of The Essentials by AACN does not constitute or imply any endorsement of any company and/or any of its products, services or written work product. AACN is not responsible for any errors or omissions in the translation or reproduction of The Essentials by any third party.

Previous editions copyrighted 2022, 2019, 2016, 2013, 2010, 2007, 2004, 2001, 1998, 1994, and 1990.

Executive Content Strategist: Lee Henderson
Senior Content Development Manager: Lisa P. Newton
Publishing Services Manager: Julie Eddy
Senior Project Manager: Rachel E. McMullen
Design Direction: Brian Salisbury

Printed in Canada

Last digit is the print number: 9 8 7 6 5 4 3 2 1



To Pat and Al Rosenthal—You continue to be an inspiring couple.

LDR

To my son, Jade, my daughter-in-law, Violetta, and my husband, Tony, always. I believe I must be the most fortunate person in the world just to have you in my life.

JRB

About the Authors



Jacqueline Rosenjack Burchum, DNSc, FNP-BC, CNE, has been a registered nurse since 1981 and a family nurse practitioner since 1996. She completed her Doctor of Nursing Science degree in 2002.

Dr. Burchum currently serves as an associate professor for the University of Tennessee Health Science Center (UTHSC) College of Nursing. She is credentialed as a certi-

fied nurse educator by the National League for Nursing. She is a three-time recipient of the UTHSC Student Government Association's Excellence in Teaching Award and a recipient of the UT Alumni Association's Outstanding Teacher Award. Dr. Burchum was also the 2016 to 2017 Faculty Innovation Scholar for the UTHSC Teaching and Learning Center.

Dr. Burchum has a special interest in online teaching and program quality. To this end, she serves as an on-site evaluator for the Commission on Collegiate Nursing Education, a national agency that accredits nursing education programs. In addition, she is a peer reviewer for Quality Matters, a program that certifies the quality of online courses, and the *Journal of Nursing Education*.

In her spare time, she enjoys gathering with her large extended family, working on the family hobby farm, and cutting fabric into small pieces that she sews back together.



Laura D. Rosenthal, RN, DNP, ACNP-BC, FAANP, has been a registered nurse since graduating with her Bachelor of Science in Nursing degree from the University of Michigan in 2000. She completed her Master of Science in Nursing degree in 2006 at Case Western Reserve University in Cleveland, Ohio. She finished her nursing education at the University of Colorado, College of Nursing,

graduating with her Doctor of Nursing Practice degree in 2011. Her background includes practice in acute care and inpatient medicine. While working as a nurse practitioner at the University of Colorado Hospital, she assisted in developing one of the first fellowships for advanced practice clinicians in hospital medicine.

Dr. Rosenthal serves as an Assistant Dean for DNP Programs at the University of Colorado, College of Nursing, where she teaches within the undergraduate and graduate programs. She received the Dean's Award for Excellence in Teaching in 2013. She serves on the board of the Colorado Nurses Association. In her spare time, Dr. Rosenthal enjoys running, skiing, and fostering retired greyhounds for Colorado Greyhound Adoption.

Contributors and Reviewers

CONTRIBUTOR

Courtney Charles, BSP, BCGP

Lecturer
College of Pharmacy and Nutrition
University of Saskatchewan
Saskatoon, Saskatchewan, Canada
Appendix A

REVIEWERS

Kathryn Tierney, MSN, APRN, FNP-BC, FAANP

Medical Director
Middlesex Health Center for Gender Medicine and Wellness
Middlesex Health
Division of Endocrinology
Middletown, Connecticut

James Graves, PharmD

Clinical Pharmacist
University of Missouri Inpatient Pharmacy
Columbia, Missouri

Preface

Pharmacology pervades all phases of nursing practice and relates directly to patient care and education. Yet despite its importance, many students—and even some teachers—are often uncomfortable with the subject because traditional texts have stressed *memorizing* rather than *understanding*. In this text, the guiding principle is to establish a basic understanding of drugs, after which secondary details can be learned as needed.

This text has two major objectives: (1) to help you, the nursing student, establish a knowledge base in the basic science of drugs; and (2) to show you how that knowledge can be applied in clinical practice. The methods by which these goals are achieved are described in the following sections.

LAYING FOUNDATIONS IN BASIC PRINCIPLES

To understand drugs, you need a solid foundation in basic pharmacologic principles. To help you establish that foundation, this text has major chapters on the following topics: basic principles that apply to all drugs ([Chapters 4 through 9](#)), basic principles of drug therapy across the lifespan ([Chapters 11 through 13](#)), basic principles of neuropharmacology ([Chapter 14](#)), basic principles of antimicrobial therapy ([Chapter 88](#)), and basic principles of cancer chemotherapy ([Chapter 106](#)).

REVIEWING PHYSIOLOGY AND PATHOPHYSIOLOGY

To understand the actions of a drug, it is useful to understand the biologic systems influenced by the drug. Accordingly, for all major drug families, relevant physiology and pathophysiology are reviewed. In almost all cases, these reviews are presented at the beginning of each chapter rather than in a systems review at the beginning of a unit. This juxtaposition of pharmacology, physiology, and pathophysiology is designed to help you understand how these topics interrelate.

TEACHING THROUGH PROTOTYPES

Within each drug family, we can usually identify a prototype—a drug that embodies the characteristics shared by all members of the group. Because other family members are similar to the prototype, to know the prototype is to know the basic properties of all family members.

The benefits of teaching through prototypes can be appreciated with an example. Let's consider the nonsteroidal anti-inflammatory drugs (NSAIDs), a family that includes aspirin, ibuprofen (Motrin), naproxen (Aleve), celecoxib (Celebrex), and more than 20 other drugs. Traditionally, information on

these drugs is presented in a series of paragraphs describing each drug in turn. When attempting to study from such a list, you are likely to learn many drug names and little else; the important concept of similarity among family members is easily lost. In this text, the family prototype—*aspirin*—is discussed first and in depth. After this, the small ways in which individual NSAIDs differ from aspirin are pointed out. Not only is this approach more efficient than the traditional approach, but it is also more effective in that similarities among family members are emphasized.

USING CLINICAL REALITY TO PRIORITIZE CONTENT

This book contains two broad categories of information: pharmacology (the basic science about drugs) and therapeutics (the clinical use of drugs). To ensure that content is clinically relevant, we use evidence-based treatment guidelines as a basis for deciding what to stress and what to play down. Unfortunately, clinical practice is a moving target. Guidelines change when effective new drugs are introduced and when clinical trials reveal new benefits or new risks of older drugs, so we need to work hard to keep this book current. Despite our best efforts, the book and clinical reality may not always agree: Some treatments discussed here will be considered inappropriate before the 12th edition is published. Furthermore, in areas where controversy exists, the treatments discussed here may be considered inappropriate by some clinicians right now.

NURSING IMPLICATIONS: DEMONSTRATING THE APPLICATION OF PHARMACOLOGY IN NURSING PRACTICE

The principal reason for asking you to learn pharmacology is to enhance your ability to provide patient care and education. To show you how pharmacologic knowledge can be applied to nursing practice, nursing implications are integrated into the body of each chapter. That is, as specific drugs and drug families are discussed, the nursing implications inherent in the pharmacologic information are noted side by side with the basic science.

To facilitate access to nursing content, nursing implications are also summarized at the end of most chapters. These summaries serve to reinforce the information presented in the chapter body. These summaries have been omitted in chapters that are especially brief or that address drugs that are infrequently used. Even in these chapters, however, nursing implications are incorporated into the main chapter text.

In addition, “Safety Alert” features throughout draw attention to important safety concerns related to contraindications, adverse effects, pregnancy categories, and more.

WHAT'S NEW IN THE BOOK?

Lehne's Pharmacology for Nursing Care has been revised cover to cover to ensure that the latest and most accurate information is presented. One new chapter helps to focus on an identified gap in knowledge for health care providers—transgender care. Approximately 2.6 million people in the United States identify as transgender. Historical lack of access to competent and compassionate care providers remains a barrier to transgender people receiving quality, evidence-based care. As nursing focuses on care of all individuals, it is important to include this information.

In addition, **thoroughly updated drug content** reflects the latest US Food and Drug Administration drug approvals, withdrawals, and therapeutic uses with revisions to the corresponding nursing content.

Learning Supplements for Students

- Online Evolve Resources accompany this edition and include **Downloadable Key Points, Next-Generation NCLEX® (NGN) Examination–Style Case Studies, Review Questions, Unfolding Case Studies**, and more. These resources are available at <http://evolve.elsevier.com/Lehne>.
- The **Study Guide**, which is keyed to the book, includes—study questions; critical thinking, prioritization, and delegation questions; case studies, and new NGN-style questions.

Teaching Supplements for Instructors

- The Instructor Resources for the 12th edition are available online and include Next-Generation NCLEX® Examination–Style Questions, TEACH® for Nurses Lesson Plans, a Test Bank, a PowerPoint Collection, and an Image Collection.

WAYS TO USE THIS TEXTBOOK

Thanks to its focus on essentials, this text is especially well suited to serve as the primary text for a course dedicated

specifically to pharmacology. In addition, the focused approach makes it a valuable resource for pharmacologic instruction within an integrated curriculum and for self-directed learning by students, teachers, and practitioners.

How is this focus achieved? Four primary techniques are used: (1) teaching through prototypes, (2) using standard print for essential information and small print for secondary information, (3) limiting discussion of adverse effects and drug interactions to information that matters most, and (4) using evidence-based clinical guidelines to determine what content to stress. To reinforce the relationship between pharmacologic knowledge and nursing practice, nursing implications are integrated into each chapter. To provide rapid access to nursing content, nursing implications are summarized at the end of most chapters using a nursing process format, along with cognitive skills from the NCSBN Clinical Judgment Measurement Model. In addition, key points are listed at the end of each chapter. As in previous editions, the 12th edition emphasizes conceptual material—reducing rote memorization, promoting comprehension, and increasing reader friendliness.

Pharmacology can be an unpopular subject because of the vast and rapidly changing area of content. Often, nursing students believe that pharmacology is one of the most difficult classes to master. We hope that this book makes the subject of pharmacology easier and more enjoyable for you to understand by allowing you to focus on the most important umbrella concepts of pharmacology as they relate to nursing care and the safety of patients.

ACKNOWLEDGMENTS

We would like to acknowledge the support of our colleagues at Elsevier, including Executive Content Strategist Lee Henderson, Senior Content Development Manager Lisa P. Newton, and Senior Project Manager Rachel E. McMullen.

Finally, we would like to express our gratitude to Richard A. Lehne for his dedication to this book for eight editions. We are honored to be able to continue his work.

*Jacqueline Rosenjack Burchum
Laura D. Rosenthal*

Contents

UNIT I

INTRODUCTION

- 1 Orientation to Pharmacology 1
- 2 Application of Pharmacology in Nursing Practice 5
- 3 Drug Regulation, Development, Names, and Information 14

UNIT II

BASIC PRINCIPLES OF PHARMACOLOGY

- 4 Pharmacokinetics 25
- 5 Pharmacodynamics 45
- 6 Drug Interactions 56
- 7 Adverse Drug Reactions and Medication Errors 64
- 8 Individual Variation in Drug Responses 76
- 9 Genetic and Genomic Considerations 81
- 10 Introduction to Immunomodulators 87

UNIT III

DRUG THERAPY ACROSS THE LIFESPAN

- 11 Drug Therapy During Pregnancy and Breastfeeding 94
- 12 Drug Therapy in Pediatric Patients 102
- 13 Drug Therapy in Older Adults 107

UNIT IV

PERIPHERAL NERVOUS SYSTEM DRUGS

- 14 Basic Principles of Neuropharmacology 113
- 15 Physiology of the Peripheral Nervous System 119
- 16 Muscarinic Agonists 132
- 17 Muscarinic Antagonists 138
- 18 Cholinesterase Inhibitors and Their Use in Myasthenia Gravis 149
- 19 Drugs That Block Nicotinic Cholinergic Transmission 157
- 20 Adrenergic Agonists 167
- 21 Adrenergic Antagonists 181
- 22 Indirect-Acting Antiadrenergic Agents 198

UNIT V

CENTRAL NERVOUS SYSTEM DRUGS

- 23 Introduction to Central Nervous System Pharmacology 204
- 24 Drugs for Parkinson Disease 207
- 25 Drugs for Alzheimer Disease 226
- 26 Drugs for Multiple Sclerosis 237
- 27 Drugs for Seizure Disorders 254
- 28 Drugs for Muscle Spasm and Spasticity 283
- 29 Local Anesthetics 292
- 30 General Anesthetics 298
- 31 Opioid Analgesics, Opioid Antagonists, and Nonopioid Centrally Acting Analgesics 306

- 32 Pain Management in Patients With Cancer 327
- 33 Drugs for Headache 343
- 34 Antipsychotic Agents and Their Use in Schizophrenia 355
- 35 Antidepressants 372
- 36 Drugs for Bipolar Disorder 392
- 37 Sedative-Hypnotic Drugs 401
- 38 Management of Anxiety Disorders 416
- 39 Central Nervous System Stimulants and Attention-Deficit/Hyperactivity Disorder 423
- 40 Substance Use Disorders I: Basic Considerations 434
- 41 Substance Use Disorders II: Alcohol 441
- 42 Substance Use Disorders III: Nicotine 452
- 43 Substance Use Disorders IV: Major Drugs of Abuse Other Than Alcohol and Nicotine 459

UNIT VI

DRUGS THAT AFFECT FLUID AND ELECTROLYTE BALANCE

- 44 Diuretics 476
- 45 Agents Affecting the Volume and Ion Content of Body Fluids 488

UNIT VII

DRUGS THAT AFFECT THE HEART, BLOOD VESSELS, AND BLOOD

- 46 Review of Hemodynamics 493
- 47 Drugs Acting on the Renin-Angiotensin-Aldosterone System 500
- 48 Calcium Channel Blockers 516
- 49 Vasodilators 525
- 50 Drugs for Hypertension 531
- 51 Drugs for Heart Failure 550
- 52 Antidysrhythmic Drugs 568
- 53 Drugs That Help Normalize Cholesterol and Triglyceride Levels 587
- 54 Drugs for Angina Pectoris 609
- 55 Anticoagulant, Antiplatelet, and Thrombolytic Drugs 622
- 56 Management of ST-Elevation Myocardial Infarction 649
- 57 Drugs for Hemophilia 656
- 58 Drugs for Deficiency Anemias 665
- 59 Hematopoietic Agents 680

Unit VIII

DRUGS FOR ENDOCRINE DISORDERS

- 60 Drugs for Diabetes Mellitus 690
- 61 Drugs for Thyroid Disorders 727
- 62 Drugs Related to Hypothalamic and Pituitary Function 739
- 63 Drugs for Disorders of the Adrenal Cortex 748

UNIT IX**Reproductive Health**

- 64 Estrogens and Progestins: Basic Pharmacology and Noncontraceptive Applications 756
- 65 Birth Control 771
- 66 Drug Therapy for Infertility 786
- 67 Drugs That Affect Uterine Function 795
- 68 Androgens 807
- 69 Drugs for Erectile Dysfunction and Benign Prostatic Hyperplasia 816
- 70 Transgender Health 829

UNIT X**ANTI-INFLAMMATORY, ANTIALLERGIC, AND IMMUNOLOGIC DRUGS**

- 71 Review of the Immune System 842
- 72 Childhood Immunization 853
- 73 Immunosuppressants 871
- 74 Antihistamines 882
- 75 Cyclooxygenase Inhibitors: Nonsteroidal Antiinflammatory Drugs and Acetaminophen 890
- 76 Glucocorticoids in Nonendocrine Disorders 908

UNIT XI**DRUGS FOR BONE AND JOINT DISORDERS**

- 77 Drug Therapy for Rheumatoid Arthritis 919
- 78 Drug Therapy for Gout 936
- 79 Drugs Affecting Calcium Levels and Bone Mineralization 943

UNIT XII**RESPIRATORY TRACT DRUGS**

- 80 Drugs for Asthma and Chronic Obstructive Pulmonary Disease 968
- 81 Drugs for Allergic Rhinitis, Cough, and Colds 999

UNIT XIII**GASTROINTESTINAL DRUGS**

- 82 Drugs for Peptic Ulcer Disease 1007
- 83 Laxatives 1021
- 84 Other Gastrointestinal Drugs 1031

UNIT XIV**NUTRITION AND COMPLEMENTARY THERAPY**

- 85 Vitamins 1045
- 86 Drugs for Weight Loss 1058
- 87 Complementary and Alternative Therapy 1067

UNIT XV**THERAPY OF INFECTIOUS DISEASES**

- 88 Basic Principles of Antimicrobial Therapy 1084
- 89 Drugs That Weaken the Bacterial Cell Wall I: Penicillins 1099

- 90 Drugs That Weaken the Bacterial Cell Wall II: Other Drugs 1108
- 91 Bacteriostatic Inhibitors of Protein Synthesis: Tetracyclines, Macrolides, and Others 1119
- 92 Aminoglycosides: Bactericidal Inhibitors of Protein Synthesis 1129
- 93 Sulfonamide Antibiotics and Trimethoprim 1136
- 94 Drug Therapy for Urinary Tract Infections 1146
- 95 Antimycobacterial Agents: Drugs for Tuberculosis 1152
- 96 Miscellaneous Antibacterial Drugs: Fluoroquinolones, Metronidazole, Daptomycin, Rifampin, Rifaximin, and Fidaxomicin 1168
- 97 Antifungal Agents 1174
- 98 Antiviral Agents I: Drugs for Non-HIV Viral Infections 1186
- 99 Antiviral Agents II: Drugs for HIV Infection and Related Opportunistic Infections 1212
- 100 Drug Therapy for Sexually Transmitted Infections 1248
- 101 Antiseptics and Disinfectants 1260

UNIT XVI**CHEMOTHERAPY OF PARASITIC DISEASES**

- 102 Anthelmintics 1267
- 103 Antiprotozoal Drugs I: Antimalarial Agents 1274
- 104 Antiprotozoal Drugs II: Miscellaneous Agents 1283
- 105 Ectoparasiticides 1288

UNIT XVII**CANCER CHEMOTHERAPY**

- 106 Basic Principles of Cancer Treatment 1293
- 107 Anticancer Drugs I: Cytotoxic Agents 1307
- 108 Anticancer Drugs II: Hormonal Agents, Targeted Drugs, and Other Noncytotoxic Anticancer Drugs 1326

UNIT XVIII**MISCELLANEOUS DRUGS AND THERAPIES**

- 109 Drugs for Eye Conditions and Diseases 1348
- 110 Drugs for Skin Conditions 1362
- 111 Drugs for Ear Conditions 1388

UNIT XIX**TOXICOLOGY**

- 112 Management of Poisoning 1395
- 113 Potential Weapons of Biologic, Radiologic, and Chemical Terrorism 1400

APPENDIX A

Canadian Drug Information, 1410

APPENDIX B

Prototype Drugs and Their Major Uses, 1414

Orientation to Pharmacology

Four Basic Terms, 1

Drug, 1

Pharmacology, 1

Clinical Pharmacology, 2

Therapeutics, 2

Properties of an Ideal Drug, 2

The Big Three: Effectiveness, Safety, and Selectivity, 2

Additional Properties of an Ideal Drug, 2

No Drug Is Ideal, 3

The Therapeutic Objective, 3

Factors That Determine the Intensity of Drug Responses, 3

Administration, 3

Pharmacokinetics, 4

Pharmacodynamics, 4

Sources of Individual Variation, 4

Key Points, 4

By now, you've been hitting the science books for many years and have probably asked yourself, "What's the purpose of all these prerequisite science courses?" In the past, your question may have lacked a satisfying answer. Happily, now you have one: Those courses have provided an excellent background for your studies in pharmacology!

Pharmacology is a science that draws on information from multiple disciplines, such as anatomy, physiology, chemistry, microbiology, and psychology. Consequently, before you could study pharmacology, you had to become familiar with these other sciences. Now that you've established the requisite knowledge base, you're finally ready to learn about drugs.

FOUR BASIC TERMS

Before you begin, it is important to define four basic terms: *drug*, *pharmacology*, *clinical pharmacology*, and *therapeutics*. As we consider these terms, I will indicate the kinds of information that we will and will not discuss in this text.



(Copyright iStock Photo; Credit: FatCamera.)

Drug

A drug is defined as *any chemical that can affect living processes*. By this definition, virtually all chemicals can be considered drugs because, when exposure is sufficiently high, all chemicals will have some effect on life. Clearly, it is beyond the scope of this text to address all compounds that fit the definition of a drug. Accordingly, rather than discussing all drugs, we will focus primarily on drugs as medications that have therapeutic applications.

Pharmacology

Pharmacology can be defined as *the study of drugs and their interactions with living systems*. Under this definition, pharmacology encompasses the study of the physical and chemical properties of drugs, as well as their biochemical and physiologic effects. In addition, pharmacology includes knowledge of the history, sources, and uses of drugs and knowledge of drug absorption, distribution, metabolism, and excretion. Because pharmacology encompasses such a broad spectrum of information, it would be impossible to address the entire scope of pharmacology in this text. Consequently, we limit consideration to information that is *clinically relevant* (i.e., related to therapy).

Clinical Pharmacology

Clinical pharmacology is defined as the study of drugs in humans. This discipline includes the study of drugs in patients and in healthy volunteers (during new drug development). Because clinical pharmacology encompasses all aspects of the interaction between drugs and people and because our primary interest is the use of drugs to treat patients, clinical pharmacology includes some information that is outside the scope of this text. For our purposes, we will focus our study on how medications affect the patients who will be in our care.

Therapeutics

Therapeutics, also known as pharmacotherapeutics, is defined as the use of drugs to diagnose, prevent, or treat disease or to prevent pregnancy. Alternatively, therapeutics can be defined simply as the medical use of drugs.

In this text, therapeutics is our principal concern. Accordingly, much of our discussion focuses on the basic science that underlies the clinical use of drugs. This information is intended to help you understand how drugs produce their therapeutic and adverse (undesirable) effects; the reasons for giving a particular drug to a particular patient; and the rationale underlying the selection of dosage, route, and schedule of administration. This information will also help you understand the strategies used to promote beneficial drug effects and to minimize undesired effects. Armed with this knowledge, you will be well prepared to provide drug-related patient care and education. In addition, by making drugs less mysterious, this knowledge should make working with drugs more comfortable and perhaps even more satisfying.

PROPERTIES OF AN IDEAL DRUG

If we were developing a new drug, we would want it to be the best drug possible. To approach perfection, our drug should have certain properties, such as effectiveness and safety. In the discussion that follows, we consider these two characteristics as well as others that an ideal drug might have. However, please note that the ideal medication exists in theory only: In reality, *there is no such thing as a perfect drug*. The truth of this statement will become apparent as we consider the properties that an ideal drug should have.

The Big Three: Effectiveness, Safety, and Selectivity

The three most important characteristics that any drug can have are effectiveness, safety, and selectivity.

Effectiveness

An ideal drug is effective. An effective drug is one that elicits the responses for which it is given. *Effectiveness is the most important property a drug can have*. Regardless of its other virtues, if a drug is not effective—that is, if it doesn't do what it is intended to do—there is no justification for giving it. Current U.S. law requires that all new drugs be proved effective before being released for marketing.

Safety

An ideal drug is safe. A safe drug is defined as one that cannot produce harmful effects—even if administered in very

high doses and for a very long time. All drugs have the ability to cause injury, especially with high doses and prolonged use. The chances of producing harmful effects can be reduced by proper drug selection and proper dosing. Nevertheless, the risk of harmful effects can never be eliminated. The following examples illustrate this point:

- Certain anticancer drugs (e.g., cyclophosphamide, methotrexate), at usual therapeutic doses, always increase the risk for serious infection.
- Opioid analgesics (e.g., morphine, meperidine), at high therapeutic doses, can cause potentially fatal respiratory depression.
- Aspirin and related drugs, when taken long term in high therapeutic doses, can cause life-threatening gastric ulceration, perforation, and bleeding.

Clearly, drugs have both benefits and risks. This fact may explain why the Greeks used the word *pharmakon*, which can be translated as both *remedy* and *poison*.

Selectivity

An ideal drug is selective. A selective drug is defined as one that elicits *only* the response for which it is given. *There is no such thing as a wholly selective drug because all drugs cause side effects*. Common examples include the drowsiness that can be caused by many antihistamines; the peripheral edema that can be caused by calcium channel blockers; and the sexual dysfunction commonly caused by certain antidepressants.

Additional Properties of an Ideal Drug

Reversible Action

An ideal drug has effects that are reversible. In most cases, we want drug actions to subside within an appropriate time. For example, general anesthetics would be useless if patients never woke up. Likewise, it is unlikely that oral contraceptives would find wide acceptance if they caused permanent sterility. However, for a few drugs, reversibility is not desirable. For example, with antibiotics, we want the toxicity to microbes to endure.

Predictability

An ideal drug has predictable effects. It would be very helpful if, before drug administration, we could know with certainty just how a given patient will respond. Unfortunately, because each patient is unique, the accuracy of predictions cannot be guaranteed. Some patients respond better to certain drugs than other patients. Some patients have severe adverse effects, whereas others do not experience problems. Accordingly, to maximize the chances of eliciting the desired responses, we must tailor therapy to the individual.

Ease of Administration

An ideal drug is easy to administer. For example, taking a tablet by mouth is much simpler than drawing medicine up in a syringe and injecting it. Ideal drug administration should also be convenient. For example, it is more convenient to give a drug once a day than several times daily.

Ease of administration has two benefits: (1) It can decrease risk of harm, and (2) it can enhance patient adherence to the medication regimen. Whenever skin integrity is broken, as is the case when drugs are given by injection, there is a risk of

infection and injection-site pain or discomfort. Furthermore, when a medication is taken once daily, patients are less likely to forget a dose or get off-schedule.

Lack of Drug Interactions

An ideal drug does not interact with other agents. When a patient is taking two or more drugs, those drugs may interact in ways that either augment or reduce drug responses. For example, respiratory depression caused by diazepam (Valium), which is normally minimal, can be greatly *intensified* by alcohol. Conversely, the antibacterial effects of tetracycline can be greatly *reduced* by taking the drug with iron or calcium supplements. Because of the potential for interaction among drugs, when a patient is taking more than one drug, the possible impact of drug interactions must be considered. Unfortunately, few medicines are devoid of significant interactions.

Low Cost

An ideal drug is affordable. The cost of drugs can be a substantial financial burden. As an example, treatment with adalimumab (Humira), a drug for rheumatoid arthritis and Crohn disease, cost more than \$110,000 per year in 2022. More commonly, expense becomes a significant factor when a medication must be taken long term. For example, people with hypertension, arthritis, or diabetes may take medications every day for life. The cumulative expense of such treatment can be exorbitant—even for drugs of moderate price.

Chemical Stability

An ideal drug is chemically stable. Some drugs lose effectiveness during storage. Others that may be stable on the shelf can rapidly lose effectiveness when put into solution (e.g., in preparation for infusion). These losses in effectiveness result from chemical instability. Because of chemical instability, drugs eventually expire and must be discarded.

No Drug Is Ideal

From the preceding criteria for ideal drugs, we can see that available medications are not ideal. All drugs have the potential to produce side effects. Drug responses may be difficult to predict

and may be altered by drug interactions. Drugs may be expensive, unstable, and hard to administer. Because medications are not ideal, all members of the health care team must exercise care to promote therapeutic effects and minimize drug-induced harm.

THE THERAPEUTIC OBJECTIVE

The therapeutic objective of drug therapy is to provide maximum benefit with minimal harm. If drugs were ideal, we could achieve this objective with relative ease; however, because drugs are not ideal, we must exercise skill and care if treatment is to result in more good than harm. As detailed in [Chapter 2](#), you have a critical responsibility in achieving the therapeutic objective. To meet this responsibility, you must understand drugs. The primary purpose of this text is to help you achieve that understanding.

FACTORS THAT DETERMINE THE INTENSITY OF DRUG RESPONSES

Our ultimate concern when administering a drug is the intensity of the response. Multiple factors determine how an individual will respond to a prescribed dose of a particular drug ([Fig. 1.1](#)). By understanding these factors, you will be able to think rationally about how drugs produce their effects. As a result, you will be able to promote achievement of the therapeutic objective.

Working our way up from the bottom of [Fig. 1.1](#), we can see that the intensity of the response is determined by the concentration of a drug at its sites of action. The drug dosage, route, and timing of administration are important determinants of drug responses. Accordingly, the prescriber will consider these variables with care. The steps leading from the prescribed dose to the intensity of the response are considered in the sections that follow.

Administration

When administration is performed correctly, the dose that was given will be the same as the dose that was prescribed. If drugs




Fig. 1.1 ■ Factors that determine the intensity of drug responses.

are not taken or administered as prescribed, the result may be toxicity if the dosage is too high or treatment failure if the dosage is too low.

Sometimes patients do not take medications as prescribed. This is called *poor adherence*. To help minimize errors caused by poor adherence, you should give patients complete instructions about their medication and how to take it.

Medication errors made by hospital or clinic staff may result in a drug being administered by the wrong route, in the wrong dose, at the wrong time, or even to the wrong patient. Medication errors are discussed at length in Chapter 7.

Pharmacokinetics

Pharmacokinetic processes determine how much of an administered dose gets to its sites of action. There are four major pharmacokinetic processes: (1) drug absorption, (2) drug distribution, (3) drug metabolism, and (4) drug excretion. Collectively, these processes can be thought of as the *impact of the body on drugs*. These pharmacokinetic processes are discussed at length in Chapter 4.

Pharmacodynamics

Once a drug has reached its sites of action, pharmacodynamic processes determine the nature and intensity of the response. Pharmacodynamics can be thought of as the *impact of drugs on the body*. In most cases, the initial step leading to a response is

the binding of a drug to its receptor. This drug-receptor interaction is followed by a sequence of events that ultimately results in a response. As indicated in Fig. 1.1, the patient's functional state can influence pharmacodynamic processes. For example, a patient who has developed tolerance to morphine will respond less intensely to a particular dose than will a patient who lacks tolerance. Placebo effects also help determine the responses that a drug elicits. Pharmacodynamics is discussed at length in Chapter 5.

Sources of Individual Variation

Characteristics unique to each patient can influence pharmacokinetic and pharmacodynamic processes and, by doing so, can help determine the patient's response to a drug. As indicated in Fig. 1.1, sources of individual variation include physiologic variables (e.g., age, gender, weight); pathologic variables (especially diminished function of the kidneys and liver, the major organs of drug elimination); and genetic variables. Genetic factors comprise a third variable that can affect the intensity of drug responses. Not only can they alter the metabolism of drugs, but they can also predispose the patient to unique drug reactions.

Because individuals differ from one another, no two patients will respond identically to the same drug. Accordingly, to achieve the therapeutic objective, we must tailor drug therapy to the individual. Individual variation in drug responses is the subject of Chapter 8.

KEY POINTS

- The most important properties of an ideal drug are effectiveness, safety, and selectivity.
- Other properties of an ideal drug are reversible action, predictability, ease of administration, lack of drug interactions, low cost, and chemical stability.
- No drug is an ideal drug.
- Drugs have both benefits and risks.
- The therapeutic objective of drug therapy is to provide maximum benefit with minimum harm.
- The intensity of drug response is determined by proper administration, pharmacokinetics, pharmacodynamics, and individual variation.
- Because all patients are unique, drug therapy must be tailored to each individual.

Application of Pharmacology in Nursing Practice

Nursing Responsibilities Regarding Drugs, 5

Limitations of the Five Rights, 5
The Nurse as Patient Advocate, 6

Application of Pharmacology in Patient Care, 6

Preadministration Assessment, 6
Dosage and Administration, 6
Promoting Therapeutic Effects, 7
Minimizing Adverse Effects, 7
Minimizing Adverse Interactions, 7
Making PRN Decisions, 7
Evaluating Responses to Medication, 8
Managing Toxicity, 8

Application of Pharmacology in Patient Education, 8

Dosage and Administration, 8
Promoting Therapeutic Effects, 9
Minimizing Adverse Effects, 9
Minimizing Adverse Interactions, 9

Application of the Nursing Process and Clinical Judgment Measurement Model in Drug Therapy, 9

Review of the Nursing Process, 9
Review of the Clinical Judgment Measurement Model, 10

Applying the Nursing Process and Clinical Judgment Measurement Model in Drug Therapy, 11

Use of a Modified Nursing Process and Clinical Judgment Measurement Model Format to Summarize Nursing Implications, 13

Key Points, 13

Our principal goal in this chapter is to answer the question “Why should a nursing student learn pharmacology?” By addressing this question, I want to give you some extra motivation to study. Why do I think you might need some motivation? Because pharmacology can be challenging, and other topics in nursing are often more alluring. Hopefully, when you complete the chapter, you will be convinced that understanding drugs is essential for nursing practice and that putting time and effort into learning about drugs will be a good investment.



(Copyright iStock Photo; Credit: monkeybusinessimages.)

NURSING RESPONSIBILITIES REGARDING DRUGS

Nurses administer drugs to patients in a variety of settings. In the past, a nurse’s responsibility regarding medications focused on the Five Rights of Drug Administration (the Rights)—namely, give the right drug to the right patient in the right dose by the right route at the right time. More recently, various other rights—right assessment, right documentation, right evaluation, the patient’s rights to education, and the patient’s right of refusal—have been recommended for inclusion. Clearly, the original five Rights and their subsequent additions are important. Nevertheless, although these basics are vital, much more is required to achieve the therapeutic objective. The Rights guarantee only that a drug will be administered as prescribed, but correct administration, without additional interventions, cannot ensure that treatment will result in maximum benefit and minimum harm.

Limitations of the Five Rights

The limitations of the Rights can be illustrated with this analogy: The nurse who sees nursing’s responsibility as being complete after correct drug administration would be like a major league baseball pitcher who believes that his responsibility is over once he throws the ball toward the batter. As the pitcher must be ready to respond to the consequences of the interaction between ball and bat, you must be ready to respond to the consequences of the interaction between drug and patient. Put another way, although both the nurse and the pitcher have a clear obligation to deliver their objects in the most appropri-

ate fashion, proper delivery is only the beginning of their responsibilities: *Important events will take place after the object is delivered, and these must be responded to.* Like the pitcher, the nurse can respond rapidly and effectively only by anticipating what the possible reactions to the drug might be.

To anticipate possible reactions, both the nurse and the pitcher require certain kinds of knowledge. Just as the pitcher must understand the abilities of the opposing batter, you must understand the patient and the disorder for which the patient is being treated. As the pitcher must know the most appropriate pitch (e.g., fastball, slider) to deliver in specific circumstances, you must know what medications are appropriate for the patient and must check to ensure that the ordered medication is an appropriate one. Conversely, as the pitcher must know what pitches *not* to throw at a particular batter, you must know what drugs *not* to administer to the patient. As the pitcher must know the most likely outcome after the ball and bat interact, you must know the probable consequences of the interaction between drug and patient.

Although this analogy is not perfect (the nurse and patient are on the same team, whereas the pitcher and batter are not), it does help us appreciate that the nurse's responsibility extends well beyond the Rights. Consequently, in addition to the limited information needed to administer drugs in accordance with the Rights, you must acquire a broad base of pharmacologic knowledge to contribute fully to achieving the therapeutic objective.

The Nurse as Patient Advocate

Nurses, together with health care providers and pharmacists, participate in a system of checks and balances designed to promote beneficial effects and minimize harm. Nurses are especially important in this system because it is the nurse who follows the patient's status the most closely. As a result, you are likely to be the first member of the healthcare team to observe and evaluate drug responses and to intervene if required. To observe and evaluate drug responses, and to intervene rapidly and appropriately, you must know *in advance* the responses that a medication is likely to elicit. The better your knowledge of pharmacology, the better you will be able to *anticipate* drug responses and not simply react to them after the fact.

Within our system of checks and balances, the nurse has an important role as a patient advocate. It is your responsibility to detect mistakes made by pharmacists and prescribers. For example, the prescriber may overlook potential drug interactions, be unaware of alterations in the patient's status that would prohibit use of a particular drug, or select the correct drug but order an inappropriate dosage or route of administration. Because the nurse actually administers the drugs, the nurse is the last person to check medications before they are given. Consequently, *you are the patient's last line of defense against medication errors.* It is ethically and legally unacceptable for you to administer a drug that is harmful to the patient—even though the medication has been prescribed by a licensed prescriber and dispensed by a licensed pharmacist.

The two major areas in which you can apply pharmacologic knowledge are patient care and patient education. The application of pharmacology in patient care and patient education is considered in the following two sections.

APPLICATION OF PHARMACOLOGY IN PATIENT CARE

In discussing the applications of pharmacology in patient care, we focus on eight aspects of drug therapy: (1) preadministration assessment, (2) dosage and administration, (3) promoting therapeutic effects, (4) minimizing adverse effects, (5) minimizing adverse interactions, (6) making “as needed” (PRN) decisions, (7) evaluating responses to medication, and (8) managing toxicity.

Preadministration Assessment

All drug therapy begins with an assessment of the patient. Assessment has three basic goals: (1) to collect baseline data needed to evaluate therapeutic and adverse (i.e., undesired) responses, (2) to identify high-risk patients, and (3) to assess the patient's capacity for self-care. The first two goals are highly specific for each drug. Accordingly, we cannot achieve these goals without understanding pharmacology. The third goal applies generally to all drugs, and thus it does not usually require specific knowledge of the drug you are about to give.

Collecting Baseline Data

Baseline data are needed to evaluate both therapeutic and adverse drug responses. Without these data, we would have no way of determining the effectiveness of our drug. For example, if we plan to give a drug to lower blood pressure, we must know the patient's blood pressure before treatment. Similarly, if we are planning to give a drug that can damage the liver, we need to assess baseline liver function to evaluate this potential toxicity. Obviously, to collect appropriate baseline data, we must first know the effects that a drug is likely to produce.

Identifying High-Risk Patients

Multiple factors can predispose an individual to adverse reactions from specific drugs. Important predisposing factors are pathophysiology (especially liver and kidney impairment), genetic factors, drug allergies, and life span considerations, such as pregnancy or very young or advanced age.

Patients with a penicillin allergy provide a dramatic example of those at risk because giving penicillin to such a patient can be fatal. Accordingly, whenever treatment with penicillin is under consideration, we must determine whether the patient has had an allergic reaction to a penicillin in the past and note the type of reaction. If there is a history of true penicillin allergy, an alternative antibiotic should be prescribed.

From the preceding example, we can see that, when planning drug therapy, we must identify patients who are at high risk for reacting adversely. To identify such patients, we use three principal tools: the patient history, physical examination, and laboratory data. Of course, if identification is to be successful, you must know what to look for (i.e., you must know the factors that can increase the risk of severe reactions to the drug in question). Once the high-risk patient has been identified, we can take steps to reduce the risk.

Dosage and Administration

Earlier, we noted the Rights of Drug Administration and agreed on their importance. Although you can implement

the Rights without a detailed knowledge of pharmacology, having this knowledge can help reduce your contribution to medication errors. The following examples illustrate this point:

- Certain drugs have more than one indication, and dosage may differ depending on which indication the drug is used for. For example, aspirin is given in low doses to relieve pain and in high doses to suppress inflammation. If you do not know about these differences, you might administer too much aspirin to the patient with pain or too little to the patient with inflammation.
- Many drugs can be administered by more than one route, and dosage may differ depending on the route selected. For example, morphine may be administered by mouth or injection. Oral doses are generally much larger than injected doses. Accordingly, if a large dose intended for oral use were to be mistakenly administered by injection, the resulting overdose could prove fatal. The nurse who understands the pharmacology of morphine is unlikely to make this error.
- Certain intravenous (IV) agents can cause severe local injury if the drug extravasates (seeps into the tissues surrounding the IV line). The infusion must be monitored closely, and if extravasation occurs, corrective steps must be taken immediately. The nurse who does not understand the dangers of these drugs will be unprepared to work with them safely.

The following guidelines can help ensure correct administration:

- Read the medication order carefully. If the order is unclear, verify it with the prescriber.
- Verify the identity of the patient by comparing the name on the wristband with the name on the drug order or medication administration record or by scanning the wristband electronically.
- Read the medication label carefully. Verify the identity of the drug, the amount of drug (per tablet, volume of liquid, etc.), and its suitability for administration by the intended route.
- Verify dosage calculations.
- Implement any special handling the drug may require.
- Do not administer any drug if you do not understand the reason for its use.

Measures to minimize medication errors are discussed further in Chapter 7.

Promoting Therapeutic Effects

Drug therapy can often be enhanced by nonpharmacologic measures. Examples include (1) enhancing drug therapy of asthma through breathing exercises, biofeedback, and emotional support; (2) enhancing drug therapy of arthritis through exercise, physical therapy, and rest; and (3) enhancing drug therapy of hypertension through weight reduction, smoking cessation, and sodium restriction.

Short-term interventions are also helpful. For instance, mild to moderate pain may be experienced more intensely by the patient who lies slumped down in an uncomfortable bed compared with the patient who is carefully positioned for

maximum comfort. Similarly, the pediatric patient with mild to moderate pain who is in a nonstimulating environment may experience the pain more acutely than the patient for whom toys, games, or videos provide distraction.

As a nurse, you will have many opportunities to seek out creative solutions to promote therapeutic effects. You may provide these supportive measures directly or by coordinating the activities of other health care providers. Be sure to include these interventions in your patient education to empower patients and their families in optimal self-care.

Minimizing Adverse Effects

All drugs have the potential to produce undesired effects. Common examples include gastric erosion caused by aspirin, sedation caused by older antihistamines, hypoglycemia caused by insulin, and excessive fluid loss caused by diuretics. When drugs are used properly, the incidence and severity of such events can be reduced. Measures to reduce adverse events include identifying high-risk patients, ensuring proper administration, and teaching patients to avoid activities that might precipitate an adverse event.

When untoward effects cannot be avoided, discomfort and injury can often be minimized by appropriate intervention. For example, timely administration of glucose will prevent brain damage from insulin-induced hypoglycemia. To help reduce adverse effects, you must know the following about the drugs you administer:

- The major adverse effects the drug can produce
- When these reactions are likely to occur
- Early signs that an adverse reaction is developing
- Interventions that can minimize discomfort and harm

Minimizing Adverse Interactions

When a patient is taking two or more drugs, those drugs may interact with one another to diminish therapeutic effects or intensify adverse effects. For example, the ability of oral contraceptives to protect against pregnancy can be reduced by concurrent therapy with carbamazepine (an antiseizure drug), and the risk of thromboembolism from oral contraceptives can be increased by smoking cigarettes.

As a nurse, you can help reduce the incidence and intensity of adverse interactions in several ways. These include taking a thorough drug history, advising the patient to avoid over-the-counter (OTC) drugs that can interact with the prescribed medication, monitoring for adverse interactions *known* to occur between the drugs the patient is taking, and being alert to the possibility of *as-yet-unknown* interactions.

Making PRN Decisions

PRN stands for *pro re nata*, a Latin phrase meaning as needed. A PRN medication order is one in which the nurse has discretion regarding when to give a drug and, in some situations, how much of the drug to give. PRN orders are common for drugs that promote sleep, relieve pain, and reduce anxiety. To implement a PRN order rationally, you must know the reason the drug is prescribed and be able to assess the patient's

medication needs. Clearly, the better your knowledge of pharmacology, the better your PRN decisions are likely to be.

Evaluating Responses to Medication

Evaluation is one of the most important aspects of drug therapy. After all, this is the process that tells us whether a drug is producing a benefit or is causing harm. Because the nurse follows the patient's status most closely, the nurse is in the best position to evaluate therapeutic responses.

To make an evaluation, you must know the rationale for treatment and the nature and time course of the intended response. When desired responses do *not* occur, it may be essential to identify the reason quickly so that timely implementation of alternative therapy may be ordered.

When evaluating responses to a drug that has more than one application, you can do so only if you know the specific indication for which the drug is being used. For example, nifedipine is given for both hypertension and angina pectoris. When the drug is used for hypertension, you should monitor for a reduction in blood pressure. In contrast, when this drug is used for angina, you should monitor for a reduction in chest pain. Clearly, if you are to make the proper evaluation, you must understand the reason for drug use.

Managing Toxicity

Some adverse drug reactions are extremely dangerous. To minimize harm, you must know the early signs of toxicity and the procedure for toxicity management. If toxicity is not identified early and responded to quickly, irreversible injury or death can result.

APPLICATION OF PHARMACOLOGY IN PATIENT EDUCATION

Very often, the nurse is responsible for educating patients about medications. In your role as a patient educator, you must give the patient the following drug information:

- Drug name and therapeutic category (e.g., penicillin is an antibiotic)
- Dosage
- Dosing schedule
- Route and technique of administration
- Expected therapeutic response, and when it should develop
- Nondrug measures to enhance therapeutic responses
- Duration of treatment
- Method of drug storage
- Symptoms of major adverse effects, and measures to minimize discomfort and harm
- Major adverse drug-drug and drug-food interactions
- Whom to contact in the event of therapeutic failure, severe adverse reactions, or severe adverse interactions

To communicate this information effectively and accurately, you must first understand it. That is, to be a good drug educator, you must know pharmacology.

In the following discussion, we consider the relationship between patient education and the following aspects of drug therapy: dosage and administration, promoting therapeutic effects, minimizing adverse effects, and minimizing adverse interactions.

Dosage and Administration

Drug Name

Patients should know the name of the medication they are taking. If the drug has been prescribed by brand name, the patient should be given its generic name too. This information will reduce the risk for overdose that can result when a patient fails to realize that two drugs with different names actually contain the same medicine.

Dosage and Schedule of Administration

Patients must be told how much of a drug to take and when to take it. For some medications, dosage must be adjusted by the patient. Insulin is a good example. For insulin therapy to be most beneficial, the patient may need to adjust doses to accommodate changes in diet and subsequent glucose levels.

With PRN medications, the schedule of administration is not fixed. Rather, these drugs are taken as needed. For example, some people with asthma experience exercise-induced bronchospasm. To minimize such attacks, they can take medication before anticipated exertion. It is your responsibility to teach patients when PRN drugs should be taken.

The patient should also know what to do if a dose is missed. For example, with certain oral contraceptives, if one dose is missed, the omitted dose should be taken together with the next scheduled dose. However, if three or more doses are missed, a new cycle of administration must be initiated.

Patient Adherence

Adherence—also known as compliance or concordance—may be defined as the extent to which a patient's behavior coincides with medical advice. If we are to achieve the therapeutic objective, adherence to the prescribed drug regimen is essential. Drugs that are self-administered in the wrong dose, by the wrong route, or at the wrong time cannot produce maximum benefit and may even prove harmful. Obviously, successful therapy requires active and informed participation by the patient. By educating patients about the drugs they are taking, you can help elicit the required participation.

Some patients have difficulty remembering whether they have taken their medication. Possible causes include mental illness, advanced age, and complex regimens. To facilitate adherence for these patients, one solution is to provide the patient with a pill organizer that has separate compartments for each day of the week, and then to teach the patient or family member to load the compartments weekly. To determine whether a dose of medication has been taken, patients and their families can simply check the day of the week in the pill organizer to see whether the drugs have been removed.

Technique of Administration

Patients must be taught how to administer their drugs. This is especially important for routes that may be unfamiliar (e.g., sublingual for nitroglycerin) and for techniques that can be difficult (e.g., subcutaneous injection of insulin). Patients taking oral medications may require special instructions. For example, some oral preparations must not be chewed or crushed; some should be taken with fluids; and some should be taken with meals, whereas others should be taken on an empty stomach. Careful attention must be paid to the patient who, because

of disability (e.g., visual or intellectual impairment, limited manual dexterity), may find self-medication difficult.

Duration of Drug Use

Just as patients must know when to take their medicine, they must know when to stop. In some cases (e.g., treatment of acute pain), patients should discontinue drug use as soon as symptoms subside. In other cases (e.g., treatment of hypertension), patients should know that therapy will probably continue lifelong. For some conditions (e.g., gastric ulcers), medication may be prescribed for a specific time interval, after which the patient should return for reevaluation.

Drug Storage

Certain medications are chemically unstable and deteriorate rapidly if stored improperly. To ensure that patients take the drug prescribed rather than some altered version, those who are using unstable drugs must be taught how to store them correctly (e.g., under refrigeration, in a lightproof container). All drugs should be stored where children cannot reach them.

Promoting Therapeutic Effects

To participate fully in achieving the therapeutic objective, patients must know the nature and time course of expected beneficial effects. With this knowledge, patients can help evaluate the success or failure of treatment. By recognizing treatment failure, the informed patient will know to return to the health care provider for changes in therapy.

With some drugs, such as those used to treat depression and schizophrenia, beneficial effects may take several weeks to become maximally effective. Awareness that treatment may not produce immediate results allows the patient to have realistic expectations and helps reduce anxiety about therapeutic failure.

As noted, nondrug measures can complement drug therapy. For example, although drugs are useful in managing high cholesterol, exercise and diet are also important. Teaching the patient about nondrug measures can greatly increase the chances of success.

Minimizing Adverse Effects

Knowledge of adverse drug effects will enable the patient to avoid some adverse effects and minimize others through early detection. The following examples underscore the value of educating patients about the undesired effects of drugs:

- Insulin overdose can cause blood glucose levels to drop precipitously. Early signs of hypoglycemia include shakiness, perspiration, and anxiety. The patient who has been taught to recognize these early signs can respond by ingesting glucose or other fast-acting carbohydrate-rich foods, thereby restoring blood sugar to a safe level. In contrast, the patient who fails to recognize evolving hypoglycemia and does not ingest glucose or similar substances may become comatose and may even die.
- Many anticancer drugs predispose patients to acquiring serious infections. The patient who is aware of this possibility can take steps to avoid contagion by avoiding

contact with people who have an infection and by avoiding foods likely to contain pathogens. In addition, the informed patient is in a position to notify the health care prescriber at the first sign that an infection is developing, thereby allowing early treatment. In contrast, the patient who has not received adequate education is at increased risk for illness or death from an untreated infectious disease.

- Some side effects, although benign, can be disturbing if they occur without warning. For example, rifampin (a drug for tuberculosis) imparts a harmless red-orange color to urine, sweat, saliva, and tears. Your patient will appreciate knowing about this in advance.

Minimizing Adverse Interactions

Patient education can help avoid hazardous drug-drug and drug-food interactions. For example, phenelzine (an antidepressant) can cause dangerous elevations in blood pressure if taken in combination with certain drugs (e.g., amphetamines) or certain foods (e.g., sauerkraut, aged or smoked meats, most cheeses). Accordingly, it is essential that patients taking phenelzine are given specific and emphatic instructions regarding the drugs and foods they must avoid. For patients taking multiple drugs, the opportunity for drug interactions is increased. For these patients, providing a link to a reliable medication interaction checker will be helpful.

APPLICATION OF THE NURSING PROCESS AND CLINICAL JUDGMENT MEASUREMENT MODEL IN DRUG THERAPY

The nursing process is a conceptual framework that nurses use to guide health care delivery. The Clinical Judgment Measurement Model (CJMM), formerly known as the Clinical Judgment Model, is a framework for assessing the soundness of clinical decision-making. In this section, we compare the nursing process and the CJMM and examine how they can be applied to drug therapy.

Review of the Nursing Process

The nursing process is a method of problem-solving that has been used to guide nursing care for more than half a decade. In its simplest form, the nursing process can be viewed as a cyclic procedure that has five basic steps: (1) assessment, (2) analysis, (3) planning, (4) implementation, and (5) evaluation (Fig. 2.1).

Assess

Assessment consists of collecting data about the patient. These data are used to identify actual and potential health problems. The database established during assessment provides a foundation for subsequent steps in the process. Important methods of data collection are the patient interview, medical and drug-use histories, the physical examination, observation of the patient, and findings of screening or diagnostic studies (e.g., laboratory and radiologic test results).



Fig. 2.1 ■ The nursing process.

Analyze

In this step, the nurse analyzes information in the database to determine actual and potential health problems. These problems may be physiologic, psychological, or sociologic.

Plan

In the planning step, the nurse identifies specific interventions directed at solving or preventing the problems identified in the analysis phase. These interventions form a component of the nursing care plan, a broader individualized plan of care for which the nurse defines goals, sets priorities, identifies nursing interventions, and establishes criteria for evaluating success. The planning phase is an ongoing process that must be modified as new data are gathered and the patient’s situation changes.

Implement

Implementation is the process of executing the plan. Some interventions are collaborative, whereas others are independent. Collaborative interventions require a health care provider’s order, whereas independent interventions do not. In addition to carrying out interventions, implementation involves coordinating the actions of other members of the health care team.

Evaluate

Evaluation is performed to determine the degree to which treatment has succeeded. By evaluating the outcomes of treatment, nurses identify those interventions that should be continued, those that should be discontinued, and potential new interventions that may be implemented. Evaluation is accomplished by analyzing the data collected after implementation. This step completes the initial cycle of the nursing process and provides the basis for beginning the cycle anew.

Review of the Clinical Judgment Measurement Model

The CJMM was developed by the National State Boards of Nursing (NCSBN) as a framework for constructing questions for the Next Generation NCLEX (NGN) nursing

TABLE 2.1 ■ Relationship Between the Nursing Process and the Clinical Judgment Measurement Model

Nursing Process	Clinical Judgment Measurement Model
Assess	Recognize Cues
Analyze	Analyze Cues
	Prioritize Hypotheses
Plan	Generate Solutions
Implement	Take Action
Evaluate	Evaluate Outcomes

licensure exam. It consists of six cognitive skills used in clinical decision-making. These are (1) recognize cues, (2) analyze cues, (3) prioritize hypotheses, (4) generate solutions, (5) take action, and (6) evaluate outcomes.

Recognize Cues

The nurse collects subjective and objective data about the patient. The main sources of information include the patient’s health history, assessment, and the results of any laboratory or other studies. The nurse then examines the collected data to distinguish which findings are relevant given the patient’s situation.

Analyze Cues

In this step, the nurse analyses the relevant data as it applies to the patient’s situation or presenting concerns. The analysis is used to identify the patient’s probable needs and problems.

Prioritize Hypotheses

After the hypotheses (probable needs and problems) are identified, they are prioritized. Considerations in prioritization include the urgency with which a problem needs to be addressed and whether the problem has actually occurred or is at risk of occurring. Decisions related to prioritization are often decided on an individual basis.

Generate Solutions

In this step, the nurse first establishes desired patient outcomes. Then the nurse identifies interventions that can be used to achieve those outcomes.

Take Action

Next, the nurse implements the solutions generated in the previous step. Because we cannot manage all problems simultaneously, actions are prioritized to address the most urgent problems first. Less severe problems are relegated to lower positions when prioritizing care.

Evaluate Outcomes

The final step determines whether the actions taken were effective. This is done by evaluating patient outcomes and comparing them with the desired outcomes that were established when solutions were generated.

Although it is a six-step model, the CJMM aligns well with the nursing process (Table 2.1).

Applying the Nursing Process and Clinical Judgment Measurement Model in Drug Therapy

Having reviewed the nursing process and CJMM, we can now discuss the process as it pertains to drug therapy. Recall that the overall objective of drug therapy is to produce maximum benefit with minimum harm. In addition, keep in mind that this is somewhat modified because the process is being applied to drug therapy rather than to a patient with individualized needs.

In the discussion that follows, the headings reflect the phase of the nursing process followed by associated the CJMM skill (i.e., nursing process/CJMM).

Assess/Recognize Cues

A preadministration assessment establishes the baseline data needed to tailor drug therapy to the individual. By identifying the variables that can affect an individual's response to a drug, we can adapt treatment so as to maximize benefits and minimize harm. Preadministration assessment has two basic goals:

- Collection of baseline data needed to evaluate therapeutic effects
- Collection of baseline data needed to evaluate adverse effects

These goals are specific to the particular drug being used. Accordingly, to achieve these goals, you must know the pharmacology of the drug under consideration.

Important methods of data collection include interviewing the patient and family, observing the patient, performing a physical examination, checking the results of laboratory and radiologic tests, and taking the patient's medical and drug histories. The drug history should include prescription drugs, OTC drugs, herbal remedies, and drugs taken for nonmedical or recreational purposes (e.g., alcohol, nicotine, caffeine, and illegal drugs). Prior adverse drug reactions should be noted, including drug allergies and idiosyncratic reactions (i.e., reactions unique to the individual).

Baseline Data Needed to Evaluate Therapeutic Effects.

Drugs are administered to achieve a desired response. To know whether we have produced that response, we need to establish baseline measurements of the parameter that therapy is directed at changing. For example, if we are giving a drug to lower blood pressure, we need to know what the patient's blood pressure was before treatment. Without this information, we have no basis for determining the effectiveness of our drug.

Baseline Data Needed to Evaluate Adverse Effects.

All drugs have the ability to produce undesired effects. In most cases, the adverse effects that a particular drug can produce are known. In many cases, the development of an adverse effect will be completely obvious in the absence of any baseline data. For example, we do not need special baseline data to know that hair loss after cancer chemotherapy was caused by the drug. However, in other cases, baseline data are needed to determine whether an adverse effect has occurred. For example, some drugs can impair liver function. To know whether a drug has compromised liver function, we need to know the state of liver function before drug use. Without this information, we cannot tell from later measurements whether liver dysfunction was preexisting or caused by the drug.

Analyze/Analyze Cues and Prioritize Hypotheses

With respect to drug therapy, three important objectives for this step are:

- Identify high-risk patients
- Determine the patient's capacity for self-care
- Judge the appropriateness of the prescribed regimen.

Identify High-Risk Patients. Because of individual characteristics, a particular patient may be at high risk for experiencing an adverse response to a particular drug. Just which individual characteristics will predispose a patient to an adverse reaction depends on the drug under consideration. For example, if a drug is eliminated from the body primarily by renal excretion, an individual with impaired kidney function will be at risk for having this drug accumulate to a toxic level. Similarly, if a drug is eliminated by the liver, an individual with impaired liver function will be at risk for having that drug accumulate to a toxic level.

Multiple factors can increase the patient's risk for adverse reactions to a particular drug. Impaired liver and kidney function were just mentioned. Other factors include age, body composition, pregnancy, diet, genetic heritage, other drugs being used, and practically any pathophysiologic condition. These factors are discussed at length in Chapters 8 and 9.

When identifying factors that put the patient at risk, you should distinguish between factors that put the patient at extremely high risk versus factors that put the patient at moderate or low risk. The terms *contraindication* and *precaution* are used for this distinction. A *contraindication* is defined as a condition that prohibits the use of a particular drug under all but the most critical of circumstances. For example, a previous severe allergic reaction to penicillin would be a contraindication to using penicillin again—unless the patient has a life-threatening infection that cannot be effectively treated with another antibiotic. In this situation, in which the patient *will* die if the drug *is not* administered yet the patient *may* die if the drug *is* administered, the health care provider may decide to give the penicillin along with other drugs and measures to decrease the severity of the allergic reaction. By contrast, a *precaution* can be defined as a condition that significantly increases the risk for an adverse reaction to a particular drug but not to a degree that is life-threatening. For example, sedating antihistamines pose a risk to elderly patients who are at risk of falling, which would constitute a precaution against using this drug in older adults. That is, the drug may be used, but greater than normal caution must be exercised. Preferably, an alternative nonsedating antihistamine would be selected.

Determine the Patient's Capacity for Self-Care. If drug therapy is to succeed, the outpatient must be willing and able to self-administer medication as prescribed. Accordingly, the patient's capacity for self-care must be determined. If the assessment reveals that the patient is incapable of self-medication, alternative care must be arranged.

Multiple factors can affect the capacity for self-care and the probability of adhering to the prescribed regimen. Patients with reduced visual acuity or limited manual dexterity may be unable to self-medicate, especially if the technique for administration is complex. Patients with limited intellectual ability may be incapable of understanding or remembering what they are supposed to do. Patients with severe mental illness (e.g., depression, schizophrenia) may lack the understanding

or motivation needed to self-medicate. Some patients may lack the money to pay for drugs. Others may fail to take medications as prescribed because of individual or cultural attitudes toward drugs. For example, a common cause for failed self-medication is a belief that the drug was simply not needed in the dosage prescribed. A thorough assessment will identify these factors, thereby enabling you to account for them when developing the patient care plan.

Judge the Appropriateness of the Prescribed Regimen. As the last link in the patient's chain of defense against inappropriate drug therapy, you must analyze the cues to determine whether the proposed treatment has a reasonable likelihood of being effective and safe. This judgment is made by considering the medical diagnosis, the known actions of the prescribed drug, the patient's prior responses to the drug, and the presence of contraindications to the drug. You should question the drug's appropriateness if (1) the drug has no actions that are known to benefit individuals with the patient's medical diagnosis, (2) the patient failed to respond to the drug in the past, (3) the patient had a serious adverse reaction to the drug in the past, or (4) the patient has a condition or is using a drug that contraindicates the prescribed drug. If any of these conditions apply, you should consult with the prescriber to determine whether the drug should be given.

The analysis must identify potential adverse effects and drug interactions. This is accomplished by integrating knowledge of the drug under consideration and the data collected during the assessment. Knowledge of the drug will indicate adverse effects that practically all patients are likely to experience. Data on the individual patient will indicate additional adverse effects and interactions to which the particular patient is predisposed.

Plan/Generate Solutions

Planning consists of defining goals, establishing priorities, identifying specific interventions, and establishing criteria for evaluating success. Good planning will allow you to promote beneficial drug effects. Of equal or greater importance, good planning will allow you to anticipate adverse effects rather than react to them after the fact.

Defining Goals. When planning care and generating solutions, it is important to first identify the desired outcomes of drug therapy. In all cases, the goal of drug therapy is to produce maximum benefit with minimum harm. That is, we want to use drugs in such a way as to maximize therapeutic responses, while preventing or minimizing adverse reactions and interactions. The objective of planning is to formulate ways to achieve this goal.

Setting Priorities. Priority setting requires knowledge of the drug under consideration and the patient's unique characteristics—and even then, setting priorities can be difficult. The highest priority is given to life-threatening conditions (e.g., anaphylactic shock, ventricular fibrillation). These may be drug induced or the result of disease. High priority is also given to reactions that cause severe, acute discomfort and to reactions that can result in long-term harm.

Identifying Interventions. The heart of planning is the identification of nursing interventions. For medication purposes, these interventions can be divided into four major groups: (1) drug administration, (2) interventions to enhance therapeutic effects, (3) interventions to minimize adverse effects and

interactions, and (4) patient education (which encompasses information in the first three groups).

When planning drug administration, you must consider the dosage and route of administration, as well as less obvious factors, including the timing of administration with respect to meals and with respect to the administration of other drugs. Timing with respect to side effects is also important. For example, if a drug causes sedation, it may be desirable to give the drug at bedtime, rather than in the morning; conversely, a diuretic, which increases urination, is better given earlier in the morning rather than at bedtime.

Nondrug measures can help promote therapeutic effects and should be included in the plan. For example, drug therapy for hypertension can be combined with weight loss (in overweight patients), salt restriction, and smoking cessation.

Interventions to prevent or minimize adverse effects are of obvious importance. When planning these interventions, you should distinguish between reactions that develop quickly and reactions that are delayed. A few drugs can cause severe adverse reactions (e.g., anaphylactic shock) shortly after administration. When planning to administer such a drug, you should ensure that facilities for managing possible reactions are immediately available. Delayed reactions can often be minimized, if not avoided entirely. The plan should include interventions to do so.

Well-planned patient education is central to success. Patient education is discussed at length earlier in this chapter.

Establishing Criteria for Evaluation. The need for objective criteria by which to measure desired drug responses is obvious: Without such criteria, we could not determine how well our drug achieved the therapeutic objective. As a result, we would have no rational basis for making dosage adjustments or for deciding whether a drug should be continued.

Criteria for evaluation vary depending on the drug and its purpose. For an analgesic, the criterion for evaluation is a decrease or resolution of pain. For the patient prescribed thyroid hormones for hypothyroidism, a criterion for evaluation is typically a laboratory test (e.g., thyroid stimulating hormone level and free thyroxine level within normal range). Conversely, for the patient prescribed an antihypertensive, a criterion for evaluation may be a target blood pressure goal. Often, there are several criteria for evaluating a given drug.

If the drug is to be used on an outpatient basis, follow-up visits for evaluation should be planned. It is important to educate the patient on the importance of these visits even if the patient is feeling well.

Implement/Take Action

The nurse implements the care plan and takes action by carrying out the solutions that were generated to target the patient's problems. In drug therapy, this phase has four major components: (1) drug administration, (2) patient education, (3) interventions to promote therapeutic effects, and (4) interventions to minimize adverse effects. These critical nursing activities are discussed at length in the previous section.

Evaluate/Evaluate Outcomes

Over the course of drug therapy, the patient must be evaluated for (1) therapeutic responses, (2) adverse drug reactions and interactions, (3) adherence to the prescribed regimen, and (4) satisfaction with treatment. How frequently evaluations are performed depends on the expected time course of therapeutic and adverse effects. Like assessment, evaluation is based on laboratory tests,

observation of the patient, physical examination, and patient interviews. The conclusions drawn during the evaluation provide the basis for modifying nursing interventions and the drug regimen.

Therapeutic responses are evaluated by comparing the patient's current status with the baseline data. To evaluate treatment, you must know the reason for drug use, the criteria for evaluation, and the expected time course of responses (some drugs act within minutes, whereas others may take weeks to produce beneficial effects).

The need to anticipate and evaluate adverse effects is self-evident. To make these evaluations, you must know which adverse effects are likely to occur, how they manifest, and their probable time course. The method of monitoring is determined by the expected effect. For example, if hypotension is expected, blood pressure is monitored; if constipation is expected, bowel function is monitored. Because some adverse effects can be fatal in the absence of timely detection, it is impossible to overemphasize the importance of monitoring and being prepared for rapid intervention.

Evaluation of adherence is desirable in all patients—and is especially valuable when therapeutic failure occurs or when adverse effects are unexpectedly severe. Methods of evaluating adherence include measuring plasma drug levels, interviewing the patient, and counting pills. The evaluation should determine whether the patient understands when to take the medication, what dose to take, and the technique of administration, as well as whether the patient is taking the drug(s) exactly as prescribed.

Patient satisfaction with drug therapy increases quality of life and promotes adherence. If the patient is dissatisfied, an otherwise effective regimen may not be taken as prescribed. Factors that can cause dissatisfaction include unacceptable side effects, inconvenient dosing schedule, difficulty of administration, and high cost. When evaluation reveals dissatisfaction, an attempt should be made to alter the regimen to make it more acceptable.

Use of a Modified Nursing Process and Clinical Judgment Measurement Model Format to Summarize Nursing Implications

Throughout this text, nursing information is integrated with basic science information to reinforce the relationship between pharmacologic knowledge and nursing practice. In addition to being integrated, for those chapters that focus on specific drugs (as opposed to those such as this one), nursing implications are summarized at the end of the chapters under the heading “Summary of Major Nursing Implications.” The purpose of these summaries is to provide a concise and readily accessible reference on patient care and patient education related to specific drugs and drug families.

The format used for summarizing nursing implications reflects the nursing process and CJMM. Some headings have been modified to accommodate the needs of pharmacology instruction and to keep the summaries concise.

KEY POINTS

- Nursing responsibilities with regard to drugs extend far beyond the Rights of Drug Administration.
- You are the patient's last line of defense against medication errors.
- Your knowledge of pharmacology has a wide variety of practical applications in patient care and patient education.
- By applying your knowledge of pharmacology, you will make a large contribution to achieving the therapeutic objective of maximum benefit with minimum harm.
- Application of the nursing process and Clinical Judgment Measurement Model in drug therapy is directed at individualizing treatment, which is critical to achieving the therapeutic objective.
- The goal of assessment and recognizing cues is to gather data needed for the evaluation of therapeutic and adverse effects.
- The analysis and analyzing cues phase of treatment is directed at (1) identifying high-risk patients, (2) assessing the patient's capacity for self-care, and (3) judging the appropriateness of the prescribed therapy.
- Planning and generating solutions are directed at (1) defining goals, (2) establishing priorities, (3) identifying interventions, and (4) establishing criteria for evaluating success.
- Implementation and taking action center on carrying out the solutions that were generated in developing the patient's plan of care. In drug therapy, this phase has four major components: (1) drug administration, (2) patient education, (3) interventions to promote therapeutic effects, and (4) interventions to minimize adverse effects.
- In the evaluation stage, the objective is to evaluate: (1) therapeutic responses, (2) adverse reactions and interactions, (3) patient adherence, and (4) patient satisfaction with treatment.

Drug Regulation, Development, Names, and Information

Landmark Drug Legislation, 14

1900 to 1970, 14

1990 to Present, 15

Hazardous Drug Exposure, 16

Health Care Worker Safety, 16

Hazardous Drug Identification, 16

New Drug Development, 16

The Randomized Controlled Trial, 16

Stages of New Drug Development, 18

Limitations of the Testing Procedure, 18

Exercising Discretion Regarding New Drugs, 19

Drug Names, 20

The Three Types of Drug Names, 20

Which Name to Use, Generic or Brand?, 20

Over-The-Counter Drugs, 22

Benefits of Over-the-Counter Drugs, 22

Risks of Over-the-Counter Drugs, 22

Sources of Drug Information, 23

Newsletters, 23

Reference Books, 23

The Internet, 23

Key Points, 24

In this chapter, we complete our introduction to pharmacology by considering five diverse but important topics. These are (1) drug regulation, (2) new drug development, (3) the annoying problem of drug names, (4) over-the-counter (OTC) drugs, and (5) sources of drug information.

LANDMARK DRUG LEGISLATION

The history of drug legislation in the United States reflects an evolution in our national posture toward regulating the pharmaceutical industry. That posture has changed from one of minimal control to one of extensive control. For the most part, increased regulation has been beneficial, resulting in safer and more effective drugs.



(Copyright iStock Photo; Credit: yalax.)

1900 to 1970

The first American law to regulate drugs was the *Federal Pure Food and Drug Act* of 1906. This law set standards for drug quality and purity in addition to strength. It specifically focused on product labeling and required that any variations from the standards be placed on the label.

The *Food, Drug, and Cosmetic Act*, passed in 1938, was the first legislation to address drug safety. The motivation behind the law was a tragedy in which more than 100 people died after using a new medication. The lethal preparation contained sulfanilamide, an antibiotic, plus diethylene glycol as a solubilizing agent. Tests showed that the solvent was the cause of death. (Diethylene glycol is commonly used as automotive antifreeze.) To reduce the chances of another such tragedy, Congress required that all new drugs undergo testing for safety. The results of these tests were to be reviewed by the *U.S. Food and Drug Administration* (FDA), and only those drugs judged safe would receive FDA approval for marketing.

In 1962, Congress passed the *Harris-Kefauver Amendments* to the Food, Drug, and Cosmetic Act. This bill was created in response to the thalidomide tragedy that occurred in Europe in the early 1960s. Thalidomide is a sedative now known to cause birth defects and fetal death. Because the drug was used widely by pregnant patients, thousands of infants were born with phocomelia, a rare birth defect characterized by the gross malformation or complete absence of arms or legs. This tragedy was especially poignant in that it resulted from nonessential drug use: The women who took thalidomide could have managed their conditions without it. Thalidomide was not a

problem in the United States because the drug never received approval by the FDA.

Because of the European experience with thalidomide, the Harris-Kefauver Amendments sought to strengthen all aspects of drug regulation. A major provision of the bill required that drugs be proved *effective* before marketing. Remarkably, this was the first law to demand that drugs actually offer some benefit. The new act also required that all drugs that had been introduced between 1932 and 1962 undergo testing for effectiveness; any drug that failed to prove useful would be withdrawn. Lastly, the Harris-Kefauver Amendments established rigorous procedures for testing new drugs. These procedures are discussed later in this chapter under *New Drug Development*.

In 1970, Congress passed the *Controlled Substances Act* (Title II of the Comprehensive Drug Abuse Prevention and Control Act). This legislation set rules for the manufacture and distribution of drugs considered to have the potential for abuse. One provision of the law defines five categories of controlled substances, referred to as Schedules I, II, III, IV, and V. Drugs in Schedule I have no accepted medical use in the United States and are deemed to have a high potential for abuse. Examples include heroin, mescaline, and lysergic acid diethylamide (LSD). Drugs in Schedules II through V have accepted medical applications but also have a high potential for abuse. The abuse potential of these agents becomes progressively less as we proceed from Schedule II to Schedule V. The Controlled Substances Act is discussed further in Chapter 40.

1990 to Present

In 1992, FDA regulations were changed to permit *accelerated approval* of drugs for acquired immunodeficiency syndrome (AIDS) and cancer. Under these guidelines, a drug could be approved for marketing before the completion of phase III trials (discussed later in the chapter), provided that rigorous follow-up studies (phase IV trials) were performed. The rationale for this change was that (1) medications are needed, even if their benefits may be marginal, and (2) the unknown risks associated with early approval are balanced by the need for more effective drugs. Although accelerated approval seems like a good idea, in actual practice, it has two significant drawbacks. First, manufacturers often fail to conduct or complete the required follow-up studies. Second, if the follow-up studies—which are more rigorous than the original—fail to confirm a clinical benefit, the guidelines have no clear mechanism for removing the drug from the market.

The *Prescription Drug User Fee Act* (PDUFA), passed in 1992, was a response to complaints that the FDA was taking too long to review applications for new drugs. Under the Act, drug sponsors pay the FDA fees that are used to fund additional reviewers. In return, the FDA must adhere to strict review timetables. Because of the PDUFA, new drugs now reach the market much sooner than in the past.

The *Food and Drug Administration Modernization Act* (FDAMA) of 1997—an extension of the PDUFA—called for widespread changes in FDA regulations. For health professionals, four provisions of the act are of particular interest:

- The fast-track system created for AIDS drugs and cancer drugs now includes drugs for other serious and life-threatening illnesses.
- Manufacturers who plan to stop making a drug must inform patients at least 6 months in advance, thereby giving them time to find another source.
- A clinical trial database is required for drugs directed at serious or life-threatening illnesses. These data allow clinicians and patients to make informed decisions about using experimental drugs.
- Drug companies can now give prescribers journal articles and certain other information regarding off-label uses of drugs. (An *off-label use* is a use that has not been evaluated by the FDA.) Before the new act, clinicians were allowed to prescribe a drug for an off-label use, but the manufacturer was not allowed to promote the drug for that use—even if promotion was limited to providing potentially helpful information, including reprints of journal articles. In return for being allowed to give prescribers information regarding off-label uses, manufacturers must promise to do research to support the claims made in the articles.

Two laws—the *Best Pharmaceuticals for Children Act* (BPCA), passed in 2002, and the *Pediatric Research Equity Act* (PREA) of 2003—were designed to promote much-needed research on drug efficacy and safety in children. The BPCA offers a 6-month patent extension to manufacturers who evaluate a drug already on the market for its safety, efficacy, and dosage in children. The PREA gives the FDA the power, for the first time, to require drug companies to conduct pediatric clinical trials on new medications that might be used by children. (In the past, drugs were not tested in children, so there was a general lack of reliable information upon which to base therapeutic decisions.)

In 2007, Congress passed the *FDA Amendments Act* (FDAAA), the most important legislation on drug safety since the Harris-Kefauver Amendments of 1962. The FDAAA expands the mission of the FDA to include rigorous oversight of drug safety *after* a drug has been approved. (Before this act, the FDA focused on drug efficacy and safety *before* approval but had limited resources and authority to address drug safety after a drug was released for marketing.) Under the new law, the FDA has the legal authority to require postmarketing safety studies, to order changes in a drug's label to include new safety information, and to restrict distribution of a drug based on safety concerns. In addition, the FDA was required to establish an active postmarketing risk surveillance system, mandated to include 25 million patients by July 2010 and 100 million by July 2012. Because of the FDAAA, adverse effects that were not discovered before drug approval came to light much sooner than in the past, and the FDA now has the authority to take action (e.g., limit distribution of a drug) if postmarketing information shows a drug to be less safe than previously understood.

In 2009, Congress passed the *Family Smoking Prevention and Tobacco Control Act*, which, at long last, allows the FDA to regulate cigarettes, which are responsible for about one in five deaths in the United States each year. Under the act, the FDA was given the authority to strengthen advertising restrictions, including a prohibition on marketing to youth; require revised and more prominent warning labels; require

disclosure of all ingredients in tobacco products and restrict harmful additives; and monitor nicotine yields and mandate gradual reduction of nicotine to nonaddictive levels. The *Comprehensive Addiction and Recovery Act (CARA) of 2016* and the *Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act of 2018* were developed to combat a nationwide opioid epidemic by addressing the crisis from multiple approaches. To that end, they provide grants to support efforts directed toward prevention, treatment, and rehabilitation/recovery; opioid overdose reversal by first responders, law enforcement officers, and families; and the establishment of opioid recovery centers. Implications for nursing are significant because nurses have important roles in the expanded drug education and other prevention programs and in drug addiction treatment and recovery programs. In addition, nurses are often in roles in which they serve as first responders.

HAZARDOUS DRUG EXPOSURE

Health Care Worker Safety

Exposure to certain drugs can be dangerous for nurses and other health care workers who handle them. It is imperative to ensure your own safety as well as the safety of your patients.

The NIOSH, established in 1970, has the responsibility to promote and enhance worker safety. Thus NIOSH identifies which of the thousands of drugs are hazardous for handling and publishes guidance on the safe handling of these drugs.

Hazardous Drug Identification

In their publication *NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016* (available, with updates, online at <https://www.cdc.gov/niosh/docs/2016-161>), the NIOSH identifies a drug as hazardous for handling if it meets one or more of the following criteria:

- Carcinogenicity
- Teratogenicity or developmental toxicity
- Reproductive toxicity
- Organ toxicity at low doses
- Genotoxicity
- New drugs with structure and toxicity profiles similar to drugs previously determined to be hazardous

It is probably not surprising to find that antineoplastic drugs (drugs that kill cancer cells) are included in the list, but common drugs such as oral contraceptives (birth control pills) are also included. You will learn about these throughout the textbook, and the full listing is also available in the NIOSH publication.

The NIOSH provides instructions on how nurses and other health care workers can use protective equipment and environmental controls to prevent the potentially harmful effects associated with these drugs. These guidelines are provided in [Table 3.1](#).

NEW DRUG DEVELOPMENT

The development and testing of new drugs is an expensive and lengthy process, requiring 10 to 15 years for completion. Of the thousands of compounds that undergo testing, only a few enter clinical trials, and of these, only one in five gains approval. According to an article in the March 2020 issue of the *Journal of the American Medical Association (JAMA)*, the estimated average research and development investment to bring a new drug to market is \$1335.9 million.

Rigorous procedures for testing have been established so that newly released drugs can be both safe and effective. Unfortunately, although testing can determine effectiveness, it cannot guarantee that a new drug will be safe. For example, significant adverse effects may evade detection during testing, only to become apparent after a new drug has been released for general use.

The Randomized Controlled Trial

RCTs are the most reliable way to objectively assess drug therapies. RCTs have three distinguishing features: use of controls, randomization, and blinding. All three serve to minimize the influence of personal bias on the results.

Use of Controls

When a new drug is under development, researchers want to know how it compares with a standard drug used for the same disorder or perhaps how it compares with no treatment at all. To make these comparisons, some subjects in the RCT are given the new drug and some are given either (1) a standard treatment or (2) a placebo (i.e., an inactive compound formulated to look like the experimental drug). Subjects receiving either the standard drug or the placebo are referred to as controls. Controls are important because they help us determine whether the new treatment is more (or less) effective than standard treatments or at least whether the new treatment is better (or worse) than no treatment at all. Likewise, controls allow us to compare the safety of the new drug with that of the old drug, a placebo, or both.

Randomization

In an RCT, subjects are randomly assigned to either the control group or the experimental group (i.e., the group receiving the new drug). The purpose of randomization is to prevent allocation bias, which results when subjects in the experimental group are different from those in the control group. For example, in the absence of randomization, researchers could load the experimental group with patients who have mild disease and load the control group with patients who have severe disease. In this case, any differences in outcome may well be because of the severity of the disease rather than differences in treatment. Moreover, even if researchers try to avoid bias by purposely assigning subjects who appear similar to both groups, allocation bias can result from unknown factors that can influence outcome. By assigning subjects randomly to the control and experimental groups, all factors—known and unknown, important and unimportant—should be equally represented in both groups. As a result, the influences of these factors on outcome should tend to cancel each other out, leaving differences in the treatments as the best explanation for any differences in outcome.

- Neurolytic nerve block, for cancer pain, 337, 576
- Neuromuscular blockers
 competitive (nondepolarizing), 160–162
 depolarizing, 163
 endotracheal intubation, 160
 mechanical ventilation, facilitation of, 159–160
 muscle relaxation during surgery, 159
 therapeutic uses of, 158–160
- Neuromuscular blocking agents, 132, 301
- Neuromuscular weakness, stavudine, 1221
- Neuronal degeneration, 226
- Neurontin. *See* Gabapentin
- Neuropathic pain, 250, 328, 569
- Neuropharmacology
 defined, 113
 importance of, 113
 multiple drug receptors and selective drug action, 116–117, 117f
 peripheral nervous system drugs, 116–117
 learning approach, 117
 physiologic processes, 113–114, 114f
 sites of action
 axonal conduction, 114
 receptors, 114
 synaptic transmission, 114
- Neurostabilizers, for cluster headache, 352t
- Neurotoxicity, opioid-induced, 310, 336, 579
- Neurotransmitters, 204, 205t
 CNS disorder and, 205t
- Neutralizing antibodies, 241, 245
 growth hormone and, 742
- Neutropenia
 with ACE inhibitors, 507
 antimicrobial prophylaxis in, 1097
 with cancer chemotherapy, 1301–1302
 TNF inhibitors and, 928–929
 tocilizumab and, 931
- Neutrophils, 844, 844t
- Nevirapine (Viramune, Viramune XR), 1223t, 1224–1225
- New Delhi Metallo- β -Lactamase 1 (NDM-1)* gene, 1088
- New drug development, 16–20
 discretion, 19–20
 limitations, 18–19, 19t
 RCTs, 16–18
 stages of, 18, 18t
- New England Journal of Medicine*, 1069
- New-generation antiepileptic drugs, 259t, 260–261, 269–278
 pharmacokinetics, 272t
 preparations, dosage, and administration, 269t–271t
- New York Heart Association (NYHA),
 classification of HF severity of, 553, 553f
- Nexavar. *See* Sorafenib
- Nexiclon XR. *See* Clonidine
- NGU. *See* Nongonococcal urethritis
- NHIS. *See* National Health Interview Survey
- Niacin (nicotinic acid), 1048t–1050t, 1053–1054
- Niacinamide. *See* Nicotinamide
- Niaspan. *See* Niacin
- Nicardipine, 522t
- Nicorette. *See* Nicotine chewing gum
- Nicorette Inhaler. *See* Nicotine inhaler
- Nicorette Lozenge. *See* Nicotine lozenges
- Nicotinamide (Niacinamide), 1053
- Nicotine
 acute poisoning, 454–455
 chronic toxicity, 455
 dependence, 454
 mechanism of action, 452
- Nicotine (*Continued*)
 pharmacokinetics, 453
 pharmacologic effects of, 453–454
 polacrilex, 456–457
 smoking. *See* Smoking
 tolerance, 454
 vaping, 452, 453b
- Nicotine chewing gum, 456–457
- Nicotine inhaler, 457
- Nicotine lozenges, 457
- Nicotine nasal spray, 458
- Nicotine replacement therapy (NRT), 456–458
 nicotine chewing gum, 456–457
 nicotine inhaler, 457
 nicotine lozenges, 457
 nicotine nasal spray, 458
 nicotine transdermal systems, 457, 457t
- Nicotinic receptors, 126t, 128
- Nifedipine (Procardia), 520–522, 796, 796t–798t
 adverse effects, 521–522
 drug interactions, 522
 hemodynamic effects, 520–521
 immediate-release, 522b
 pharmacokinetics, 521
 preparations, dosage, and administration, 520, 522t
 safety alert, 522b
 therapeutic uses, 521
 toxicity, 522
 vs. verapamil, 520, 521t
- Nilandron. *See* Nilutamide
- Nilotinib (Tasigna), 1337t–1338t
- Nilutamide (Nilandron, Anandron), 1333t
- Nimodipine, 522t
- Nipent. *See* Pentostatin
- Niravam. *See* Alprazolam
- Nirmatrelvir/ritonavir, 1208
- Nisoldipine, 522t
- Nitazoxanide (Alinia), 1286–1287, 1286t
 actions of, 1286
 adverse effects of, 1286
 drug interactions with, 1286–1287
 pharmacokinetics, 1284t
 therapeutic uses for, 1286
- Nitrates, sildenafil and, 820
- Nitrites, volatile, 473
- Nitrofurantoin (Furadantin, Macrochantin, Macrobid), 1149t
 adverse effects
 birth defects, 1150
 gastrointestinal effects, 1150
 hematologic effects, 1150
 hepatotoxicity, 1150
 peripheral neuropathy, 1150
 pulmonary reactions, 1150
 antimicrobial spectrum, 1149–1150
 mechanism of action, 1149
 therapeutic use, 1149–1150
 urinary tract infections (UTIs), 1149–1150, 1149t
- Nitrogen mustards
 bendamustine, 1309
 chlorambucil, 1309
 cyclophosphamide, 1309
 ifosfamide, 1309
 melphalan, 1309
- Nitroglycerin, 611–615, 651
 for acute care, 557
 adverse effects, 612–613
 antianginal effects mechanism, 612
 discontinuing, 615
 drug interactions, 613
 metabolism of, 39
- Nitroglycerin (*Continued*)
 pharmacokinetics, 612
 preparations and routes of administration, 613–615, 613t–614t
 intravenous infusion, 615
 sublingual tablets and powder, 614
 sustained-release oral capsules, 614
 topical ointment, 615
 transdermal delivery systems, 615
 translingual spray, 615
 therapeutic uses, 615
 tolerance, 613
 vasodilator actions, 612, 612f
- Nitropruss. *See* Sodium nitroprusside
- Nitrosoureas, 1309
 carmustine (BCNU), 1309
 lomustine (CCNU), 1309
 streptozocin, 1309
- Nitrous oxide, 302–303
- Nix. *See* Permethrin
- Nizatidine, for PUD, 1011–1012
- Nizoral. *See* Ketoconazole
- NMS. *See* Neuroleptic malignant syndrome
- Nociceptive pain, 328, 569
- Nolvadex. *See* Tamoxifen
- Nolvadex-D. *See* Tamoxifen
- Nonadherence
 defined, 80
 variability due to, 80
- Nonanthracyclines, 1316
- Nonarteritic ischemic optic neuropathy (NAION), with sildenafil, 819
- Noncatecholamines, 169, 169f
- Noncompetitive antagonists, 51, 52f
- Non-cytotoxic drugs
 for breast cancer, 1327–1329
 hormonal agents and immunotherapies, 1327
 treatment modalities, 1327
 for prostate cancer, 1332
 drug choices, 1332
 treatment modalities, 1332
- Nondiabetic nephropathy, 505–506
- Non-dihydropyridines, 518–520
- Nondrug methods, poison removal, 1397
- Nongonococcal urethritis (NGU), 1256
 characteristics, 1256
 definition, 1256
 treatment, 1256, 1257b
- Nongrowth-hormone-deficient (NGHD) short stature, pediatric, 742
- Non-HIV viral infections, 1186–1211, 1187t
- Noninsulin medications, 704–713, 705t
 adjunctive oral agents, 713
 adverse effects, 704, 705t
 alpha-glucosidase inhibitors, 711, 712t
 amylin mimetic (pramlintide), 716
 biguanides (metformin), 704–708, 706t, 708t
 combination injectable agents, 716
 combination oral products, 713, 714t
 dipeptidyl peptidase-4 inhibitors, 711–712, 712t
 glucagon-like peptide-1 receptor agonists, 713–715, 714t–715t
 meglitinides, 709, 710t
 sodium-glucose Co-transporter 2 inhibitors, 712–713, 713t
 sulfonylureas, 708–709, 709t
 thiazolidinediones, 710–711, 711t
 tirzepatide (Mounjaro), 716
- Non-nicotine therapy, 458
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs), 1154–1155, 1216, 1222–1225
 adverse effects, 1223
 doravirine, 1225

- Non-nucleoside reverse transcriptase inhibitors (NNRTIs) (*Continued*)
 drug interactions, 1223
 efavirenz, 1223–1224
 etravirine, 1225
 mechanism of action, 1222–1223
 nevirapine, 1224–1225
 pharmacokinetic properties, 1223, 1223t
 preparation and dosage, 1223, 1223t
 rilpivirine, 1225
- Nonoccupational postexposure prophylaxis, 1238
- Nonopioid analgesics, 332–333, 333t, 571, 579t
- Nonopioid antitussives, 1005
- Nonradioactive iodine, 735–736, 735t
- Nonsedative central nervous system effects, of
 H₁ antagonists, 886
- Nonsteroidal anti-inflammatory drugs (NSAIDs), 804, 891–892
 ACE inhibitors, 507
 alcohol and, 446
 for allergic conjunctivitis, 1356
 for cancer pain management, 333, 571
 clinical pharmacology of, 898t
 first-generation, 892–897, 892b
 adverse effects of, 893t
 aspirin, 892–897
 ibuprofen, 897–898, 898t–900t
 indications for, 893t
 inhibition, 891–892
 and glucocorticoid therapy, 914
 for gout, 936–937, 937t–938t
 indications for, 899t–900t
 interactions of, with lithium, 397
 nonaspirin
 indications for, 897
 interaction with aspirin, 897
 properties of, 897
 nursing implications for, 905–907
 for PUD, 1008
 for RA
 classification of, 921
 dosages of, 921, 922t
 drug selection of, 921
 first-generation, 922t
 given with DMARDs, 921
 role, 920
 second-generation, 922t
 therapeutic role, 921
 second-generation, celecoxib, 900–901
- Nonstimulants alpha₂-adrenergic agonists, for
 ADHD, 431–432
- Norditropin, 742, 744t. *See also* Somatropin
 (human growth hormone)
- Norepinephrine (NE), 122, 175
 inactivation, inhibition of, 168
 life cycle of, 130f, 129–130
 release, 168
 reuptake, 168
- Norpramin. *See* Desipramine
- North American Menopause Society, 809
- Nortriptyline (Aventyl, Pamelor), 336t,
 374t–375t, 572t
- Norvir. *See* Ritonavir
- Novantrone. *See* Mitoxantrone
- Novavax COVID-19 vaccine, 1208,
 1208t–1209t
- Novo-AZT. *See* Zidovudine
- Nplate. *See* Romiplostim
- NRT. *See* Nicotine replacement therapy
- NRTIs. *See* Nucleoside/nucleotide reverse
 transcriptase inhibitors
- NSAIDs. *See* Nonsteroidal anti-inflammatory
 drugs (NSAIDs)
- NS5A inhibitors, 1195–1197, 1197t–1198t
- NS5B inhibitors, 1197–1198, 1197t–1198t
- NSF International, 1070
- Nuclear bombs, 1407
 radioactive fallout of, 1407
- Nuclear power plants, attack on, 1407
- Nucleic acid amplification (NAA) test, to
 identify infecting organism, 1093
- Nucleoside analogs, 1197t–1198t, 1200t–1201t,
 1201–1202
 adefovir (Hepsera), 1201–1202
 entecavir (Baraclude), 1202
 lamivudine (Epivir HBV, Heptovir), 1201
 tenofovir, 1202
- Nucleoside/nucleotide reverse transcriptase
 inhibitors (NRTIs), 1216–1222
 abacavir, 1218–1220
 adverse effects, 1218
 combination products, 1217
 didanosine, 1221
 drug interactions, 1218
 emtricitabine, 1222
 fixed-dose combination, 1217, 1217t–1218t
 lamivudine, 1220
 mechanism of action, 1218
 pharmacokinetic properties, 1218, 1219t
 preparation, dosage, and administration,
 1218, 1219t
 stavudine, 1221–1222
 tenofovir disoproxil fumarate, 1222
 zidovudine, 1220–1221
- Nurse, as patient advocate, 6
- Nursing interventions, identification of, 12
- Nutropin, 744t. *See also* Somatropin (human
 growth hormone)
- Nuvigil. *See* Armodafinil
- NVICP. *See* National Vaccine Injury
 Compensation Program
- NVX-CoV2373 COVID-19 vaccine,
 1208t–1209t
- Nyaderm. *See* Nystatin
- Nystagmus, 262–263
- Nystatin, 1183
- Nytol. *See* Diphenhydramine
- O**
- Obesity
 as chronic disease, 1058
 lifestyle therapy components, 1060, 1061b
 pathophysiology, 1060
 pediatric, 1058
 prevalence of, 1058
 treatment, 1060–1061
 goal, 1060
 modalities, 1061
 stages, 1060
- Obiltoximab, for inhalational anthrax, 1401
- Obsession, defined, 419–420
- Obsessive-compulsive disorder (OCD),
 419–420
 characteristics of, 419–420
 drug therapy for, 416, 417t
 treatment of, 420
- Occupational Postexposure Prophylaxis,
 1238–1239
- OCD. *See* Obsessive-compulsive disorder
- Octreotide (Sandostatin, Sandostatin LAR
 Depot), 742, 743t
- Ocular herpes infections
 ganciclovir gel, 1191
 trifluridine ophthalmic solution, 1191
- Ofatumumab (Arzerra), 1339t–1340t
- Off-label use, 15
- Ofirmev. *See* Acetaminophen
- OGTT. *See* Oral glucose tolerance test
- Ointments, 1363
- Olanzapine (Seroquel, Zyprexa), 358t–359t,
 363t, 394t
 in BPD, 394t
- Olanzapine/fluoxetine (Symbyax), 394t
- Older adults
 adrenal cortex drugs for, 749t
 alcohol, 447t
 aminoglycosides, 1131t
 and androgen therapy, 808t–809t
 anthelmintics for, 1271t
 antibacterial drugs, 1170t
 antidepressants, 379t
 antiemetics, 1036t
 antifungal drugs, 1178t
 antihistamine for, 885t
 antiinflammatory agents, 973t
 antimalarial drugs for, 1280t
 antimicrobials for, 1095t
 antiprotozoal drugs, 1285t
 and bisphosphonates, 952t
 bronchodilator, 980t
 calcium channel blockers, 520t
 cancer pain management in, 338–339, 579
 carbapenems for, 1113t
 CCR5 antagonists, 1233t
 cephalosporins for, 1113t
 CNS stimulants for, 426t
 disease-modifying antirheumatic drugs, 923t
 diuretics, 481t
 drug avoidance in, 110t
 and drugs affecting bone, 961t
 drug therapy, 107–112
 dyslipidemia, 592t
 ectoparasitocides for, 1292t
 estrogens and, 760t
 first-line drug for TB, 1154t
 glucocorticoids in, 913t
 gout drugs
 hepatitis B, 1201t
 hepatitis C, 1195t
 herpes virus and varicella zoster virus
 infections, 1189t
 HIV fusion inhibitors, 1233t
 hypertension, 544–545, 545t
 immunosuppressants in, 872t
 integrase strand transfer inhibitors, 1233t
 laxative use of, 1022t
 monoclonal antibodies, asthma, 978t
 multiple sclerosis, 240t
 nonnucleoside reverse transcriptase
 inhibitors, 1225t
 NSAIDs for, 896t
 nucleoside reverse transcriptase inhibitors,
 1220t
 opioid analgesics, 323t
 Parkinson disease, 218t
 penicillin care in, 1104t
 pharmacodynamic changes in, 108
 post-attachment inhibitors, 1233t
 progestins and, 762t
 protease inhibitors, 1228t
 PUD in, 1016t
 RAAS inhibitors, 502t
 sexually transmitted infections, 1253t
 sulfonamides, 1139t
 tetracyclines in, 1121t
 trimethoprim, 1139t
 urinary tract infections, 1150t
 vasodilators, 528t
 weight-loss drugs for, 1064t
- Oleptro. *See* Trazodone
- Olopatadine (Patanase), 887
 for allergic rhinitis, 1001t
- Olysio. *See* Simeprevir
- Omalizumab (Xolair), 88, 977–978, 978t, 1004

- Omeclamox-Pak, 1011
- Omeprazole (Prilosec, Zegerid, Losec), 1014–1016
adverse effects of, 1014–1015
mechanism of action, 1013f, 1014
pharmacokinetics, 1014
therapeutic use, 1014
- Omnitrope, 744t. *See also* Somatropin (human growth hormone)
- Onchocerciasis, 1269
- Oncogenes, and cancer cells, 1295
- Ondansetron (Zofran, Zofran ODT, Zuplenz), 1032, 1033t–1034t, 1036t
- Oxol. *See* Paclitaxel
- Onychomycosis (fungal infection of the nails), 1181
- Opicapone (Ongentys), 219, 219t
- Opioid agonists
clinical pharmacology and pharmacokinetics, 313t–314t
codeine, 316–317
fentanyl, 313–315
meperidine, 315
methadone, 315–316
moderate to strong, 316–317, 316t
- Opioid analgesics
for cancer pain, 333–336, 571–572
for breakthrough pain, 335, 574–575
dosage of, 334, 573
drug selection for, 334, 572
mechanism of action and classification, 334, 572
routes of administration, 334–335, 573
side effects of, management of, 335–336, 574–575
tolerance and physical dependence on, 334, 572
for migraine headaches, 345t
- Opioid antagonists, 318–319
morphine and, 312
naloxone as, 318–319
- Opioid antitussives, 1004–1005
- Opioid family, 306
- Opioid receptors, 307
- Opioids, 300, 460–463
abuse liability of, 308t
antidiarrheal agents, 1037–1038
for cancer-related pain, 323
clinical use of, 320–323
dosing guidelines for, 321
avoiding a withdrawal reaction in, 321
dosage determination in, 321
pain assessment in, 321
endogenous peptides of, 306–307
with FDA-approved labeling describing abuse-deterrent properties, 321t
maximal pain relief of, 308t
for myocardial infarction, 323
patient-controlled analgesia with, 321–322
for postoperative pain, 322–323
prototype drugs for, 308b
receptors of, 307
terminology for, 306–307
- Opioid use disorder (OUD), 339–340, 580
long-term management of, 461–462, 462t
buprenorphine, 461–462
methadone, 461
naltrexone, 462
patterns of use, 460
subjective and behavioral effects, 460
tolerance and physical dependence, 461
treatment of acute toxicity, 461
- Opium tincture, 1038, 1038t
- Opioids, 849
- Oral administration, 103–104
of opioids, 334
- Oral antidiabetic drugs, 706t
- Oral calcium salts
adverse effects, 946
drug interactions, 946–947
food interactions, 947
nursing implications, 964–965
preparations and dosage, 947, 947t
therapeutic uses, 946
- Oral candidiasis, 1181
- Oral contraceptives (OCs)
for acne in women, 1371
combination, 773–778
adverse effects, 773–776, 774t
components, 773, 773t
dosing schedules, 777
drug interactions, 776
effectiveness, 773
mechanism of action, 773
missed doses, 777–778
noncontraceptive benefits, 776
nursing implications, 784–785
preparations, 776–777, 777t
safety, 773–776
side effects, 775, 776t
long-acting, 779
depot medroxyprogesterone acetate, 779–780
intrauterine devices, 780
subdermal etonogestrel implants, 779
menorrhagia, 804
progestin-only, 778
transdermal contraceptive patch, 778
vaginal contraceptive ring, 778–779
- Oral drug administration, 31t, 33, 33f
- Oral glucocorticoids
adverse effects, 974
preparations, dosage, and administration, 974–975
therapeutic use, 973
- Oral glucose tolerance test (OGTT), 693
- Oral hypoglycemics, 914
- Oral poliovirus vaccine (OPV), 862
- Oral potassium chloride, 490–491
- Oral spray (Zolpimist), 412t
- Oral sumatriptan, 346
- Oral therapy
aminoglycosides, 1130–1131
for onychomycosis, 1181
tetracyclines, 1120
urinary tract infections, 1147, 1147t
- Orap. *See* Pimozide
- Orencia. *See* Abatacept
- Orexin antagonist, 408
- Orexin receptor antagonist, 406t
- Organic nitrates
brand names and dosages, 614t
nitroglycerin, 611–615
time course of action, 613t
- Organic solvents, 473
- Organ-specific toxicity, 65–66
hepatotoxic drugs, 65–66, 66t
QT interval drugs, 66, 67t
- Oritavancin (Orbactiv), 1115, 1116t, 1171t
- Orlistat (Xenical, Alli), 1061–1062
actions and use of, 1061–1062
adverse effects of, 1062
contraindications, 1062
drug and nutrient interactions with, 1062
and hypothyroidism, 1062b
pharmacokinetics, 1062t
preparations, dosages, and administration, 1063t
- Ornidyl. *See* Eflornithine
- Orphenadrine, 284t–286t
- Orthopedic surgery, for RA, 920
- Orthostatic hypotension, 497–498, 612
from alpha-adrenergic antagonists, 183
with FGAs, 361
with MAOIs, 383–384
morphine and, 309
in Parkinson disease patient, 222
with SGAs, 365
with TCAs, 380
- Oseltamivir (Tamiflu)
actions and uses, 1205
adverse effects and interactions, 1205–1206
pharmacokinetics, 1205, 1205t
preparation and dosage, 1205, 1206t
prophylactic therapy, indications for, 1206
- Osmolality disorders, 488–489
- Osmotic diuretics, 484
adverse effects, 484
mechanism of action, 484
pharmacokinetics, 484
therapeutic uses, 484
- Osmotic laxatives, 1023t–1024t, 1026–1027
- Osteomalacia, 949
- Osteonecrosis of jaw (ONJ)
with denosumab, 960
with zoledronate, 957
- Osteoporosis, 960–962
bone mass in, 961
diagnosing, 961–962
economic burden of, 961
fracture risk assessment, 961–962, 962t
general considerations, 960–962
glucocorticoid-induced, 954
in men, 954, 962
monoclonal antibodies for, 959–960
pharmacokinetics, 955t
prevention, 765
primary prevention of, 961
with prolonged systemic glucocorticoid therapy, 912
in women, 954, 962
- Otitis externa (OE), 1392–1393
acute, 1392–1393
fungal, 1393
necrotizing, 1393
- Otitis media (OM)
acute
antibacterial drugs for, 1390t
antibiotic-resistant, 1391
characteristics of, 1388
diagnosis of, 1389
microbiology of, 1388
observation vs. antibacterial therapy for, 1390t
pathogenesis of, 1388
prevention of, 1391
treatment of, 1389–1391
causes of, 1388
definition of, 1388
with effusion, 1392
prophylactic antibacterial therapy for, 1391–1392
recurrent, 1391–1392
tympanostomy tubes for, 1392
short-term antibacterial therapy for, 1391
- Ototoxic drugs, 1133
- Ototoxicity
aminoglycosides, 1132, 1132b
risk of, 1132
with furosemide, 481
with vancomycin, 1115
- Ovarian hyperstimulation syndrome, 791
- Overactive bladder (OAB)
anticholinergic therapy, 139t, 143
characteristics, 142–143
drugs for, 143–147

INDEX

- Overactive bladder (OAB) (*Continued*)
 pharmacokinetics, 145t
 preparation, dosage, and administration, 144t
 treatment, 143
- Over-the-counter (OTC) drugs
 benefits of, 22
 defined, 22
 risks of, 22–23
- Over-the-counter products, 20–21, 21t
- Overweight, prevalence of, 1060
- Ovide. *See* Malathion
- Oxacillin, 1104–1105, 1105t
- Oxaliplatin (Eloxatin), 1314
- Oxaliplatin (generic), 1314t
- Oxaprozin (Daypro)
 clinical pharmacology of, 898t
 indication and dosing of, 899t–900t
- Oxazepam, 403
 applications of, 404t
- Oxcarbazepine, 268–278
 adverse effects, 268
 drug interactions, 268–269
 mechanism of action, 268
 monitoring, 269
 preparation, dosage, administration, 269, 269t–271t
 therapeutic uses, 268
- Oxecta. *See* Oxycodone
- Oxidative stress, 1051b
- Oxybarbiturates, 303
- Oxybutynin, 143–145, 144t–145t
 topical gel, 145
 transdermal patch, 145
- Oxychlorosene sodium (Clorpactin WCS 90), 1261t, 1262
- Oxycodone, 317, 461
 preparation and dosage, 316t
- OxyContin. *See* Oxycodone
- Oxygen, 651
- Oxygen demand, 609–610
- Oxygen supply, 610
- OxyIR. *See* Oxycodone
- Oxymetazoline (Afrin 12-Hour, Neo-Synephrine 12-Hour, Dristan 12-Hour, others), for nasal decongestion, 1003t
- Oxymorphone, 316, 316t
- Oxytocic drugs, 795, 796t
- Oxytocin (Pitocin), 739–740
 cervical ripening and induction, labor, 801–802
 abortion, 802
 augmentation of labor, 802
 physiologic and pharmacologic effects, 801
 postpartum use, 802
 nursing implications, 805–806
 postpartum hemorrhage, 802
- P**
- Paclitaxel (Abraxane, Onxol, Taxol), 1322t
 for breast cancer, 1328t–1329t
- Paget disease of bone, 946, 954
- Pain
 in cancer patients, 328, 569
 defined, 570, 327
 management, 658–659
 neurophysiologic basis of, 327–328, 569
 nociceptive vs. neuropathic, 328, 569
 pathophysiology of, 327–328, 569–571
- Pain intensity scales, 330, 331f, 570–571, 570f
- Pain management, for cancer
 around-the-clock (ATC) schedule for, 332, 581
 assessment of, 328–331, 569–571
 barriers to, 331, 571
- Pain management, for cancer (*Continued*)
 comprehensive initial assessment, 330, 569–571
 diagnostic tests, 330, 570
 pain intensity scales, 330, 331f, 570–571, 570f
 patient self-report of, 330, 570
 physical and neurologic examinations, 330, 570
 psychosocial, 330, 570
 barriers to, 328t, 574t
 in children, 574, 331
 drug therapy for, 331–337, 571
 adjuvant analgesics, 336–337, 575
 nonopioid analgesics, 332–333, 333t, 571, 579t
 opioid analgesics, 333–336, 571–572
 World Health Organization (WHO)
 analgesic ladder for, 331–332, 332f, 573f, 574
 flow chart, 328–329, 329f, 569f, 571
 nondrug therapy of, 337–338, 576
 invasive procedures for, 337, 576
 physical and psychosocial interventions for, 337–338, 576–580
 in older adults, 338–339, 579
 ongoing evaluation, 330–331, 571
 opioid use disorder, 339–340, 580
 patient education in, 340, 580
 in young children, 339, 579
 assessment of, 339, 579
 preverbal and nonverbal, 339, 580
 treatment for, 339, 580
 verbal, 339, 579–580
- Palifermin (Kepivance), 1043
- Palivizumab (Synagis), 868, 1205t–1206t, 1207
- Palonosetron (Aloxi), 1033t, 1034, 1036, 1036t
- Pamelor. *See* Nortriptyline
- Pamidronate (Aredia)
 indications, preparation, and dosage, and administration, 953t–954t
 pharmacology of, 957, 1332
- Pancreas, effect of alcohol on, 443
- Pancreatic enzymes, 1043–1044
- Pancreatitis, 1221
 stavudine, 1221
- Pancrelipase, 1043
- Pancuronium, 163
- Panic disorder
 benzodiazepines for, 419
 characteristics of, 418–419
 drugs for, 417t
 etiology, 419
 symptoms, 418–419
 treatment for, 419
- Panitumumab (Vectibix), 1337t–1338t
- Pantoprazole, for PUD, 1010t
- Pantothenic acid (vitamin B₅), 1048t–1050t, 1053t, 1056
- Papanicolaou (Pap) test, 859, 867
- Papaverine plus phentolamine, 822
- Para*-aminobenzoic acid (PABA), 1136, 1137f
 antituberculosis drugs, 1163–1164
- Paracoccidioidomycosis, systemic mycoses, drugs of, 1175t
- PARADIGM-HF study, 556
- Paradoxical effect
 with benzodiazepines, 404
 defined, 65
- Parasitic worms, classification of, 1267
- Parasympathetic nervous system
 anatomy, 121–122, 121f
 functions, 119–120
- Parasympatholytic drugs. *See* Muscarinic antagonists
- Parasympathomimetic agents. *See* Muscarinic antagonists
- Parathyroid hormone (PTH) analogs, 959
 abaloparatide, 955t, 959
 teriparatide, 955t, 959
- Parathyroid hormone (PTH), and calcium levels, 945, 945t
- Paregoric, 1038
- Parenteral calcium salts
 adverse effects, 947
 dosage and administration, 947, 947t
 drug interactions, 947
 nursing implications, 965
 therapeutic use, 947
- Parenteral drug administration, 31t, 33–34
- Parenteral fentanyl, 314
- Parenteral therapy, aminoglycosides, 1130
- Paricalcitol (Zemlar), 950, 951t
- Parkinson disease (PD), 207
 clinical guidelines, 209
 dopaminergic agents for, 209t
 motor symptoms, 207–208
 drug selection, 209
 drugs used, 209
 management, 208–209
 pharmacology of drugs, 210–222
 therapeutic goal, 208
 nonmotor symptoms, 222–223
 autonomic symptoms, 222
 neuropsychiatric symptoms, 223
 sleep disturbances, 222–223
 pathogenesis, 207
 pathophysiology, 207–208, 208f
 pharmacokinetics of drugs for, 212t
 pharmacology, 210–222
 adenosine receptor antagonist, 221–222, 221t
 catechol-*O*-methyltransferase inhibitors, 218–219, 219t
 centrally acting anticholinergic drugs, 221t, 222
 dopamine receptor agonists, 215–218, 217t
 levodopa, 210–214, 210t, 211f, 212t
 MAO-B inhibitors, 219–220, 220t
 N-methyl-*D*-aspartate receptor antagonist, 220–221, 221t
 prototype drugs, 216b
- Parkinsonism, 360t
 antipsychotic-induced, 360
- Paromomycin, 1284t, 1286t, 1287
- Paroxetine (Paxil, Paxil CR, Pexeva), 374t–376t
 for GAD, 417
 for OCD, 420
 for panic disorder, 419
 for PTSD, 421
 for social anxiety disorder, 420
- Partial agonists, 52
- Pasireotide, 742, 743t
- Passive tubular reabsorption, 39–40
- Pastes, 1364
- Patanase. *See* Olopatadine
- Patient-controlled analgesia (PCA), 321–322, 334–335, 573–574
- Patient education
 for cancer pain management, 340, 580
 for patient-controlled analgesia, 322
- Patient teaching, in bone marrow suppression, 1301
- Paxil. *See* Paroxetine
- Paxil CR. *See* Paroxetine
- Pazopanib (Votrient), 1337t–1338t
- PCA. *See* Patient-controlled analgesia
- Peace pill. *See* Phencyclidine
- Peak concentration, drug, 43
- Pediatric Endocrine Society, 831b

- Pediatric patients, drug therapy, 102–106
 Pediatric Research Equity Act (PREA), 15, 102
 Pediculicides, for lice infestation, 1288
 Pediculosis
 body lice, 1288
 head lice, 1288
 infestation with lice, 1288–1289
 pubic lice, 1288–1289
 PedvaxHIB (Hib vaccine), 863
 Peer support groups, for pain management, 338, 579
 Peg-asparaginase (Oncaspar), 1324t
 Pegfilgrastim (Neulasta), 685
 for neutropenia, 1302
 Peginterferon alfa-2a, 1187t, 1197t–1198t, 1199–1201, 1200t–1201t
 Peglax. *See* Polyethylene glycol
 Pegloticase (Krystexxa), 941–942, 942b
 adverse effects of, 941–942
 mechanism of action, 941
 pharmacokinetics of, 938t
 preparations, dosages, and administration of, 937t–938t
 reduce uric acid levels, 940, 940f
 therapeutic use, 941–942
 Pegvisomant (Somavert), 742, 743t
 Pellagra, 1054
 Pelvic inflammatory disease, 1249b, 1257
 characteristics, 1257
 treatment, 1257, 1257b–1258b
 Pemetrexed (Alimta), 1314, 1317t–1318t
 Penciclovir (Denavir), 1190t
 herpes labialis, 1191
 Penicillamine (Cuprimine), 926
 Penicillin, 1099–1101
 allergic reaction to, 1103–1104, 1103b
 aminoglycosides, 1132
 bacterial resistance to, 1099–1101
 altered penicillin-binding proteins, 1100–1101
 beta-lactamases in, 1100–1101
 gram-negative cell envelope, 1099–1100, 1100f
 with beta-lactamase inhibitor, 1106
 broad-spectrum, 1105–1106
 amoxicillin, 1105–1106
 ampicillin, 1105, 1105t
 chemistry of, 1101
 classification of, 1101, 1103t
 dosages for, 1105t
 drug interactions with, 1104
 extended-spectrum, 1106
 mechanism of action for, 1099, 1100f
 nursing implications for, 1107
 penicillinase-resistant, 1104–1105
 properties of, penicillin G, 1101–1104, 1103f
 sexually transmitted diseases, 1251
 Penicillin allergy, 1103–1104, 1391
 and anaphylaxis, 1103b
 cross-sensitivity to cephalosporins, 1103
 development of, 1104
 general considerations, 1103
 management of patients with history of, 1104
 skin tests for, 1104
 types of allergic reactions, 1103–1104
 Penicillinases (beta-lactamases), 1100–1101, 1100f
 Penicillin-binding proteins (PBPs), 1099, 1100f, 1101
 Penicillin G, 1101–1104, 1105t, 1254
 antimicrobial spectrum for, 1101
 pharmacokinetics of, 1101–1103, 1103f
 side effects and toxicities of, 1103
 Penicillin V, 1104, 1105t
 Penicillin VK, 1104
 Penlac Nail Lacquer. *See* Ciclopirox
 Pentasa. *See* Mesalamine
 Pentazocine, 317–318, 317t
 Pentetate calcium trisodium, 1407–1408
 Pentetate zinc trisodium, for radiation emergencies, 1407–1408
 Pentostatin (Nipent), 1314, 1317t–1318t
 Peppermint (*Mentha piperita*), 1079
 Pepsin, in PUD, 1008
 Peptic ulcer disease (PUD)
 antibiotics employed, 1011
 atropine for, 140
 bicarbonate in, 1007–1008
 blood flow in, 1008
 drugs for
 antibacterial drugs, 1009–1011
 antibiotic regimens, 1011, 1012t
 antiulcer drugs, 1016–1017
 Helicobacter pylori-associated ulcers, 1009
 NSAID-induced ulcers, 1009
 proton pump inhibitors, 1014–1016
 Helicobacter pylori, tests for, 1011
 histamine₂ receptor antagonists for, 1011–1014
 mucus in, 1007
 nondrug therapy for, 1009
 nursing implications, 1019–1020
 pathogenesis of, 1007–1009
 aggressive factors of, 1008–1009
 defensive factors of, 1007–1008
 prostaglandins in, 1008
 prototype drugs for, 1012b
 risk with glucocorticoid therapy, 913
 tetracyclines for, 1120
 treatment of, 1009, 1010t
 Peramivir, 1206
 Perampanel (Fycompa), 275
 Perindopril, 505t, 508
 Periodontal disease, tetracyclines for, 1120
 Periostat. *See* Doxycycline
 Peripartum depression (PPD), 387–389
 etiology of, 388
 incidence of, 388
 treatment of, 388–389
 Peripheral circulation, 493
 Peripheral effects, H₁ antagonists, 884
 Peripheral nervous system (PNS), 119
 adrenergic receptor subtypes, 125f, 127t, 128–129
 adrenergic transmitters, receptor specificity, 129, 129t
 cholinergic receptor subtypes, 125f, 126t, 128
 drugs, 116–117
 learning approach, 117
 drug structure and receptor selectivity, 124f
 receptors, 122–123
 locations, 125
 subtypes, 123–125, 123t
 transmitters of, 123f, 122
 Peripheral neuropathy, stavudine, 1221
 Perjeta. *See* Pertuzumab
 Permethrin (Nix, Elimite, Acticin, Kwellada-P), 1288, 1289t, 1290, 1291t
 adverse effects of, 1290
 pharmacokinetics of, 1290
 preparations and administration, 1290
 resistance to, 1290
 Perphenazine, 358t–359t
 Personalized medicine, 81
 Pertussis
 characteristics of, 857
 products for immunization against, 862t
 Pertuzumab (Perjeta), 1328t–1329t
 Petit mal seizure. *See* Absence seizures
 Pexeva. *See* Paroxetine
 Pfizer-BioNTech COVID-19 vaccine, 1208, 1208t–1209t
 P-glycoprotein (PGP), 27, 1082
 in drug chemotherapy, 1299
 Pharmacodynamics
 defined, 45
 dose-response relationships, 45–47
 features, 45–46, 46f
 maximal efficacy, 46–47, 46f
 relative potency, 46f, 47
 drug-receptor interactions, 47–52
 agonists, 51
 antagonists, 51–52
 cell membrane-embedded enzymes, 48
 defined, 47
 G protein-coupled receptor systems, 48
 ligand-gated ion channels, 48
 modified occupancy theory, 50–51
 for norepinephrine, 48f
 partial agonists, 52
 properties of, 47
 receptor families, 48, 49f
 and selectivity, 48–50, 49f
 sensitivity regulation, 52
 simple occupancy theory, 50, 50f
 transcription factors, 48
 drug responses, 52–53
 clinical implications, interpatient variability, 53–54
 ED₅₀, 53
 interpatient variability, 53–54, 53f
 therapeutic index, 54, 54f
 Pharmacodynamic tolerance, 78
 Pharmacogenomics, 81–82
 application of, 82, 83t
 barriers to, 85–86
 defined, 79, 81
 genetic resources, 83t
 genetic variants
 alter drug metabolism, 82–84
 alter drug targets, 84–85
 alter immune responses, 85
 influence of, 81–82
 testing, 85
 warfarin package, 82f
 Pharmacokinetics
 absorption, 29–34
 adrenergic agonists, 174t
 alpha-adrenergic antagonists, 184t
 alpha₂ agonists, centrally acting, 200t
 chemophobes, 26
 children 1 year and older, 104–105
 dissimilarity to adults, 105
 similarity to adults, 104
 cholinesterase inhibitors, 151, 151t
 competitive (nondepolarizing) neuromuscular blockers, 161, 162t
 distribution, 34–36
 drugs passage
 cell membrane, 26–29
 membrane structure, 26–27, 27f
 epinephrine, 173–174
 excretion, 39–40
 growing pediatric patient
 adherence, 105, 106t
 adverse drug reactions, 105, 105t
 dosage determination, 105
 hydralazine, 527
 inhalation anesthetics, 299–300
 for interferon beta preparations, 245, 247t
 levodopa, 210, 212t
 metabolism, 36–39
 mitoxantrone, 247, 247t
 muscarinic agonists, 133–134, 134t
 muscarinic antagonists, 139

- Pharmacokinetics (*Continued*)
 neonates and infants, 103–104, 104f
 absorption, 103–104
 distribution, 104
 drug sensitivity, 103
 excretion, 104
 metabolism, 104
 in nursing practice, 26
 in older adults
 absorption, 107–108
 adherence promotion measures, 110–111
 adverse drug reactions, 108–109, 109t
 distribution, 108
 end-of-life care, 111, 111t–112t
 excretion, 108
 metabolism, 108
 nonadherence, 109–110, 111t
 physiologic changes, 107, 108t
 processes, 25, 26f
 therapeutic application of, 25–26
 time course of drug responses, 40–43
- Pharmacology
 application of
 patient care, 6–8
 patient education, 8–9
 defined, 1
- Pharmacotherapeutics, 2
- Pharyngeal infection, 1252
 trimethoprim/sulfamethoxazole, 1142–1143
- Phenadoz. *See* Promethazine
- Phencyclidine
 chemistry and pharmacokinetics, 471
 mechanism of action, 471
 subjective and behavioral effects, 471–472
- Phenelzine, 374t–375t
- Phenergan. *See* Promethazine
- Phenobarbital, 267, 463
- Phenothiazines, 1033t, 1035
 H₁ antagonists
 brand names, routes, and dosage, 888t
 pharmacologic effects of, 886t
- Phenoxybenzamine, 184t, 186, 186t
- Phentermine, 1064–1065
- Phentermine/topiramate (Qsymia)
 actions and use, 1065
 adverse effects, 1065
 contraindications, 1065
 drug interactions with, 1065
 pharmacokinetics, 1062t
 preparations, dosages, and administration, 1063t
- Phentolamine, 184t, 185, 186t
- Phenylephrine (Neo-Synephrine, others), 177, 1003
 adverse effects of, 1356
 for mydriasis, 1355–1356
 for nasal decongestion, 1003t
- Phenytek. *See* Phenytoin
- Phenytoin (Dilantin), 261–268, 261b
 adverse effects, 262–263
 antifungal drugs, 1179t
 drug interactions, 263–264
 mechanism of action, 261
 monitoring, 264
 pharmacokinetics, 261–262, 262f, 262t
 preparations, dosage, and administration, 264
 safety alert, 263b
 therapeutic uses, 261
- Pheochromocytoma, 182–183, 188
- Phosphate, and PTH levels, 945t
- Phosphodiesterase-4 inhibitor, 992
 roflumilast, 979–980
- Phosphodiesterase inhibitors, in heart failure, 557
- Phosphodiesterase type 5 (PDE5) inhibitors, 613b, 817
 avanafil, 820t, 821
 comparison of, 819t
 of erectile dysfunction, 816–817
 nursing implications, 828
 sildenafil, 817–821, 820t
 tadalafil, 820t, 821
 vardenafil, 820t, 821
- Phospholipids, 26–27
- Phosphorylation, 91
- Photochemotherapy (PUVA therapy), for psoriasis, 1378
- Photodynamic therapy, for ARMD, 1359
- Photophobia, anticholinergic agents, 1355
- Photosensitivity, with tetracyclines, 1121
- Phototherapy, for psoriasis, 1378
- Phototoxicity, ciprofloxacin, 1170
- Physical dependence
 alcohol, 445
 barbiturates, 463
 defined, 65, 205, 311
 opioid use, 461
- Physical therapy, for RA, 920
- Physicians' Desk Reference, 23
- Physostigmine, 152
 pharmacokinetics, 151t
 preparations, dosage, and administration, 152t
- Phytoestrogens, 761
- Pilocarpine, 134t, 135, 1352–1353, 1353t
- Pimecrolimus, 871
- Pimecrolimus 1% cream (Elidel), for eczema, 1381–1382
- Pimozide (Orap), antifungal drugs, 1179t
- Pinworm infestation, 1268
- Piperacillin, 1105t, 1106
- Piperazines, H₁ antagonists
 brand names, routes, and dosage, 888t
 pharmacologic effects of, 886t
- Piperidines, H₁ antagonists
 brand names, routes, and dosage, 888t
 pharmacologic effects of, 886t
- Piper methysticum. *See* Kava
- Piroxicam (Feldene)
 clinical pharmacology of, 898t
 indication and dosing of, 899t–900t
- Pitocin. *See* Oxytocin
- Pituitary function, drugs related to, 739–747
- Pituitary gland
 anatomy of, 739, 740f
 anterior
 feedback regulation of, 740, 740f
 hormones of, 739
 thyroid function regulation by, 728–729, 728f
 posterior, hormones of, 739–740
 widespread effects of, 739, 740f
- Pituitary hormones, menstrual cycle, 757
- Placebo effect, 78
- Placental drug transfer, 35–36, 35f, 95
- Plant stanol, 605–606
- Plasma-Derived Factor VIII, 659
- Plasma drug levels, 40–41
 clinical significance, 41
 minimum effective concentration, 41
 therapeutic range, 41, 41f
 toxic concentration, 41
- Plasma lipid levels, 597–601
- Plasma lipoproteins, 588–590
 properties of, 589t
 structure of, 588f
- Plasmodium*, 1274
- Plasmodium falciparum*, 1138, 1275–1276, 1275t
- Plasmodium vivax*, 1275–1276, 1275t
- Platelets, 843f
 aggregation, aspirin in, 893–894
- Platinum compounds, 1311–1314
 carboplatin, 1314
 characteristics of, 1314, 1314t
 cisplatin, 1313–1314
 mechanism of action, 1311
 oxaliplatin, 1314
 prototype for, 1313–1314
 shared properties of, 1311–1313
 toxicities and adverse effects, 1313
- Plavix. *See* Clopidogrel
- Plecanatol (Trulance), 1023t–1025t, 1027
- Pletal. *See* Cilostazol
- Plummer disease, 730–731
- Pneumococcal conjugate vaccine (PCV) (Prevnar), 860t, 865, 1388
 ACIP recommendation, 865
 adverse effects and dosing, 865
 description, 865
- Pneumococcal infection, characteristics of, 858
- Pneumococcal polysaccharide vaccine (PPV), 860t, 865
- Pneumocystis jirovecii*, 1138, 1142
- Pneumocystis pneumonia* (PCP), 1212–1213, 1239
 sulfamethoxazole (SMZ), 1142
 trimethoprim (TMP), 1142
- Pneumonia, 1250
 enfuvirtide (Fuzeon), 1232
 omeprazole and, 1014
- Pneumonic plague, 1403
- Pneumovax 23 (PPV), 865
- Podofilox, for venereal warts, 1383
- Podophyllin (podophyllum resin) (Podocon-25 Podofilm), to remove warts, 1382–1383, 1383t
- Poisoning
 absorption minimization, 1396–1397
 activated charcoal, 1396
 gastric lavage and aspiration, 1397
 surface decontamination, 1397
 whole-bowel irrigation, 1396–1397
 control centers, 1396
 defined, 1395
 fundamentals, 1395–1396
 poison identification, 1395–1396
 poison removal, 1396
 nondrug methods, 1397
 renal excretion, 1397
 prevention, 1396
 specific antidotes, 1397–1398, 1399t
 fomepizole, 1397–1398
 heavy metal antagonists, 1397, 1398t
 supportive care, 1395
- Polacrilex. *See* Nicotine chewing gum
- Polarization, 157–158
- Polar molecules, 28, 28f
- Poliomyelitis, characteristics of, 857
- Poliovirus vaccine, 860t
 adverse effects and dosing of IPV, 863
 preparations and efficacy, 862–863
- Polycarbophil, 1023t–1025t, 1030
- Polycystic ovary syndrome (PCOS), 707, 787
- Polyene antibiotics
 superficial mycoses, 1183
 systemic mycoses, 1175t
- Polyethylene glycol (PEG) (MiraLax, GlycoLax, Peglax), 222, 1023t–1025t, 1026
- Polyethylene glycol-electrolyte solutions (CoLyte, GoLYTELY, others), 1023t–1024t, 1027–1028, 1028t
- Polygander, 829

- Polymerase chain reaction (PCR) test, to identify infecting organism, 1093
- Polyuria, 396
- Ponatinib (Iclusig), 1337t–1338t
- Ponstan. *See* Mefenamic acid
- Ponstel. *See* Mefenamic acid
- Poor adherence, 4
- Pork roundworm infestation, 1269
- Pork tapeworm infestation, 1269
- Posaconazole (Noxafil), 1177t
- Postanesthetic medications, 301
- Postantibiotic effect, 1129
- Post-attachment inhibitors, 1234
- Post-fever-few syndrome, 1073
- Postganglionic neurons, 121–122
- Postmenopausal women, osteoporosis in, 954
- Post-MI therapy, 599
- Postoperative pain, opioids for, 322–323
- Postpartum hemorrhage
 - drugs for, 802–803
 - carboprost tromethamine (Hemabate), 802
 - ergot alkaloids, 802–803
 - misoprostol (Cytotec), 802
 - oxytocin (Pitocin), 802
 - pharmacokinetics, 803t
 - preparations, dosages, and administration, 803t
- Post-traumatic stress disorder (PTSD), 421
 - characteristics of, 421
 - drugs for, 417t
 - epidemiology of, 421
 - treatment for, 421
- Postural hypotension
 - defined, 497–498
 - vasodilators, 525–526
- Postvaccinial encephalitis, 1405
- Potassium efflux promotion, 256
- Potassium imbalances
 - hyperkalemia, 491
 - hypokalemia, 490
 - prevention and treatment, 490–491
- Potassium intake, in hypertension, 534–535
- Potassium iodide (ThyroShield), for radiation emergencies, 1407
- Potassium loss, and glucocorticoid therapy, 913
- Potassium-sparing diuretics, 482–483
 - amiloride, 484
 - dosages, and time course of effects, 483t
 - for heart failure, 554
 - for hypertension, 539
 - spironolactone, 482–483
 - triamterene, 483
- Potency, 47
- Potentiative interaction, 56
- Povidone-iodine, 1261t, 1262
- Powders, 1364
- Pradax. *See* Dabigatran etexilate
- Pradaxa. *See* Dabigatran etexilate
- Prader-Willi syndrome (PWS)
 - fatality in patient with, 742
 - pediatric short stature associated with, 742
- Pralatrexate (Folotyn), 1317t–1318t
 - mechanism of action of, 1314
- Pralidoxime, 153–154
- Praluent. *See* Alirocumab
- Pramipexole, 216, 217t
- Pramlintide (Symlin), 716
- Praziquantel (Biltricide), 1270t–1271t, 1272
- Prazosin, 184–186
 - actions and uses, 184
 - adverse effects, 184
 - pharmacokinetics, 184
 - preparations, dosage, and administration, 184–185
- Preadministration assessment, nursing practice, 6
- Preanesthetic medications, 300–301
- Precaution, defined, 11
- Precision medicine, 81
- Precinical testing, 18
- Prediabetes, 693
- Prednisolone, 911t, 915t
- Prednisone (Rayos), 336t, 572t, 911t, 915t
 - for adrenocortical insufficiency, 753, 753t
 - for cluster headache, 352t
- Preeclampsia, 547
- Pregabalin (Lyrica), 275–276, 336, 336t, 572t, 576
- Preganglionic neurons, 121–122
- Pregnancy
 - alcohol and, 443–444
 - aminoglycosides, 1131t
 - and androgen therapy, 808t–809t, 811
 - antibacterial drugs, 1170t
 - antiemetics for, 1036t
 - antifungal drugs, 1178t
 - antihistamines in, 887
 - antiprotozoal drugs, 1285t
 - aspirin use during, 896
 - benzodiazepines in, 404
 - casprofungin in, 1179
 - celecoxib use during, 901
 - cocaine use during, 464
 - diabetes mellitus and, 692
 - drugs for hypertensive disorders of, 546–547
 - drug therapy during, 94–95
 - adverse reactions, 95
 - drug risk minimization, 98
 - lack of clinical trials, 95
 - physiologic changes, 95
 - placental drug transfer, 95
 - risk categories, 98
 - teratogenesis, 95–98, 96f
 - teratogen exposure, 98
 - teratogens identification, 96–98, 97t
 - weighing benefits vs. risks, 95
 - epilepsy management during, 278b
 - fluoxetine effect in, 378
 - glucocorticoids during, 913t
 - hepatitis B, 1201t
 - hepatitis C, 1195t
 - herpes virus and varicella zoster virus infections, 1189t
 - hypothyroidism, 730
 - lithium use in, 399
 - methimazole effects in, 734
 - misoprostol in, 1017b
 - nausea and vomiting of, 1036–1037
 - nicotine effect during, 454
 - oral contraceptives, 775, 776t
 - phenytoin effect on, 263
 - progesterone effects during, 761–762
 - ramelteon in, 407–408
 - saw palmetto and, 1081b
 - statins and, 600–601
 - sulfonamides, 1139t
 - trimethoprim, 1139t
 - urinary tract infections, 1150t
 - vitamin A in, 1047b
- Pregnancy and Lactation Labeling Rule (PLLR), 98, 99t
- Pregnant patients
 - alcohol, 447t
 - antidepressants, 379t
 - calcium channel blockers, 520t
 - diuretics, 481t
 - ectoparasitocides for, 1292t
 - multiple sclerosis, 240t
 - opioid analgesics, 323t
 - RAAS inhibitors, 502t
 - vasodilators, 528t
- Pregnant women
 - adrenal cortex drugs for, 749t
 - anthelmintics for, 1271t
 - antihistamine for, 885t
 - antiinflammatory agents, 973t
 - antimalarial drugs for, 1280t
 - antimicrobials for, 1095t
 - and bisphosphonates, 952t
 - bronchodilators, 980t
 - carbapenems for, 1113t
 - CCR5 antagonists, 1233t
 - cephalosporins for, 1113t
 - CNS stimulants for, 426t
 - disease-modifying antirheumatic drugs, 923t
 - and drugs affecting bone, 961t
 - dyslipidemia, 592t
 - estrogens and, 760t
 - first-line drug for TB, 1154t
 - gout drugs
 - HIV fusion inhibitors, 1233t
 - hypertension, 545t
 - immunosuppressants in, 872t
 - integrase strand transfer inhibitors, 1233t
 - laxative use of, 1022t
 - monoclonal antibodies, asthma, 978t
 - nonnucleoside reverse transcriptase inhibitors, 1225t
 - NSAIDs for, 896t
 - nucleoside reverse transcriptase inhibitors, 1220t
 - Parkinson disease, 218t
 - penicillin care in, 1104t
 - post-attachment inhibitors, 1233t
 - progestins and, 762t
 - protease inhibitors, 1228t
 - PUD in, 1016t
 - sexually transmitted infections, 1253t
 - tetracyclines in, 1121t
 - weight-loss drugs for, 1064t
- Pre-heart failure, 563–564
- Preload, defined, 495
- Premature ejaculation, 822
 - definition, 822
 - drug therapy for, 822–823
 - clomipramine, 823
 - selective serotonin reuptake inhibitors, 823
 - topical anesthetics, 823
 - tramadol and opioids, 823
 - pathophysiology, 822
- Premature epiphyseal closure, 811
- Prematurity prevention, progestin and, 762
- Prepidil. *See* Dinoprostone
- Prepopik. *See* Magnesium oxide/anhydrous citric acid/sodium picosulfate
- Prescription Drug User Fee Act (PDUFA), 15
- Presynaptic/prejunctional receptors, 128
- Preterm labor, 795–799
 - antibiotics, 799
 - hydroxyprogesterone caproate, 799
 - suppress, drugs used, 795–799, 798t
- Prevalite. *See* Cholestyramine
- Prevnar. *See* Pneumococcal conjugate vaccine
- Prezista. *See* Darunavir
- Priapism, with sildenafil, 819
- Priftin. *See* Rifapentine
- Prilocaine (Citanext Plain Dental), for premature ejaculation, 823
- Prilosec. *See* Omeprazole
- Primaquine, 1276t, 1277
 - actions and use, 1277
 - adverse effects of, 1277
 - pharmacokinetics of, 1280t
 - preparation and dosage, 1278t–1279t
- Primary hypertension, 532

- Primary open-angle glaucoma (POAG), 1348–1349
 characteristics, 1348
 management of, 1348–1349, 1349t
 risk factors for, 1348–1349
- Primary progressive multiple sclerosis (PPMS), 238
- Primaxin. *See* Imipenem
- Primidone, 267–268
- Primsol. *See* Trimethoprim
- Prinivil. *See* Lisinopril
- Prinzmetal angina, 611
- Pristiq. *See* Desvenlafaxine
- Privine. *See* Naphazoline
- PRN decisions, 7–8
- ProAir HFA. *See* Albuterol
- ProAir RespiClick. *See* Albuterol
- Probenecid, 941
 adverse effects of, 941
 drug interactions, 941
 mechanism of action, 941
 pharmacokinetics of, 938t
 preparations, dosages, and administration of, 937t–938t
 reduce uric acid levels, 940, 940f
 therapeutic use, 941
- Probiotics, 1079
- Procarbazine (Matulane), 1324, 1324t
- Procardia. *See* Nifedipine
- Procardia XL. *See* Nifedipine
- Prochlorperazine (formerly Compazine) in migraine therapy, 344
- Procrit. *See* Epoetin alfa
- Proctitis, 1258
 characteristics, 1258
 treatment, 1258, 1259b
- Prodrugs, 38
- Progestin-only oral contraceptives, 778, 785
- Progestins, 761–762, 762t
 adverse effects, 762–763
 biosynthesis, 761
 in cancer therapy, 1377
 doses of, 762
 estrogen plus, 762b
 hazardous drug status, 763
 mechanism of action, 761
 menstrual cycle, 757, 761
 nursing implications for, 770
 oral contraceptive, 773, 773t
 physiologic effects, 761–762
 preparations and routes of administration, 763
 prototype drugs, 764b
 therapeutic uses, 762
- Prograf. *See* Tacrolimus
- Progressive multifocal leukoencephalopathy (PML), 241
 rituximab associated with, 930, 1343
- Progressive vaccinia, 1405
- Prokinetic agents, 1042–1043
 metoclopramide, 1042–1043
- Prolactin, 743
 dopamine agonists' suppression of, 743
 hypersecretion of, 743
 regulation of release of, 743
- Proleukin. *See* Aldesleukin
- Prolia, 960
- Promethazine (Phenergan, Phenadoz)
 as antiemetic, 1033t
 respiratory depression, 886b
- Propecia. *See* Finasteride
- Prophylactic therapy, 660–661
- Prophylaxis, for ulcer, 1009
- Propionibacterium acnes, 1366
- Propionic acid derivatives, 333t, 579t
 clinical pharmacology of, 897–898, 898t
- Propofol (Diprivan), 303–304
- Propranolol (Inderal), 189–191
 social anxiety disorder, 421
- Proprotein convertase subtilisin/Kexin type 9 inhibitors, 604–605
- Propylthiouracil (PTU), 733–734, 734t–735t
- Proscar. *See* Finasteride
- Prosorba. *See* Protein A column
- Prostaglandin analogs
 for glaucoma, 1349t, 1352
 latanoprost, 1349t, 1351–1352, 1352t
- Prostaglandin E₁, for erectile dysfunction, 821–822
- Prostaglandins
 cervical ripening and induction, labor, 800–801
 in PUD, 1008
- Prostate cancer
 and androgen, 811
 drugs for, 1333t
 cytotoxic drugs, 1333t
 sipuleucel-T, 1333t, 1336
 non-cytotoxic drugs for, 1332
 drug choices, 1332
 treatment modalities, 1332
 prevalence of, 1332
 treatment of, 1332
- Prostate-specific antigen (PSA) test, for early cancer detection, 1298t
- Prostigmin. *See* Neostigmine
- Protease-activated receptor-1 antagonists, 641–642
- Protease inhibitors (PIs), 1194–1195, 1197t–1198t, 1216, 1225–1230
 adverse effects, 1226–1227
 atazanavir, 1229
 darunavir, 1228
 drug interactions, 1227–1228
 fosamprenavir, 1229
 indinavir, 1229
 lopinavir/ritonavir, 1229
 mechanism of action, 1226
 nelfinavir, 1229
 pharmacokinetic properties, 1225, 1226t
 preparation, dosage, and administration, 1225, 1227t
 ritonavir, 1228
 saquinavir, 1229
 tipranavir, 1229–1230
- Proteasome inhibitors, 88t, 1339t–1340t, 1344
 bortezomib, 1339t–1340t, 1344
 carfilzomib, 1339t–1340t
 mechanism of action, 91, 92f
 toxicities, 92
- Protein A column (Prosorba), 926
- Protein binding, 104
 of drugs, 36, 36f
- Protein metabolism, glucocorticoids in, 749
- Protein synthesis
 bacteriostatic inhibitors of, 1119–1128
 clindamycin, 1124–1125
 erythromycin, 1122–1124, 1123t
 linezolid, 1125–1126
 mupirocin, 1126
 prototype for, 1123b
 retapamulin, 1126
 tetracyclines, 1119–1122
 inhibition of, 1085
- Proton pump inhibitors (PPIs), 1014–1016
 dexlansoprazole, 1010t
 and diarrhea, 1015b
 esomeprazole, 1010t
 lansoprazole, 1010t
 nursing implications for, 1020
 omeprazole, 1014–1016
- Proton pump inhibitors (PPIs) (*Continued*)
 pantoprazole, 1010t
 for prophylaxis, 895
 rabeprazole, 1010t
- Protopam. *See* Pralidoxime
- Protopic. *See* Tacrolimus
- Protozoal infections, 1283–1284
 cryptosporidiosis, 1283
 drugs for, 1284–1287, 1284t
 metronidazole, 1284–1285
 nitazoxanide, 1286–1287
 paromomycin, 1287
 pyrimethamine, 1287
 secnidazole, 1286
 tinidazole, 1285–1286
 giardiasis, 1283
 incidence of, 1283
 toxoplasmosis, 1283–1284
 trichomoniasis, 1284
- Protriptyline, 374t–375t, 381t
- Provenge. *See* Sipuleucel-T
- Proventil HFA. *See* Albuterol
- Provigil. *See* Modafinil
- Proximal convoluted tubule, 478
- Prozac. *See* Fluoxetine
- Prozac Weekly. *See* Fluoxetine
- Prucalopride, 1023t, 1025t, 1027
- Prussian blue (Radiogardase), for radiation emergencies, 1408
- Pseudoephedrine (Sudafed, others), 1003
 for nasal decongestion, 1003t
- Pseudomonas aeruginosa*, drugs for, 1087t
- Psilocin, 471
- Psilocybin, 471
- Psoriasis
 pathophysiology of, 1373–1374
 phototherapy for, 1378
 systemic drugs for, 1376–1377
 acitretin, 1376–1377
 cyclosporine, 1377
 interleukin antagonist, 1377–1378
 methotrexate, 1376
 tumor necrosis factor antagonists, 1377
 ustekinumab, 1377–1378
 topical drugs for
 anthralin, 1374–1376
 glucocorticoids, 1374
 tars, 1376
 tazarotene, 1374
 vitamin D₃ analogs, 1374, 1374t
 treatment for, 1374, 1374t
- Psychedelics, 469
- Psychologic dependence, and drug abuse, 435–436
- Psychologic disturbance, in glucocorticoid therapy, 912–913
- Psychosis
 vs. antimuscarinic poisoning, 147
 with excessive amphetamine use, 425
 levodopa-induced, 213
 in Parkinson disease patient, 223
- Psychosocial assessment, of pain, 330, 570
- Psychostimulants
 cocaine, 463–465
 methamphetamine, 465
 synthetic cathinones, 465–466
- Psychotherapy
 in BPD, 395
 for PTSD, 421
- Psychotomimetics, 469
 LSD, 469–470
 mescaline, psilocin, psilocybin, and dimethyltryptamine, 471
 salvia, 470–471
- Psyllium, 1023t–1025t, 1024, 1030

- Pteroylglutamic acid, 676
 Pubertal transformation, 808
 Puberty
 hormones in, 836f
 induction
 hormones for, 833
 monitoring during, 833
 initiating therapy in early, 831
 suppression
 GnRH analogue effects, 833
 monitoring during, 833
 Puberty, delayed, androgen therapy for, 809
 Public health, and immunization, 854
 Pulmicort Flexhaler. *See* Budesonide
 Pulmicort Respules. *See* Budesonide
 Pulmonary circulation, 493
 Pure manic episode (euphoric mania), of mood episodes, 392–393
 Pure opioid agonists, 307
 Pure opioid antagonists, 307–308
 Pure red-cell aplasia (PRCA), 682
 Purified protein derivative (PPD), 1156
 Purine analogs, 1314
 cladribine, 1314
 clofarabine, 1314
 fludarabine, 1314
 mercaptopurine, 1314
 nelarabine, 1314
 pentostatin, 1314
 thioguanine, 1314
 Purinethol. *See* Mercaptopurine
 Purple glove syndrome, 263
 P2Y₁₂ adenosine diphosphate receptor antagonists, 640–641, 647–648
 Pylera pack, 1011
 Pyrantel pamoate (Reese Pinworm Medicine, Combantrin), 1271t, 1272
 Pyrazinamide, antituberculosis drugs, 1162–1163
 Pyrethrins and piperonyl butoxide (A-200 Licide, RID, R&C), 1290
 Pyridostigmine (Mestinon, Regonol), 150–152
 adverse effects, 151
 chemistry, 150
 drug interactions, 151–152
 mechanism of action, 150, 151f
 pharmacokinetics, 151, 151t
 pharmacologic effects, 150–151
 precautions and contraindications, 151
 preparations, dosage, and administration, 152, 152t
 therapeutic uses, 151
 Pyridoxine (vitamin B₆), 1048t–1050t, 1053t, 1054–1055
 Pyrimethamine (Daraprim), 1284t, 1286t, 1287
 Pyrimidine analogs, 1175t
 Pyrimidines, 1314
- Q**
- Qbrexelis. *See* Lisinopril
 Qsymia. *See* Phentermine/topiramate
 QT interval drugs, 66, 67t
 QT prolongation, with erythromycin, 1124
 Quaaluin. *See* Quinine
 Quaternary ammonium compounds, 28
 Quazepam (Doral), applications of, 404t
 Questran. *See* Cholestyramine
 Questran Light. *See* Cholestyramine
 Quetiapine (Seroquel), 358t–359t, 363t, 394t
 Quinapril (Accupril), 505t, 508
 for heart failure, 555t
 Quinidine
 antifungal drugs, 1179t
 in heart failure, 562
 interaction with digoxin, 562
 Quinine (Quaaluin), 1276t, 1277–1280
 actions and use of, 1277
 adverse effects of, 1277
 pharmacokinetics of, 1280t
 in pregnancy, 1277–1280
 preparation and dosage, 1278t–1279t
- R**
- RAAS suppressants, 538t
 Rabeprazole, for PUD, 1010t
 Radiation
 for cancer, 337, 576
 and cancer cells, 1295
 emergencies, drugs for, 1407–1408
 pentetate calcium trisodium, 1407–1408
 pentetate zinc trisodium, 1407–1408
 potassium iodide, 1407
 Prussian blue, 1408
 Radioactive iodine (I¹³¹), 734–735, 735t, 738
 Radiofrequency ablation, for cancer pain, 337, 580
 Radiogardase. *See* Prussian blue
 Radiologic weapons, 1407–1408
 attacks on nuclear power plants, 1407
 dirty bombs, 1407
 nuclear bombs, 1407
 Raloxifene (Evista), 761, 958
 adverse effects of, 958
 for breast cancer, 1327
 compared with estrogen, 958t
 drug interactions, 958
 mechanism of action of, 958
 nursing implications, 967
 pharmacokinetics, 955t
 therapeutic uses for, 958
 Raltegravir (Isentress), 1220–1221, 1230–1231, 1247
 actions and use, 1230
 adverse effects, 1230
 contraindications, 1230–1231
 drug interactions, 1231
 Ramelteon (Rozerem), 407–408, 413
 abuse of, 407
 adverse effects of, 407
 drug interactions, 407
 mechanism of action of, 407
 physical dependence, 407
 precautions, 407
 in pregnancy and breastfeeding, 407–408
 therapeutic use for, 407
 Ramipril (Altace), 505t, 508
 for heart failure, 555t
 Randomized Aldactone Evaluation Study (RALES), 556
 Randomized controlled trials (RCTs), 16–18
 Random plasma glucose test, 693
 Ranexa. *See* Ranolazine
 Ranibizumab (Lucentis)
 efficacy of, 1358
 molecular structure of, 1358
 Ranitidine, 1011–1012
 Ranolazine
 actions and therapeutic use, 616
 adverse effects, 616
 drug interactions, 616–617
 pharmacokinetics, 616
 preparations, dosage, and administration, 617
 Rapaflo. *See* Silodosin
 Rapamune. *See* Sirolimus
 Rasagiline (Azilect), 220, 220t
 Rasburicase (Elitek, Fasturtec), 937t–938t, 940f, 942
 Rash
 efavirenz (Sustiva), 1224
 nevirapine, 1224
 Rasilez. *See* Aliskiren
 Raxibacumab, for inhalational anthrax, 1401
 Raynaud disease, 183
 Razadyne. *See* Galantamine
 Razadyne ER. *See* Galantamine
 R&C. *See* Pyrethrins and piperonyl butoxide
 RCTs. *See* Randomized controlled trials
 Reabsorption, kidney, 477–478
 Reactine. *See* Cetirizine
 Rebetol. *See* Ribavirin
 Rebound cardiac excitation, 189
 Rebound congestion, 1002
 Rebound hypertension, clonidine and, 200, 432
 Receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor, 959
 Receptor subtypes, 123–125
 Reclast. *See* Zoledronate
 Recombinant Erwinia asparaginase (Rylaze), 1324t
 Recombinant factor VIII, 659–660
 Recombinant uric acid oxidase, 937t–938t, 941–942, 941b
 Recombivax HB (hepatitis B vaccine), 864
 Recommended dietary allowance (RDA), 667, 667t
 explained, 1045
 and tolerable upper intake levels, 1046
 Recreational marijuana, 468
 Recruitment, in cancer chemotherapy, 1299
 Rectal administration, of opioids, 339
 Rectal infection, 1250
 Rectal suppositories, 34
 Recurrent urinary tract infection, 1147t, 1148–1149
 reinfection, 1148
 relapse, 1148–1149
 Red blood cells (RBCs), 666, 666f
 Red man syndrome, with vancomycin, 1115
 Reese Pinworm Medicine. *See* Pyrantel pamoate
 Reflex, defined, 120–121
 Reflex tachycardia, 183–184, 613
 hydralazine, 527
 minoxidil, 528
 vasodilators, 526
 Reglan. *See* Metoclopramide
 Regorafenib (Stivarga), 1337t–1338t
 Reinfection, recurrent urinary tract infection, 1148
 Relapse, recurrent urinary tract infection, 1148–1149
 Relapsing-remitting multiple sclerosis (RRMS), 238
 Relative potency, 46f, 47
 Relaxation, for pain management, 338, 579
 Relenza. *See* Zanamivir
 Relpax. *See* Eletriptan
 Remdesivir, 1208–1209
 Remeron. *See* Mirtazapine
 Remicade. *See* Infliximab
 Reminyl ER. *See* Galantamine
 Renal damage, sulfonamides and, 1140
 Renal disease, blood pressure and, 544
 Renal drug excretion, 39–40, 39f
 accelerated, 38
 factors modifying, 40
 steps in, 39–40
 Renal excretion
 of lithium, 396
 poison removal, 1397
 Renal failure
 with ACE inhibitors, 506
 with ARBs, 509
 prophylaxis of, mannitol, 484
 with vancomycin, 1115

- Renal impairment
 aspirin-induced, 895
 celecoxib causes, 901
- Renal toxicity
 lithium associated with, 397
 lithium promotion of, 399
 tenofovir disoproxil fumarate (TDF), 1222
 with tetracyclines, 1121
- Renin, 502–503
- Renin-angiotensin-aldosterone system (RAAS), 497
- ACE inhibitors, 503–508
 adverse effects, 506–507
 drug interactions, 507
 mechanism of action, 503–504, 504f
 pharmacologic effects, 503–504, 504f
 preparations, dosage, and administration, 507–508
 therapeutic uses, 504–506, 505t
- aldosterone antagonists
 eplerenone, 511
 spironolactone, 512
- angiotensin II receptor blockers, 508–509
 adverse effects, 509
 drug interactions, 509
 mechanism of action and pharmacologic effects, 508
 preparations, dosage, and administration, 509, 510t
 therapeutic uses, 508–509
- blood pressure and, 535
- blood pressure regulation by, 501f, 503
- direct renin inhibitors, 509–511
 adverse effects, 510–511
 drug interactions, 510–511
 mechanism of action, 509–510
 pharmacokinetics, 510
 preparations, dosage, and administration, 511
 therapeutic uses, 510
- in heart failure, 551
- physiology of, 500–503
- secretion of aldosterone and, 750
- Renin release, effect of digoxin on, 559
- Reperfusion therapy
 ACE inhibitors, 653–654
 anticoagulants, 653
 antiplatelet drugs, 653
 ARBs, 653–654
 fibrinolytic therapy, 652–653, 652t
 primary percutaneous coronary intervention, 652, 652t
- Replacement therapy
 in adrenal hormone insufficiency, 751–753
 in adrenocortical insufficiency, 753–754, 753t
 in adult males, 809
 dexamethasone and, 754
 in menopausal women, 809
 products for, 810t
- Repolarization, 157–158
- Reproduction, caffeine in, 427
- Resistance, drug
 agriculture-related, 1090b
 mechanisms of acquisition, 1088
 microbial mechanisms of, 1087–1088
- Reslizumab (Cinqair), 88, 978
- Respirants, 972
- Respiratory acidosis, 489–490
- Respiratory alkalosis, 489
- Respiratory arrest, from morphine, 309b
- Respiratory depression
 with barbiturates, 410
 with benzodiazepines, 404
 isoflurane and, 302
 from morphine, 309
- Respiratory depression (*Continued*)
 neonatal, naloxone for reversal of, 319
 from opioids, 335, 574–575
- Respiratory distress syndrome, prevention in preterm infants, 911
- Respiratory effects, of marijuana, 467
- Respiratory reserve, decreased, morphine and, 311
- Respiratory syncytial virus (RSV) infection, 868, 1187t, 1207
 characteristics, 859
 ongoing trials, 868
 palivizumab (Synagis), 868, 1207
 prevalence, 1207
 ribavirin, 1207
- Respiratory system, 402
 glucocorticoids in, 749
- Restasis, 1359
- Restoril. *See* Temazepam
- Resveratrol, 1080
- Retapamulin (Altabax), for impetigo, 1126, 1386t
- Retinoids
 topical, 1367
 in treatment of cancer, 1367
- Retrovir. *See* Zidovudine
- Retrovirus, 1213. *See also* Human immunodeficiency virus (HIV) infection
- Revatio. *See* Sildenafil
- Reverse transcriptase, 1213
- Reversible cholinesterase inhibitors, 149–152
- ReVia. *See* Naltrexone
- Revonto. *See* Dantrolene
- Reward circuit, in drug abuse, 436–437
- Reyataz. *See* Atazanavir
- Reye syndrome
 associated with aspirin, 895–896, 895b, 906
 and varicella vaccine, 857
- Rhabdomyolysis, 599–600
- Rheumatoid arthritis
 drug selection for, 921
 drug therapy for, 920
 biologic DMARDs, 925t, 926–932, 928t
 conventional (traditional) DMARDs, 922–926, 924t–925t
 DMARDs, 921
 glucocorticoids, 910, 920–922
 NSAIDs, 920–921
 targeted DMARDs, 925t, 932–933
 echinacea and, 1073
 incidence of, 919
 Janus kinase inhibitors, 932–933, 932t
 nondrug measures for, 920
 pathophysiology of, 919–920
 progression of joint deterioration, 919–920, 920f
 signs and symptoms, 919
 prototype drugs for, 929b
 tumor necrosis factor inhibitors, 926–930, 927t–928t
- Rheumatrex. *See* Methotrexate
- Rhinitis, allergic
 drugs for, 999–1004, 1000t
 antihistamines, 1000–1001, 1001t
 classes of, 999
 intranasal cromolyn sodium, 1001–1002
 intranasal glucocorticoids, 999–1000, 1000t
 sympathomimetics, 1002–1003, 1003t
 forms of, 999
 prototype drugs for, 1002b
- Ribasphere. *See* Ribavirin
- Ribavirin, 1198t, 1199, 1207
- Riboflavin (vitamin B₂), 351, 1048t–1050t, 1053t, 1054
- Ricin, 1406
 clinical manifestations of, 1406
 mechanism of action of, 1406
 treatment for, 1406
- Ricketts, 949
- Rickettsia, antibacterial drugs for, 1091t–1093t
- RID. *See* Pyrethrins and piperonyl butoxide
- Rifabutin, 1155, 1162
 antituberculosis drugs
 actions and uses, 1162
 drug interactions, 1162
 pharmacokinetics of, 1161t
 preparation, dosage, and administration, 1159t–1160t
 routes and adverse effects, 1158t, 1162
- Rifadin. *See* Rifampin
- Rifampin (Rifadin), 1154–1155, 1157t, 1161–1162, 1166–1167, 1172
 adverse effects, 1158t, 1161–1162
 antimicrobial activity, 1161
 drug interactions, 1162
 and isoniazid, 1157, 1157t
 mechanism of action, 1161
 as momotherapy, 1157
 preparation, dosage, and administration, 1159t–1160t
 routes, 1158t
 therapeutic use, 1161
- Rifampin-resistant tuberculosis, 1154
- Rifapentine, antituberculosis drugs, 1162
- Rifaximin (Xifaxan), 1038–1039, 1114b–1115b, 1172
- Rilpivirine (Edurant), 1223t, 1225
- Rimegepant (Nurtec ODT), 349
- Riomet. *See* Metformin
- Risedronate (Actonel, Atelvia, Actonel DR), 953t–955t, 956
- Risperdal. *See* Risperidone
- Risperdal Consta. *See* Risperidone
- Risperidone (Risperdal, Risperdal Consta), 358t–359t, 363t
- Ritalin. *See* Methylphenidate
- Ritalin LA, 430t
- Ritonavir (Norvir)
 actions and uses, 1228
 adverse effects, 1228
 drug interactions, 1228
 pharmacokinetics, 1226t
 preparation, dosage, and administration, 1227t
- Rituxan. *See* Rituximab
- Rituximab (Rituxan), 930, 1339t–1340t, 1342–1343
 actions and uses, 930
 adverse effects of, 930
 drug interactions, 930
- Rivaroxaban, 638–639
- Rivastigmine (Exelon), 229, 229t–230t
- River blindness, 1269
- Rivotril. *See* Clonazepam
- Rizatriptan (Maxalt, Maxalt MLT), 346–347
 clinical pharmacology of, 348t
 for migraines, 345t
- RNA synthesis, drug that interferes with, 1086t
- Rocaltrol. *See* Calcitriol
- Rocuronium (Zemuron), 163
- Roflumilast, 979–980
- Romazicon. *See* Flumazenil
- Rome IV criteria, for constipation, 1021–1022, 1022t
- Romidepsin (Istodax), 1339t–1340t
- Romiplostim (Nplate), 686–687
 adverse effects, 687
 mechanism of action, 687
 nursing implications, 689

- Romiplostim (Nplate) (*Continued*)
 pharmacokinetics, 687
 therapeutic use, 686–687
- Romosozumab (Evenity), 955t, 959
- Ropinirole (Requip), 216, 217t
- Rosacea, 1371–1372
 characteristics of, 1371
 management, 1371–1372
- Rose fever, 885
- Rotarix (rotavirus vaccine), 866–867
- RotaTeq (rotavirus vaccine), 866–867
- Rotavirus gastroenteritis, characteristics of, 858–859
- Rotavirus vaccine, 860t, 866–867
 ACIP recommendation, 867
 dosing, 867
 preparations and efficacy, 866–867
 safety, 867
- Rotigotine (Neupro), 216, 217t
- Roundworms. *See* Nematodes
- Routine drug therapy
 aspirin, 651
 beta blockers, 651
 morphine, 651
 nitroglycerin, 651
 oxygen, 651
- Rowasa. *See* Mesalamine
- Roxicodone. *See* Oxycodone
- Zerem. *See* Ramelteon
- Rubella
 characteristics of, 856–857
 vaccines for, 860t
- Rufinamide (Banzel), 276
- Ruxolitinib, 879
- Ryanodex. *See* Dantrolene
- Rybix ODT. *See* Tramadol
- Ryzolt. *See* Tramadol
- S**
- Sacubitril/valsartan (Entresto), for heart failure, 555–556
- S-adenosylmethionine (SAME), 387
- Safinamide (Xadago, Onstryv), 220, 220t
- Salicylates, 892
 clinical pharmacology of, 898t
- Salicylic acid, for skin, 1366
- Salicylism, 895, 906
- Salsalate, 898–900
 clinical pharmacology of, 898t
 indication and dosing of, 899t–900t
- Salvia, 470–471
- Sandimmune. *See* Cyclosporine
- Sandostatin. *See* Octreotide
- Sandostatin LAR Depot. *See* Octreotide
- Sanitization, defined, 1260
- Saphris. *See* Asenapine
- Saquinavir (SQV), 1226t–1227t, 1229
- Sarafem. *See* Fluoxetine
- Sargramostim (Leukine), 685–686, 688–689
 for neutropenia, 1302
- Sarilumab (Kevzara), 925t, 927t–928t, 932
- Sarin, 1406
- SARS-CoV-2 (COVID-19), monoclonal antibodies for, 89, 89f
- Saw palmetto, 1080–1081, 1081b
 for benign prostatic hyperplasia, 827
- Saxenda. *See* Liraglutide
- Scabies, 1289–1290
- Schedule III drugs, 813
- Schistosomiasis, 1269
- Schizophrenia
 acute episodes of, 356
 antipsychotic drugs for, 357
 clinical presentation of, 356
 clozapine for, 364
- Schizophrenia (*Continued*)
 etiology of, 356
 long-term course of, 356
 management of, 366–367
 adjunctive drugs, 367
 drug therapy, 366
 initial therapy, 367
 maintenance therapy, 367
 nondrug therapy, 367
 symptoms of, 356, 356t
- Scleroses, 237
- Scopolamine, 142, 1033t–1034t, 1037
- Screening Tool to Alert doctors to Right Treatment (START), 109
- Secnidazole, 1249b, 1284t, 1286, 1286t
- Secobarbital, 332t, 577t–578t
- Secondary hypertension, 532
- Secondary sexual characteristics, 830b, 831, 833, 836, 839
- Second-generation (atypical) antipsychotics (SGAs), 364–365
 adverse effects, 364–365
 drug interactions, 364–365
 mechanism of action, 364
 therapeutic use, 364
- Second-line antituberculosis drugs, 1163–1164
- Sedation
 with antihistamines, 885–886
 with FGAs, 361
 from morphine, 310
 with opioids, 335, 575
 with TCAs, 380
- Sedative-hypnotics, 401, 405b, 406t
 doxepin, 413
 groups of, 401
 for insomnia management, 410–413
 benzodiazepine-like drugs, 413
 benzodiazepines, 411–413
 prototype drugs for, 393b
 ramelteon, 407–408
 trazodone, 413
- Seizure, 254–255
 antiseizure drugs, 256
 brivaracetam, 271
 calcium influx suppression, 256
 cannabidiol, 271
 carbamazepine, 264–265
 cenobamate, 271
 classification, 259t, 260–261
 clobazam, 271–273
 eslicarbazepine, 273
 ethosuximide, 266–267
 ezogabine, 273
 felbamate, 273–274
 first-generation, 259t, 260
 pharmacokinetics, 262f, 262t
 first-, second-, and third- generation, 260t
 fosphenytoin, 264
 GABA, 257
 gabapentin, 274
 glutamate, 256–257
 lacosamide, 274
 lamotrigine, 274–275
 levetiracetam, 275
 new-generation, 260–261
 oxcarbazepine, 268–278
 perampanel, 275
 person-centered care, 265t
 phenobarbital, 267
 potassium efflux promotion, 256
 pregabalin, 275–276
 preparations, dosage, and administration, 258t–259t
 primidone, 267–268
 prototype drugs, 261b
- Seizure (*Continued*)
 rufinamide, 276
 sodium influx suppression, 256
 stiripentol, 276
 suicide risk, 259–260
 tiagabine, 276
 topiramate, 276–277
 valproate, 266
 vigabatrin, 277
 withdrawing, 258–259
 zonisamide, 277–278
- vs. convulsions, 254–255
 drug evaluation, 257
 with FGAs, 362
 focal-onset, 255
 follow-up care, 278
 generalized, 255–256
 generation of, 255
 patient adherence, 258
 plasma drug levels, monitoring, 257
 with SGAs, 365
 with TCAs, 382
 therapeutic goal, 257
 treatment options, 257
 types of, 255–256, 255t
- Seizure disorders
 benzodiazepines for, 403
 phenobarbital for, 410
- Selective COX-2 inhibitors, 333, 333t, 579t
- Selective estrogen receptor modulators (SERMs), 760–761, 958, 958t
 to prevent breast cancer, 1327
- Selective serotonin reuptake inhibitors (SSRIs), 376–379, 417t
 adverse effects, 377–378
 drug interactions, 378–379
 mechanism of action, 376, 376f
 for premature ejaculation, 823
 therapeutic uses, 376t, 377
 therapeutic uses for
 in GAD, 417
 in OCD, 420
 panic disorder, 419
 PTSD, 421
 in social anxiety disorder, 420
- Selective toxicity
 achieving, 1085
 defined, 1085
- Selegiline, 219–220, 374t–375t, 381t
 preparation, dosage, and administration, 220t
 transdermal (Emsam), 385–386
- Selfemra. *See* Fluoxetine
- Self-monitoring of blood glucose (SMBG), 694
- Self-report, of patient, 330, 570
- Selzentry. *See* Maraviroc
- Senna (Senokot, Ex-Lax), 1023t–1025t, 1026, 1030
- Senokot. *See* Senna
- Sensipar. *See* Cinacalcet
- Sequential therapy, 1012t
- Serial dilution procedure, to determine drug susceptibility, 1094
- Seroquel. *See* Olanzapine; Quetiapine
- Serostim, 744t. *See also* Somatotropin (human growth hormone)
- Serotonergic drugs, with MAOIs, 385
- Serotonergic reuptake inhibitors (SRIs), for GAD, 417
- Serotonin_{1B/1D} receptor agonists (Triptans), 345–347
 for migraines, 345t
 nursing implications for, 353–354
- Serotonin_{1F} receptor agonist, 347

- Serotonin/norepinephrine reuptake inhibitors (SNRIs), 379
 therapeutic uses, 376t
 venlafaxine, 379
- Serotonin receptor antagonists, 1032, 1033t–1034t
- Serotonin syndrome, 377, 1082
- Sertraline (Zoloft), 374t–376t, 379
 for OCD, 420
 for panic disorder, 419
 for PTSD, 420
- Serum thyroid-stimulating hormone, 729
- Serum T₃ test, 729
- Serum T₄ test, 729
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 1273b
- Sex, 830, 830b
 drug responses and, 79
- Sexual dysfunction
 alcohol and, 443
 with FGAs, 362
 with fluoxetine, 377
 in multiple sclerosis patients, 250
- Sexually acquired epididymitis, 1257–1258, 1258b
- Sexually transmitted diseases (STDs), 1248–1259
 acute epididymitis, 1257–1258
 bacterial vaginosis, 1254–1255
 chlamydial infections, 1248–1250
 genital herpes, 1255–1256
 gonococcal infections, 1250–1253
 herpes simplex virus (HSV), 1255–1256
 incidence of, 1248
 nongonococcal urethritis, 1256
 pelvic inflammatory disease, 1257
 proctitis, 1258
 syphilis, 1253–1254
 treatment of, 1248, 1249b
 trichomoniasis, 1255
- Sexual orientation, 830, 830b
- SGAs. *See* Second-generation (atypical) antipsychotics
- SHIFT study, 556–557
- Short-acting barbiturates, 303
- Short stature, 744t
- Side effects
 defined, 64
 in older adult patients, 338–339, 579
- Sigmoidoscopy (FSIG), for early cancer detection, 1298t
- Signifor LAR. *See* Pasireotide
- Sildenafil (Viagra, Revatio), 817–821, 834
 adverse effects of, 819–820
 drug interactions with, 820–821
 mechanism of action, 817
 for men with coronary heart disease, 821b
 preparations, dosage, and administration of, 817, 820t
 sexual benefits of, 818–819
- Silkis. *See* Calcitriol
- Silodosin (Rapaflo), 20, 824t, 825–826
 preparations, dosage, and administration of, 825t
- Silvadene. *See* Silver sulfadiazine
- Silver sulfadiazine, 1141
- Simeprevir (Olysio, Galexos), 1195, 1197t–1198t
- Simple occupancy theory, 50, 50f
- Simponi. *See* Golimumab
- Simponi Aria. *See* Golimumab
- Simulect. *See* Basiliximab
- Simvastatin (Zocor), antifungal drugs, 1179t
- Sinemet. *See* Levodopa/carbidopa
- Sinequan. *See* Doxepin
- Singulair. *See* Montelukast
- Sinoatrial (SA) node, 517
- Sipuleucel-T (Provenge), 1336
 adverse effects of, 1336
 dosage and administration, 1336
 production of, 1336
 therapeutic use for, 1336
- Sirolimus (Rapamune), 874–877
 actions, 874
 adverse effects of, 874
 drug and food interactions with, 874–877
 monitoring, 877
 nursing implications, 880–881
 preparations, dosage, and administration, 875t–876t
 therapeutic use of, 874
- Sirturo. *See* Bedaquiline
- Skelaxin. *See* Metaxalone
- Skeletal muscle
 glucocorticoids in, 749
 relaxants, 1133
- Skeletal-related events (SREs), with breast cancer, 1331–1332
- Skin
 anatomy of, 1362–1363, 1363f
 drugs for
 acne, 1366–1371
 actinic keratoses, 1378–1380
 atopic dermatitis, 1380–1382
 hair loss, 1385
 impetigo, 1386
 keratolytic agents, 1366
 local anesthetics, 1382
 onabotulinumtoxinA, 1384–1385
 psoriasis, 1373–1378
 rosacea, 1371–1372
 seborrheic dermatitis, 1385
 sunscreens, 1372–1373
 topical drug formulations, 1363–1364
 topical glucocorticoids, 1364–1366
 unwanted facial hair, 1385–1386
 warts, 1382–1384
- Sklice. *See* Ivermectin
- Sleep
 fitness, rules for, 410–411, 411t
 loss of, 410
 phases of, 410
- Sleep disturbances, 222–223
- Sleep driving, with benzodiazepines, 404
- Sleep hygiene, 410–411
- Sleeping sickness, 1385
- Small intestine bacterial overgrowth (SIBO), 1079
- Smallpox, 1403–1405
- Smallpox vaccine
 administration of, 1404
 adverse effects of, 1404–1405
 description, 1404
 duration of protection of, 1404
 efficacy, 1404
 interpreting the response, 1404
- Smoking
 chronic toxicity from, 455
 nicotine. *See* Nicotine
 in PUD, 1008
- Smoking cessation
 benefits of, 455
 bupropion ER, 458
 cholesterol and, 595
 drugs to aid, 455b
 in hypertension, 534
 internet-based resources for, 456t
 pharmacologic aids for, 455–456, 455t
- Social anxiety disorder, 420–421
 characteristics of, 420
- Social anxiety disorder (*Continued*)
 drugs for, 417t
 treatment for, 420–421
- Social factors, in substance use disorder, 436
- Society of Physician Assistants in Genetics and Genomics (SPAGG), 82
- Sodium-glucose co-transporter 2 inhibitors, 557, 564, 712–713, 713t, 725–726
- Sodium hypochlorite, 1261t, 1262
- Sodium influx suppression, 256
- Sodium nitroprusside
 adverse effects, 529
 cardiovascular effects and mechanism of action, 528–529
 for hypertensive emergencies, 546
 preparations, dosage, and administration, 527t
 therapeutic uses, 529
- Sodium phosphate, for bowel cleansing, 1023t, 1028
- Sodium, potassium-ATPase (Na⁺K⁺-ATPase), 558
- Sodium-potassium exchange, 479
- Sodium restriction, in hypertension, 534
- Sodium salicylate, 898–900
 clinical pharmacology of, 898t
 indication and dosing of, 899t–900t
- Sofosbuvir (Sovaldi), 1197t–1198t, 1198
- Solaraze. *See* Diclofenac sodium
- Solifenacin (VESicare), 144t–145t, 146
- Soltamox. *See* Tamoxifen
- Soluble guanylate cyclase (sGC) stimulators, 563
- Solu-Medrol. *See* Methylprednisolone
- Soman, 1406
- Somatic motor system, 119
 anatomy, 121f, 122
- Somatic pain, 328
- Somatropin (human growth hormone)
 nursing implications for, 746–747
 preparations, indications, and dosages of, 742–743, 744t
- Somatuline Depot. *See* Lanreotide
- Somavert. *See* Pegvisomant
- Sominex. *See* Diphenhydramine
- Sonata. *See* Zaleplon
- Sorafenib (Nexavar), 1337t–1338t
- Soriatane. *See* Acitretin
- Sorilux. *See* Calcipotriene
- Sotalol, 193
- Sotrovimab, 89
- Sovaldi. *See* Sofosbuvir
- Soy, 1081
- Spasticity
 defined, 283
 drugs for, 283–286, 284t–285t
 baclofen, 286–287
 dantrolene, 287
 management of, 283–286
 in multiple sclerosis patients, 250
 presentation and causes of, 283
- Specific acquired immunity, 842
- Specificity, in immune response, 845
- Spermatogenesis, 808
- Spermicides, 780–781, 780t
- Spinosad (Natroba), 1289t, 1290
- Spirochetes, antibacterial drugs for, 1091t–1093t
- Spirolactone (Aldactone), 483t, 512, 833
 for acne, 1371
 adverse effects, 483
 aldosterone antagonist, 482
 dosages, and time course of effects, 483t
 drug interactions, 483
 in heart failure, 483, 555t, 556
 mechanism of action, 482
 in primary hyperaldosteronism, 751
 therapeutic uses, 482–483

- Sporanox. *See* Itraconazole
- Sporotrichosis, systemic mycoses, drugs of, 1175t
- Sprue, 675
- Sprycel. *See* Dasatinib
- SSD Cream. *See* Silver sulfadiazine
- Stable angina, drugs for
 β -blockers, 615–616
 calcium channel blockers, 616
- Stage fright, beta-adrenergic antagonists, 188
- Stanol esters, 605–606
- Staphylococcus aureus*
 drugs for, 1087t
 infection with, 1102b
 penicillins for, 1101
- Starling's law, 496, 496f
- Statins, 597–601
 adverse effects, 599–600
 cholesterol reduction mechanism, 598
 clinical trials and therapeutic uses, 598–599
 drug interactions and use in pregnancy, 600–601
 pharmacokinetics, 599
 preparations, dosage, administration, and selection, 601
- Statin therapy, 594f, 595t
- Status epilepticus (SE), 256
 definition and danger, 278
 management goal, 278
- Stavudine (Zerit), 1221–1222
 actions and uses, 1221
 adverse effects, 1221
 drug interactions, 1221–1222
 pharmacokinetics, 1219t
 preparation, dosage, and administration, 1219t
- Stelara. *See* Ustekinumab
- ST-elevation myocardial infarction (STEMI)
 complications of
 cardiac rupture, 654
 cardiogenic shock, 654
 heart failure, 654
 ventricular dysrhythmias, 654
 diagnosis, 650
 ECG changes in, 650
 management of
 reperfusion therapy, 651–653, 652t
 routine drug therapy, 651
 medication therapy, 654
 pathophysiology
 acute changes, 649
 chronic changes, 650
 recovery, 654
 risk factors for, 649, 654
 secondary prevention, 654
- STEMI. *See* ST-elevation myocardial infarction
- Stendra. *See* Avanafil
- Sterility, with chemotherapeutic drugs, 1303
- Sterilization, defined, 1260
- Steroid use disorder, anabolic, 813
- Sterol esters, 605–606
- Stevens-Johnson syndrome (SJS), 1138
 acetaminophen associated with, 902, 906
- Stimulant laxatives, 1024–1026, 1025t
 bisacodyl, 1025–1026
 castor oil, 1026
 classification of, 1023t–1024t
 senna, 1026
- Stiripentol (Diacomit), 276
- Stivarga. *See* Regorafenib
- St. John's wort (*Hypericum perforatum*), 1081–1082
 adverse effects of, 1082
 for depression, 387
 effectiveness of, 1082
- St. John's wort (*Hypericum perforatum*)
 (Continued)
 interactions with drugs of, 1082
 mechanism of action, 1082
 uses of, 1081–1082
- Stomach, alcohol, 443
- Stomatitis, with chemotherapeutic drugs, 1302
- Strattera. *See* Atomoxetine
- Streptococcus pneumoniae*, 1142–1143
 vaccination against, 1391
- Streptomycin, antituberculosis drugs, 1163, 1163b
- Streptozocin (Zanosar), 1309, 1312t–1313t
- Stress
 glucocorticoids and, 749, 751b
 inoculation training, for PTSD, 421
- Stroke prevention
 ARBs for, 508
 aspirin for, 890, 892, 893t, 894
- Stroke volume, 495
- Stromectol. *See* Ivermectin
- Strongyloidiasis, 1268
- Subcutaneous drug administration, 31t, 32–33
- Subcutaneous infusion, 701
- Subcutaneous injection, 697t, 698f, 700–701, 701f
- Subcutaneous tissue, of skin, 1363
- Subdermal etonogestrel implants, 779
- Sublingual (Edluar), 412t
- Sublingual (Intermezzo), 412t
- Suboxone. *See* Buprenorphine
- Substance P, in pain management, 328
- Substance P/neurokinin₁ antagonists, 1033t–1034t, 1034
- Substance use disorder, 434
 alcohol, 441–451
 defined, 435
 diagnostic criteria, 435
 factors contributing to, 435–436
 drug availability, 436
 physical dependence, 436
 psychologic dependence, 436
 reinforcing properties of drugs, 435–436
 social factors, 436
 and vulnerability of individual, 436
 neurobiology of, 436–437
 nicotine, 452–458
 treatment, principles of, 437–438, 437t
 abstinence, 438
 comprehensive therapy, 438
- Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, 15–16
- Succinylcholine, 163
 adverse effects, 164
 drug interactions, 164
 mechanism of action, 163
 pharmacokinetics, 163
 pharmacologic effects, 163
 preparations, dosage, and administration, 164
 therapeutic uses, 164
 toxicology, 164
- Sucralfate, 1016
- Sudafed. *See* Pseudoephedrine
- Sudden cardiac death, with erythromycin, 1124
- Suicidal thinking, and atomoxetine, 431
- Suicide risk
 with antidepressants, 375
 with TCAs, 382
- Sulfacetamide, 1141
- Sulfadiazine, 1141
- Sulfamethoxazole (SMZ), 1140, 1142–1143
 adverse effects, 1143
 antimicrobial spectrum, 1142
- Sulfamethoxazole (SMZ) (Continued)
 drug interactions, 1143
 mechanism of action, 1142
 microbial resistance, 1142
 nursing implications, 1145
 pharmacokinetics, 1143
 therapeutic uses, 1142–1143
- Sulfasalazine (Azulfidine, Azulfidine EN-tabs), 924, 924t–925t, 1041
- Sulfisoxazole, 1141
- Sulfonamide allergy, due to celecoxib, 901
- Sulfonamides, 1085, 1136–1140, 1139t, 1140b
 adverse effects, 1138–1140
 hematologic effects, 1138
 hypersensitivity reactions, 1138
 renal damage, 1140
 antimicrobial spectrum, 1137
 dosages and administration, 1138, 1139t
 drug interactions, 1140
 cross-hypersensitivity, 1140
 metabolism-related interactions, 1140
 and G6PD deficiency, 1138b
 mechanism of action, 1136–1137, 1137f
 methenamine, 1151
 microbial resistance, 1137
 nursing implications, 1144–1145
 pharmacokinetics, 1138, 1138t
 preparations
 systemic, 1140–1141
 topical, 1141
 sites of action, 1137f
 therapeutic uses, 1137–1138
- Sulfonyleureas, 705t–706t, 708–709, 709t, 723
 antifungal drugs, 1179t
- Sulfur, for skin, 1366
- Sulfur mustard, 1406–1407
 clinical manifestations of, 1406–1407
 treatment for, 1407
- Sulindac (Clinoril)
 clinical pharmacology of, 898t
 indication and dosing of, 899t–900t
- Sumatriptan (Imitrex, Sumavel DosePro), 345–346
 adverse effects of, 346
 chest symptoms of, 346
 clinical pharmacology of, 348t
 coronary vasospasm, 346
 drug interactions with, 346
 mechanism of action of, 345
 for migraines, 345t
 pharmacokinetics of, 346
 teratogenesis, 346
 therapeutic use for, 346
- Sumavel DosePro. *See* Sumatriptan
- Sunitinib (Sutent), 1337t–1338t
- Sun protection factor, 1373
- Sunscreens, 1372–1373
 actions and benefits of, 1372
 adverse effects of, 1373
 compounds employed as, 1372–1373
- Superficial mycoses, 1174
 allylamines, 1183
 azoles, 1181
Candida, 1180–1181
 candidiasis, 1180–1181
 dermatophytes, 1180
 dermatophytic infections (ringworm), 1180
 drugs for, 1182t–1183t
 griseofulvin (Gris-PEG), 1181
 onychomycosis (fungal infection of the nails), 1181
 polyene antibiotics, 1183
- Superinfection
 defined, 1089
 with tetracyclines, 1121

- Supplements, harmful, 1083
 comfrey, 1083
 kava, 1083
 Ma huang, 1083
- Surface decontamination, poisoning, 1397
- Surfactant laxatives, 1024
 actions of, 1024
 classification of, 1023t–1024t
 preparation, dosage, and administration, 1024, 1025t
- Surgery, prophylactic use of antibiotics for, 1096
- Surgical drainage, and antibiotic use, 1097
- Sustained-release preparations, drugs, 34
- Sustiva. *See* Efavirenz
- Sutent. *See* Sunitinib
- Suvorexant (Belsomra), 406t, 408, 413
- Symbyax. *See* Olanzapine/fluoxetine
- Symlin. *See* Pramlintide
- Symmetrel. *See* Amantadine
- Sympathetic nervous system
 anatomy, 121f, 122
 functions, 119–120
- Sympathetic tone
 effect of digoxin on, 559
 in heart failure, 551–552
- Sympatholytic drugs, 538t, 539–540
- Sympathomimetic amines, 1064–1065
 actions and use of, 1064–1065
 adverse effects of, 1065
 contraindications, 1065
 pharmacokinetics, 1062t
 preparations, dosages, and administration, 1063t
- Sympathomimetics, 557, 1002–1003
 adverse effects of, 1002
 for allergic rhinitis, 1000t
 in heart failure, 562
- Synagis. *See* Palivizumab
- Synaptic transmission, 114
 drug effects, 115–116, 116t
 steps in, 114–115, 115f
- Synercid, given to food animals, 1090b
- Synthetic cathinones, psychostimulants, 465–466
- Synthetic marijuana, 469
- Syphilis, 1253–1254
 case reports, 1253, 1253f
 characteristics, 1253–1254
 treatment, 1254
 adults, 1254, 1254b
 infants and children, 1254, 1254b
 pregnancy infection, 1254, 1254b
- Systemic circulation, 493
 distribution of pressure within, 495f
- Systemic corticosteroid, for cluster headache, 352t
- Systemic lupus erythematosus (SLE)
 glucocorticoid therapy for, 910
 with hydralazine, 527
- Systemic mycoses, 1174
 amphotericin B (Abelcet, Amphotec, AmBisome, Fungizone), 1174–1176
 azoles, 1176–1178, 1177t, 1179t
 caspofungin, 1178–1179, 1179t
 classes of, 1174, 1175t
 drugs of, 1174, 1175t
 echinocandins, 1178, 1179t
 flucytosine (Ancobon), 1179–1180
- Systolic BP, 532, 532t
- T**
- Tablets, 34
- Tabun, 1406
- Tachycardia, 141
- Tachyphylaxis, 78
- Tacrolimus (Prograf, Astagraf XL, Protopic, Advagraf), 874, 875t–876t
 antifungal drugs, 1179t
 for eczema, 1380–1381
- Tadalafil (Cialis, Adcirca), 820t, 821, 824t, 826, 834
- Taeniasis, 1269
- Tafenoquine, 1276t, 1281
 actions and use, 1281
 adverse effects, 1281
 drug interactions, 1281
 pharmacokinetics of, 1280t
 preparation and dosage, 1278t–1279t
- Tafinlar. *See* Dabrafenib
- Tafuprost (Zioptan), for glaucoma, 1352, 1352t
- Tamiflu. *See* Oseltamivir
- Tamoxifen (Nolvadex, Soltamox, Nolvadex-D), 761, 1328t–1329t, 1329
 actions of, 1329
 adverse effects of, 1330, 1331b
 interaction with CYP2D6 inhibitors of, 1330
 pharmacokinetics of, 1341
 for prevention of breast cancer, 1329–1330
 for treatment of breast cancer, 1329
- Tamsulosin (Flomax), 20, 184t, 185
 for benign prostatic hyperplasia, 825t
- Tamsulosin + dutasteride (Jalyn), 824t–825t
- Tapentadol, 317
 preparation and dosage, 316t
- Tapeworms, 1267, 1268t
 infestation, 1269
- Tarabine PFS. *See* Cytarabine
- Tarceva. *See* Erlotinib
- Tardive dyskinesia (TD), 360t
 cause of, 361
 characteristics of, 360
 medications for, 361
- Target-cell lysis, 849
- Tars, for psoriasis, 1374t, 1376
- Tasigna. *See* Nilotinib
- Tavorole (Kerydin), 1181
- Taxanes, 1319
- Taxol. *See* Paclitaxel
- Taxotere. *See* Docetaxel
- Tazarotene (Avage, Tazorac), for acne, 1369
- Tbo-filgrastim (Granix), 685
- T-cell activation inhibitor, 930–931
- Teeth, effects of tetracyclines on, 1121
- Teflaro. *See* Ceftaroline
- Tegretol. *See* Carbamazepine
- Tegretol CR. *See* Carbamazepine
- Tegretol-SR. *See* Carbamazepine
- Tekturna. *See* Aliskiren
- Telavancin (Vibativ), 1115–1116
 actions and uses of, 1115
 adverse effects of, 1115–1116
 drug interactions with, 1116, 1116t
 pharmacokinetics of, 1115
- Teletherapy, for cancer pain, 337, 580
- Telmisartan, 508–509, 510t
- Telzir. *See* Fosamprenavir
- Temazepam (Restoril), 412t
 applications of, 404t
- Temozolomide (Temodar, Temodal), 1310, 1312t–1313t
- Temsirolimus (Torisel), 1337t–1338t, 1341
- Tenofovir, 1202
 alafenamide, 1199, 1200t–1201t
 disoproxil fumarate, 1199, 1200t–1201t
 pharmacokinetics, 1200t
- Tenofovir disoproxil fumarate (TDF), 1219t, 1222
 actions and use, 1222
 adverse effects, 1222
 drug interactions, 1222
- Tension-type headaches, 350
- Teprotumumab-trbw (Tepezza), 90
- Teratogen
 exposure, responding to, 98
 identification of, 96–98, 97t
- Teratogenesis, 95–98, 96f, 346, 378
- Teratogenic effect, defined, 65
- Teratogenicity, efavirenz (Sustiva), 1224
- Terazosin (Hytrin), for benign prostatic hyperplasia, 824t
- Terbinafine (Lamisil), 1183
- Terbutaline, 796, 798t
- Teriparatide (Forteo), 955t, 959, 962
- Terrorism, potential weapons of
Bacillus anthracis (anthrax), 1401–1402
 biotoxins, 1405–1406
 chemical weapons, 1406–1407
Francisella tularensis (tularemia), 1403
 radiologic weapons, 1407–1408
 variola virus (smallpox), 1403–1405
Yersinia pestis (pneumonic plague), 1403
- Terrorist attack, 1401
- Tessalon. *See* Benzonatate
- Testim, 812
- Testosterone, 807–808
 anabolic effects of, 808
 for axillary application, 812
 biosynthesis and secretion of, 807
 in females, 807
 in males, 807
 buccal tablets, 813
 erythropoietic effects of, 808
 esters, intramuscular, 813
 mechanism of action of, 807–808
 nasal gel (Natesto), 812
 nursing implications, 814–815
 pellets, implantable, 812–813
 physiologic effects of, 808
 in females, 808
 in males, 808
 thrombosis risk of, 808b
 topical solution, 812
 transdermal, 811–812
 treatment of transgender men, 838–840
 adverse effects, 839–840, 840t
 choice, 839
 clinical status, 840
 formulations, 839, 839t
 monitoring therapy, 840
 precautions and contraindications, 839
 product equivalencies, TRANSLINE guidelines, 839, 840t
 reversible and permanent changes, 839t
 therapeutic use, 839
 unintended drug transfer, 811b
- Testosterone cypionate (Depo-Testosterone), 813
- Testosterone enanthate (Delatestryl), 813
- Testosterone patches (Androderm), for male hypogonadism, 811
- Testosterone replacement, 809
- Tetanus
 characteristics of, 857
 products for immunization against, 862t
- Tetracyclines, 1119–1122, 1254, 1278t–1279t
 across life span, 1121t
 administration for, 1122, 1122t
 adverse effects, 1121
 antimicrobial spectrum, 1119–1120
 bacteriostatic inhibitors of, 1123b
 against chloroquine-resistant malaria, 1282
 dosage for, 1122, 1122t
 drug and food interactions with, 1121–1122
 mechanism of action of, 1119
 nursing implications for, 1127–1128

- Tetracyclines (*Continued*)
 pharmacokinetics of, 1120–1121, 1120t
 pharmacology of, 1119
 precautions with, 1122
 for PUD, 1011
 therapeutic uses for, 1119–1120
 and tooth discoloration, 1122b
- Texas Nurses Association, 831b
- Tezepelumab-ekko (Tezspire), 979
- Thalidomide, 14–15, 97
- The Endocrine Society (TES), screening for, 753
- Theophylline, 982–984, 1170. *See also* Methylxanthines
 in asthma and COPD, 982–983
 drug interactions of, 983–984
 mechanism of action, 982
 nursing implications for, 997
 pharmacokinetics, 983
 preparations, dosage, and administration, 984, 984t
 therapeutic use, 982–983
 toxicity, 983
- Therapeutic effects, nursing practice, 7, 9
- Therapeutic index, 54, 54f
- Therapeutic lifestyle changes, for cholesterol, 595
- Therapeutic range, 41, 41f
- Therapeutics
 defined, 2
 primary rule of, 1304
- Thermazene. *See* Silver sulfadiazine
- Thiamine (vitamin B₁), 1048t–1050t, 1053t, 1054
- Thiazide diuretics, 481–482
 adverse effects and drug interactions, 482
 dosages and time course of effects, 482t
 for heart failure, 554
 for hypertension, 538
 mechanism of action, 481–482
 pharmacokinetics, 481–482
 therapeutic uses, 482
- Thiazolidinediones, 705t–706t, 710–711, 711t, 723–724
- Thienopyridines, 653
- Thiocyanate toxicity, 529
- Thioguanine (Tabloid, Lanvis), 1308t, 1314, 1317t–1318t
- Thionamides, 733–734, 734t
- Thiopurines, in IBD, 1042
- Thioridazine, 358t–359t
- Thiothixene, 358t–359t
- Threadworm infestation, 1268
- Thrive. *See* Nicotine lozenges
- Thrombocytopenia, 931, 1191–1192
 with bone marrow suppression, 1302
- Thrombocytosis, 685–686
- Thromboembolic disorders, 774
- Thrombolytic (fibrinolytic) drugs, 626t
 alteplase, 643–644
 nursing implications, 648
- Thrombophlebitis, with vancomycin, 1116
- Thrombopoietin receptor agonists (TRAs)
 preparations, dosages, and administration, 686, 686t
 romiplostim, 686–687
- Thrombosis
 arterial, 625
 risk, with testosterone, 808b
 venous, 625
- Thrombotic thrombocytopenic purpura (TTP), 641
- Thymic stromal lymphopoietin blocker, 979
- Thyroid disorders
 function tests, 729, 729t
- Thyroid disorders (*Continued*)
 serum thyroid-stimulating hormone, 729
 serum T₃ test, 729
 serum T₄ test, 729
- hypothyroidism
 in adults, 729–730
 hormone preparations, 731–733, 731t
 in infants, 730
 during pregnancy, 730
 nonradioactive iodine, 735–736
 pathophysiology
 antithyroid drug preparations, 733, 735t
 Grave's disease, 730–731
 hyperthyroidism, 730–731
 hypothyroidism, 729–730
 nonradioactive iodine, 735–736
 thyrotoxic crisis, 731
 toxic nodular goiter, 731
- physiology
 chemistry and nomenclature, 727
 fate, 728
 function regulation, 728–729, 728f
 hormone actions, 728
 iodine deficiency, 729
 synthesis, 727–728, 728f
 prototype drugs, 731b
 radioactive iodine, 734–735
- Thyroid eye disease, monoclonal antibodies for, 90
- Thyroid-stimulating hormone (TSH), 728–729
- ThyroShield. *See* Potassium iodide
- Thyrotoxic crisis (thyroid storm), 731
- Thyrotropin (thyroid-stimulating hormone [TSH]), 739
- Thyrotropin-releasing hormone (TRH), 728–729
- Tiagabine (Gabitril), 276
- Tiazac. *See* Diltiazem
- TICE BCG. *See* BCG vaccine
- Tikosyn. *See* Dofetilide
- Time limitation, in immune response, 846, 846f
- Timolol, in glaucoma, 1349t–1350t, 1350
- Tindamax. *See* Tinidazole
- Tinea capitis, 1180
- Tinea corporis, 1180
- Tinea cruris, 1180
- Tinea pedis, 1180
- Tinidazole (Tindamax), 1170, 1249b, 1285–1286
 adverse effects of, 1285–1286
 drug interactions with, 1286
 mechanism of action, 1285
 pharmacokinetics, 1284t
 preparations, dosages, and administration, 1286t
 for PUD, 1011
 sexually transmitted diseases, 1249b
 therapeutic uses for, 1285
- Tiotropium, 985
- Tipranavir (TPV) (Aptivus), 1226t–1227t, 1229–1230
- Tirbanibulin (Klisyri), for actinic keratoses, 1379
- Tirzepatide (Mounjaro), 716
- Tissue factor pathway, 624
- Tissue thromboplastin, 624
- Tixagevimab/cilgavimab
- Tizanidine, 283, 286t, 289
- TLC diet, for cholesterol, 595
- Tobramycin, aminoglycosides, 1134, 1134t
- Tocilizumab (Actemra), 88–89
 actions and use, 931
 adverse effects, 931
 drug interactions, 931–932
- Tocolytic drug
 adverse effects of, 796, 797t
- Tocolytic drug (*Continued*)
 applications of, 795, 796t
 control of myometrial contraction and actions of, 795–796, 797f
 specific, 796–799
- Tofacitinib (Xeljanz, Xeljanz XR), 932–933
 actions and uses, 932
 adverse effects, 933
 drug interactions, 933
 preparations, dosage, and administration of, 932t
- Tolcapone (Tasmar), 219, 219t
- Tolerable upper intake level (TUL), 1045–1046
- Tolerance
 alcohol, 445
 barbiturates, 463
 cocaine, 464
 defined, 205, 310–311
 drug, 77–78
 and drug abuse, 435
 LSD, 470
 methamphetamine, 465
 nicotine, 454
 opioid use, 461
- Tolmetin
 clinical pharmacology of, 898t
 indication and dosing of, 899t–900t
- Tolterodine (Detrol, Detrol LA), 144t, 146
- Tonic-clonic seizures, 256
- Topamax. *See* Topiramate
- Topical anesthetics
 as adjuvant analgesic, 336, 576
 for premature ejaculation, 823
- Topical drug formulations, of skin, 1363–1364
 creams, 1363
 foams, 1364
 gels, 1364
 lotions, 1364
 ointments, 1363
 pastes, 1364
 powders, 1364
- Topical immunosuppressants, for atopic dermatitis, 1380–1382
- Topical local anesthetics, 293t
- Topical nitroglycerin ointment, 615
- Topical oxybutynin gel (Gelnique), 145
- Topical therapy
 aminoglycosides, 1131
 for onychomycosis
 ciclopirox, 1181
 efinaconazole, 1181
 tavaborole, 1181
 tetracyclines, 1120
- Topiramate (Topamax), 276–277
 for migraine prevention, 350
- Topoisomerase inhibitors, 1321–1323
 characteristics of, 1323, 1323t
 etoposide, 1323
 irinotecan, 1321–1323
 mechanism of action, 1321–1323
 topotecan, 1321–1323
 toxicities and adverse effects, 1323
- Topoisomerases, 1321–1323
- Toposar. *See* Etoposide
- Topotecan (Hycamtin), 1308t, 1321–1323, 1323t
- Toprol XL. *See* Metoprolol
- Toremifene (Fareston), 760–761, 1328t–1329t
- Torsades de pointes, 66
- Torsemide (Demadex), 480t
- Toxic epidermal necrolysis (TEN), 263
 acetaminophen associated with, 902, 906
- Toxicity
 anticancer drugs, 1296
 with cholinesterase inhibitors, 152–153

- Toxicity (*Continued*)
of competitive (nondepolarizing)
neuromuscular blockers, 162
defined, 64
of FGAs, 362–363
of LSD, 470
management, 8
of monoclonal antibodies, 90
of morphine, 312
nifedipine, 522
of proteasome inhibitors, 92
of tricyclic antidepressants, 382
of tyrosine kinase inhibitors, 91
verapamil and diltiazem, 520
- Toxic nodular goiter, 731
- Toxicology
of irreversible cholinesterase inhibitors,
153–154
of muscarinic agonists, 136
of muscarinic antagonists, 141–142
succinylcholine, 164
- Toxoid, 854, 860t
- Toxoplasmosis, 1283–1284, 1284t
- Trabectedin (Yondelis), 1310, 1312t–1313t
- Trade names. *See* Brand name
- Tralokinumab (Adbry), 1382
- Tramadol, 52, 319–320
abuse liability of, 320
adverse effects, 320
drug interactions, 320
mechanism of action, 319
for premature ejaculation, 823
suicide and, 320
therapeutic use, 319–320
- Trametinib (Mekinist), 1337t–1338t
- Trandate. *See* Labetalol
- Trandolapril, 505t, 508
for heart failure, 555t, 556
- Tranexamic acid (TA), 662, 804
- Transcription factors, 48
- Transcutaneous electrical nerve stimulation, for
pain management, 338, 579
- Transdermal absorption, 104
- Transdermal contraceptive patch, 778
- Transdermal fentanyl, 314–315
- Transdermal oxybutynin, 145
- Transdermal selegiline (Emsam), 385–386
- Transdermal testosterone, 810t, 811–812
- Transgender females, 829
estrogen, 836–838
additional monitoring, 838
adverse effects, 838
choice, 837
clinical status, 838
formulations, 837, 837t
monitoring therapy, 838
precautions and contraindications, 838,
838t
product equivalencies, TRANSLINE
guidelines, 837, 838t
reversible and permanent changes, 836,
837t
therapeutic use, 836
hormone therapy for adult, 833–834
antiandrogens, 833–834
counseling, 834
therapeutic goal, 833
time course for feminizing hormone
therapy effects, 834, 834t
- Transgender health, 829–841, 829f
clinical guidelines, 829–830, 832t
criteria for treatment, 830, 832b
GAHT for
adolescents, 833
adults, 833–835
- Transgender health (*Continued*)
individualizing therapy, 831
initiating therapy during adolescence
rationale for early transition, 831
timing of therapy initiation, 831–832
medications for transitioning
estrogen, 836–838, 837t–838t
GnRH analogues, 835–836, 836f,
836t–837t
testosterone, 838–840, 839t–840t
multidisciplinary team, 830
overview, 829–830
terminology, 830, 830b
- Transgender males
hormone therapy for adult
adjunct medications, 834–835
counseling, 835
testosterone, 834
therapeutic goal, 834
time course for masculinizing hormone
therapy effects, 835, 835t
testosterone, 838–840
adverse effects, 839–840, 840t
choice, 839
clinical status, 840
formulations, 839, 839t
monitoring therapy, 840
precautions and contraindications, 839
product equivalencies, TRANSLINE
guidelines, 839, 840t
reversible and permanent changes, 839t
therapeutic use, 839
- Transgender men, androgen therapy for, 810
- Transgender women, gender-affirmation therapy
for, 759
- Transmitter life cycles, 129–130
acetylcholine, 129f, 129
epinephrine, 130
norepinephrine, 130f, 129–130
- Transmitters, peripheral nervous system, 123f,
122
- Transmucosal fentanyl, 315
- Transpeptidases, 1099, 1100f
- Tranxene. *See* Clorazepate
- Tranxene-T. *See* Clorazepate
- Tranlycypromine, 374t–375t
- Trastuzumab (Herceptin), 1328t–1329t, 1331
actions and use of, 1331
adverse effects of, 1331, 1331b
genetic variants affecting, 84–85
hypersensitivity reactions, 1331b
- Trauma-focused therapy, for PTSD, 421
- Traveler's diarrhea, 1038–1039
- Travoprost (Travatan), for glaucoma, 1352
- Trazodone (Oleptro), 374t–375t
- Treanda. *See* Bendamustine
- Treating Tobacco Use and Dependence: 2008
Update*, 456
- Trematode infestations, 1269
- Trematodes (flukes), 1267, 1268t
- Tremor
with lithium, 396
in multiple sclerosis patients, 250
- Tretinoin (Vesanoid)
for acne, 1367
for fine wrinkles, 1367–1368
- Trexall. *See* Methotrexate
- Treximet. *See* Sumatriptan
- Triamcinolone, for allergic rhinitis, 1000t
- Triamterene, 483, 483t
- Triazolam (Halcion)
applications of, 404t
for insomnia, 412t, 413
- Trichinosis, 1269
- Trichloroacetic acid (TCA), for warts, 1383
- Trichomoniasis, 1249b, 1255, 1284, 1284t,
1286t
characteristics, 1255
treatment, 1255, 1255b
- Trichuriasis, 1268
- Triclabendazole (Egaten), 1272–1273
adverse effects, 1273
mechanism of action, 1273
pharmacokinetics of, 1271t
target organisms, 1272
- Tricor tablets, 603
- Tricyclic antidepressants (TCAs), 380–383
adverse effects of, 380–382, 381t
for cancer pain, 336, 336t, 572t, 575
chemistry of, 380
dosage and routes of administration, 382–383
drug interactions of, 382
for IBS, 1039
mechanism of action of, 380
for migraine prevention, 350
for panic disorder, 419
pharmacokinetics of, 380
therapeutic uses of, 380
toxicity of, 382
- Trifluoperazine, 358t–359t
- Trifluridine (Viroptic), 1187t, 1190t, 1191
- Trifluridine ophthalmic solution, ocular herpes
infections, 1191
- Triglyceride-lowering drugs, 597b
- Triglycerides
high, 596–597
reduction of, 597
- Trihexyphenidyl, 221t, 222
- Trimethoprim (TMP), 1139t, 1141–1142
adverse effects, 1141–1142
hematologic effects, 1142
hyperkalemia, 1142
antimicrobial spectrum, 1141
dosages and administration, 1139t
mechanism of action, 1137f, 1141
microbial resistance, 1141
nursing implications, 1144–1145
pharmacokinetics, 1138t
sites of action, 1137f
sulfamethoxazole and, 1142–1143
adverse effects, 1143
antimicrobial spectrum, 1142
drug interactions, 1143
mechanism of action, 1142
microbial resistance, 1142
nursing implications, 1145
pharmacokinetics, 1143
therapeutic uses, 1142–1143
therapeutic uses, 1141
- Trimipramine, 374t–375t
- Triptans, 345t, 351
- Triptorelin (Trelstar), 1333t
- Trospium (Sanctura XR, Trosec), 144t–145t,
146
- Trough concentration, drug, 43
- Trulance. *See* Plecanatide
- Trusopt. *See* Dorzolamide
- Tuberculosis (TB), 1152
antituberculosis drugs, 1158t, 1165
adverse effects, 1157
amikacin, 1163, 1163b
bedaquiline, 1164, 1164b
capreomycin, 1163, 1163b
cycloserine, 1164
ethambutol, 1163
ethionamide, 1164
first-line, 1158t
fluoroquinolones, 1163
isoniazid, 1158–1161, 1158t–1161t
para-aminosalicylic acid, 1163–1164

- Tuberculosis (TB) (*Continued*)
 pyrazinamide, 1162–1163
 rifabutin, 1162
 rifampin, 1161–1162
 rifapentine, 1162
 second-line, 1158t, 1163–1164
 streptomycin, 1163, 1163b
 cases and declining rate, 1152, 1152f
 death rate, 1152
 infectious process of, 1153
 latent, 1155–1157, 1156t–1157t
 pathogenesis, 1152f
 treatment of, 1153–1155
 American Thoracic Society, and Centers
 for Disease Control and Prevention,
 1153
 antituberculosis regimens, 1154, 1155t
 directly observed therapy (DOT), 1155
 drug resistance, 1153
 drug-sensitive, 1153
 drug-susceptible tuberculosis, 1154
 evaluation, 1155
 extensively drug-resistant, 1154
 first-line drugs for, 1154t
 HIV infection, 1154–1155
 isoniazid-resistant, 1154
 multidrug-resistant, 1154
 prime directive, 1153
 regimens, 1153–1155
 rifampin-resistant, 1154
 vaccination, 1157
 Tubocurarine, 28
 Tularemia, 1403
 clinical manifestations of, 1403
 treatment of, 1403
 Tumor lysis syndrome, rituximab associated
 with, 1342
 Tumor necrosis factor (TNF) antagonists, for
 psoriasis, 1377
 Tumor necrosis factor inhibitors, 928b
 adalimumab, 929–930
 adverse effects, 928–929
 infections, 928
 injection site reactions, 929
 neutropenia, 928–929
 skin reactions, 929
 etanercept, 929
 golimumab, 929–930
 indications for, 928t, 930
 infliximab, 930
 mechanism of action, 929
 nursing implications for, 934–935
 preparations, dosage, and administration,
 927t–928t, 930
 Tumor suppressor genes, and cancer cells,
 1295
 Tykerb. *See* Lapatinib
 Tylenol. *See* Acetaminophen
 Type 1 diabetes (T1DM), 691, 691t, 693–694
 Type 2 diabetes (T2DM), 691–694, 691t, 694t,
 705t
 Tyramine, dietary, hypertensive crisis from,
 384
 Tyrosine kinase, defined, 1336–1340
 Tyrosine kinase inhibitors, 88t
 mechanism of action, 90–91, 91f
 toxicities, 91
- U**
 Ubrogapant (Ubrovelvy), 349
 Ulcerative colitis, 1040–1041, 1041t
 Ulcer diet, 1009
 Uloric. *See* Febuxostat
 Ultram. *See* Tramadol
 Ultram ER. *See* Tramadol
- Ultraviolet A (UVA)
 dermatologic effects of, 1372
 intensity of, 1373
 sunscreen protection from, 1372f
 Ultraviolet B (UVB)
 dermatologic effects of, 1372
 intensity of, 1373
 sunscreen protection from, 1372f
 Ultraviolet radiation, types of, 1372
 Umeclidinium, 985
 Unfavorable cervical mucus, 786
 Unisom. *See* Doxylamine
 Unstable angina, 611
 Upadacitinib (Rinvoq), 1382
 Urecholine. *See* Bethanechol
 Urethral infection, 1250
 Urethritis, trimethoprim/sulfamethoxazole,
 1142–1143
 Urex. *See* Methenamine
 Uricosuric agents, 937t–938t, 941, 941b
 Urinary alkalinizers, methenamine, 1151
 Urinary antispasmodics, 142
 Urinary retention
 bethanechol and, 134
 morphine and, 309–310
 muscarinic antagonist and, 141
 Urinary tract infections (UTIs), 1136
 acute bacterial prostatitis, 1149
 acute cystitis, 1147–1148
 acute uncomplicated pyelonephritis, 1148
 antiseptics, 1149–1150
 methenamine, 1150–1151
 nitrofurantoin, 1149–1150, 1149t
 bacterial colonization, 1146
 cause, 1146
 classification, 1146
 community-associated infections vs. hospital-
 associated, 1146
 complicated, 1146, 1147t–1148t, 1148
 cranberry juice for, 1072
 drugs for, 1150t
 fluoroquinolones, 1168–1170
 in nonpregnant women, 1147, 1147t
 prevalence, 1146
 recurrent urinary tract infection, 1148–1149
 reinfection, 1148
 relapse, 1148–1149
 sulfamethoxazole (SMZ), 1142
 sulfonamides, 1137
 trimethoprim (TMP), 1142
 uncomplicated, 1146
 Urine production, effect of digoxin on, 559
 Uroxatral. *See* Alfuzosin
 Ursodiol (Actigall), 1044
 Ustekinumab (Stelara)
 for IBD, 1041t, 1042
 for psoriasis, 1374t, 1377–1378
 Uterine bleeding, oral contraceptives, 775
 Uterine function, 795–806
 oxytocic drugs, 795, 796t
 preterm labor, drugs for, 795–799
 prototype drugs, 795b
 tocolytic drugs
 adverse effects of, 796, 797t
 applications of, 795, 796t
 control of myometrial contraction and
 actions of, 795–796, 797f
 specific, 796–799
- V**
 Vaccination/vaccine
 adverse effects, 855
 contraindications, 855t
 COVID-19 infection, 1207–1208
 dosage, 1208t–1209t, 1209
- Vaccination/vaccine (*Continued*)
 definition, 854
 human immunodeficiency virus (HIV), 1241
 development, 1241
 obstacles to, 1241
 impact on public health, 854
 influenza, 1202–1205, 1203t
 administration, 1205
 adverse effects, 1204
 allergic reaction after, 1204–1205
 efficacy, 1204
 inactivated influenza vaccine, 1204
 live attenuated vaccines, 1204
 precautions, 1204, 1204b
 related complications, 1204, 1204b
 types, 1203–1204, 1203t
 interaction with
 acetaminophen, 903
 aspirin, 897
 killed vs. live vaccines, 854
 mandated records, 855
 tuberculosis (TB), 1157
 Vaccine Adverse Event Reporting System
 (VAERS), 856
 Vaccine-preventable diseases (VPDs), 854–855
 Vaccine risks, immunomodulators and, 241
 Vaccinia immune globulin (VIG), 1405
 Vaccinia necrosum, 1405
 Vaginal contraceptive ring, 778–779
 Vaginal suppositories, 34
 Valacyclovir (Valtrex), 1189, 1249b
 actions and uses, 1189
 adverse effects, 1189
 oral, 1190t
 pharmacokinetics, 1188t
 preparations, dosages, and administration,
 1190t
 Valerian (*Valeriana officinalis*), 1082–1083
 adverse effects of, 1082–1083
 effectiveness of, 1082
 interactions with drugs of, 1083
 mechanism of action, 1082
 uses of, 1082
 Valganciclovir (Valcyte), 1192
 adverse effects, 1192
 mechanism of action, 1192
 pharmacokinetics, 1192t
 preparations, dosages, and administration,
 1193t
 therapeutic use, 1192
 Valium. *See* Diazepam
 Valproate (divalproex sodium), 266, 394
 Valrubicin (Valstar), 1316
 Valsartan (Diovan), 508, 510t
 Valstar. *See* Valrubicin
 Valtrex. *See* Valacyclovir
 Vancocin. *See* Vancomycin
 Vancomycin (Vancocin), 1113–1115
 adverse effects of, 1115
 aminoglycosides, 1133
 antimicrobial spectrum, 1113
 for *Clostridioides difficile* infection, 1113,
 1114b–1115b
 indications, 1113
 mechanism of action, 1113
 nursing implications for, 1118
 pharmacokinetics of, 1113
 therapeutic use for, 1113
 Vandetanib (Caprelsa), 1337t–1338t
 Vaniqa. *See* Eflornithine
 Vantas. *See* Histrelin
 Vaping, smoking, 452, 453b
 Vardenafil (Levitra, Staxyn), 820t, 821
 Variant angina
 management of, 619

- Variant angina (*Continued*)
 pathophysiology, 611
 therapeutic agents, 611
 treatment strategy, 611
- Varicella virus
 characteristics, 857–858
 vaccine, 860t
 adverse effects of, 861t, 863
 for children, 864
 contraindications, 863–864
 description and efficacy, 863
 dosing, 863–864
 precautions, 863–864
- Varicella-zoster virus (VZV), 1186–1191, 1187t
 acyclovir, 1187–1189
 famciclovir, 1189–1190
 pharmacokinetics, 1188t
 preparations, dosage, and administration, 1190t
 prophylaxis and treatment, 1240
 topical drugs for
 herpes labialis, 1191
 ocular herpes infections, 1191
 valacyclovir, 1189
- Varicigat (Verquvo), 563
- Variola virus (smallpox), 1403–1405
 pathogenesis and clinical manifestations, 1403
 transmission, 1403–1404
 treatment, 1404
- Vascular smooth muscle (VSM), 516
- Vasoconstriction, angiotensin-induced, 502
- Vasodilation, 193
 with histamine, 883
- Vasodilators
 falls and, 526b
 for heart failure, 557–558
 hydralazine, 526–528
 minoxidil, 528
 person-centered care, 528t
 pharmacology
 adverse effects, 525–526
 selectivity of effects, 525, 526t
 therapeutic uses, 525
 preparations, dosage, and administration, 527t
 sodium nitroprusside, 528–529
 types, 525, 526t
- Vasopressin, 743–746, 745t. *See also*
 Antidiuretic hormone (ADH)
- Vasospastic angina, 611
- Vasotec. *See* Enalapril
- Vectal. *See* Calcitriol
- Vectibix. *See* Panitumumab
- Vecuronium (Norcuron), 163
- Velcade. *See* Bortezomib
- Vemurafenib (Zelboraf), 1337t–1338t, 1341–1342
 adverse effects of, 1342
- Venlafaxine (Effexor, Effexor XR), 336t,
 374t–376t, 572t
 adverse effects, 379
 drug interactions, 379
 for GAD, 417
 mechanism of action, 379
 therapeutic use, 379
- Ventolin HFA. *See* Albuterol
- Ventricular dysrhythmias, 654
- Verapamil (Calan, Verelan, Covera-HS), 562, 613
 adverse effects, 519
 drug and food interactions, 520
 hemodynamic effects, 518–519
 vs. nifedipine, 520, 521t
 pharmacokinetics, 518–519
 preparation, dosage, and administration, 518,
 519t
 therapeutic uses, 519
 toxicity, 520
- Verelan. *See* Verapamil
- Vermox. *See* Mebendazole
- Versacloz. *See* Clozapine
- Versed. *See* Midazolam
- Verteporfin (Visudyne), 1359
- Very-low-density lipoproteins (VLDLs), 589,
 589t
- Vesanoid. *See* Tretinoin
- Vesicants
 administering, 1309
 extravasation of, 1303
- Viagra. *See* Sildenafil
- Vibativ. *See* Telavancin
- Vibegron (Gemtesa), 144t–145t, 146
- Vibramycin. *See* Doxycycline
- Victoza. *See* Liraglutide
- Vidaza. *See* Azacitidine
- Videx. *See* Didanosine
- Videx EC. *See* Didanosine
- Vigabatrin (Sabril), 277
- Vilazodone (Viibryd), 374t–375t
- Vinblastine (Velban), 1308t, 1321, 1322t
- Vinca alkaloids, 1319
 vinblastine, 1321
 vincristine, 1321
- Vincristine (conventional) (Oncovin, Vincasar
 PFS), 1321, 1322t
 mechanism of action of, 1321
 pharmacokinetics of, 1321
 therapeutic uses for, 1321
 toxicities and adverse effects, 1321
- Vinorelbine (Navelbine), 1322t
- Viracept. *See* Nelfinavir
- Viral hepatitis, 1194–1202
 alanine aminotransferase (ALT) activity, 1194
 hepatitis B, 1199–1202
 drugs for, 1199–1202, 1200t–1201t
 interferon alfa, 1199–1201, 1200t–1201t
 nucleoside analogs, 1201–1202
 pharmacokinetics, 1200t
 preparations and dosages, 1201t
 prevalence, 1199
 hepatitis C, 1194–1199
 direct-acting antiviral (DAA) drugs, 1194
 management, 1194
 NS5A inhibitors, 1195–1197
 NS5B inhibitors, 1197–1198
 pharmacokinetics, 1197t
 preparations and dosages, 1198t
 prevalence, 1194
 properties, 1195, 1196t
 protease inhibitors, 1195
 prevalence, 1194
- Viral infection, treatment with antibiotics, 1097
- Viramune. *See* Nevirapine
- Viramune XR. *See* Nevirapine
- Virazole. *See* Ribavirin
- Viread. *See* Tenofovir
- Virilization, with androgen therapy, 810–811
- Viruses
 and cancer cells, 1295
 neutralization of, 849
- Visceral pain, 328
- Vistide. *See* Cidofovir
- Vitamin(s)
 classification of, 1046
 deficiencies, risk condition for, 1045, 1046b
 defined, 1045–1046
 dietary reference intakes for, 1045–1046
 fat-soluble, 1046–1052
 vitamin A (retinol), 1046–1047, 1047b,
 1048t–1050t
 vitamin D, 1047, 1048t–1050t
 vitamin E, 1047–1051, 1048t–1050t, 1051b
 vitamin K, 1048t–1050t, 1051–1052
- Vitamin(s) (*Continued*)
 recommended intakes for, 1048t–1049t
 water-soluble, 1052–1056
 biotin (vitamin B₇), 1048t–1050t, 1053t,
 1056, 1056b
 cyanocobalamin (vitamin B₁₂),
 1048t–1050t, 1053t, 1055
 folic acid (vitamin B₉), 1048t–1050t,
 1053t, 1055–1056
 niacin (vitamin B₃), 1048t–1050t, 1053–1054
 pantothenic acid (vitamin B₅),
 1048t–1050t, 1053t, 1056
 pyridoxine (vitamin B₆), 1048t–1050t,
 1053t, 1054–1055
 riboflavin (vitamin B₂), 1048t–1050t,
 1053t, 1054
 thiamine (vitamin B₁), 1048t–1050t, 1053t,
 1054
 vitamin C (ascorbic acid), 1048t–1050t,
 1052, 1053t
- Vitamin A (retinol), 1046–1047
 actions of, 1046
 deficiency, 1046b, 1047
 pharmacokinetics of, 1047, 1050t
 in pregnancy, 1047b
 preparations, and administration, 1047, 1050t
 RDA for, 1047
 requirements for, 1047, 1048t–1049t
 sources for, 1047
 therapeutic uses for, 1046
 toxicity, 1047
 units of, 1047
- Vitamin B₁ (thiamine), 1054
 actions, 1054
 deficiency, 1046b, 1054
 pharmacokinetics, 1050t
 preparations and administration of, 1053t
 recommended intakes, 1048t–1049t
 sources of, 1054
 therapeutic use of, 1054
 toxicity, 1054
- Vitamin B₂ (riboflavin), 1054
 actions, 1054
 deficiency, 1046b, 1054
 pharmacokinetics, 1050t
 preparations and administration of, 1053t
 recommended intakes, 1048t–1049t
 sources, 1054
 therapeutic uses, 1054
 toxicity, 1054
- Vitamin B₃ (Niacin), 1046b, 1048t–1050t,
 1053–1054
- Vitamin B₅ (pantothenic acid), 1056
 actions, 1056
 deficiency, 1046b, 1056
 pharmacokinetics, 1050t
 preparations and administration of, 1053t
 recommended intakes, 1048t–1049t
 sources, 1056
 therapeutic uses, 1056
 toxicity, 1056
- Vitamin B₆ (pyridoxine), 1054–1055
 actions of, 1054
 deficiency, 1046b, 1055
 drug interactions, 1055
 pharmacokinetics, 1050t
 preparations and administration of, 1053t
 recommended intakes, 1048t–1049t
 sources of, 1055
 therapeutic uses of, 1054
 toxicity, 1055
- Vitamin B₇ (biotin), 1056
 actions, 1056
 deficiency, 1046b, 1056
 interference with laboratory testing, 1056b

- Vitamin B₇ (biotin) (*Continued*)
 pharmacokinetics, 1050t
 preparations and administration of, 1053t
 recommended intakes, 1048t–1049t
 sources, 1056
 therapeutic uses, 1056
 toxicity, 1056
- Vitamin B₉ (folic acid), 1055–1056
 actions, 1055
 deficiency, 1046b, 1056
 forms, 1055
 pharmacokinetics, 1050t
 preparations and administration of, 1053t
 recommended intakes, 1048t–1049t
 sources, 1055–1056
 therapeutic uses, 1055
 toxicity, 1056
- Vitamin B₁₂ (cyanocobalamin), 1055
 actions, 1055
 deficiency, 1046b, 1055
 forms, 1055
 pharmacokinetics, 1050t
 preparations and administration of, 1053t
 recommended intakes, 1048t–1049t
 sources, 1055
 therapeutic uses, 1055
 toxicity, 1055
- Vitamin B₁₂ deficiency, 672–673
 biochemistry and physiology, 672, 672f
 causes, 672–673
 consequences, 673
 cyanocobalamin, 673–674
 diagnosis, 673
 vs. folic acid, 675, 675t
 guidelines for treating, 674–675
 nursing implications, 678–679
- Vitamin C (ascorbic acid), 1052
 actions of, 1052
 deficiency, 1046b, 1052
 pharmacokinetics, 1050t
 preparations and administration, 1052, 1053t
 RDAs for, 1052
 recommended intakes, 1048t–1049t
 requirements for, 1052
 sources of, 1052
 therapeutic use of, 1052
 toxicity, 1052
- Vitamin D, 948–950, 1046b, 1047, 1048t–1050t
 activation of, 948, 949f
 calcium levels and, 945, 945t
 as hormone, 949
 nursing implications, 964
 pharmacokinetics of, 949
 physiologic actions, 948
 preparations, dosage, and administration, 950, 951t
 requirements for, 948
 sources of, 948
 therapeutic uses for, 949
 toxicity, 949–950
- Vitamin D₂, 948, 949f, 950, 951t
 Vitamin D₃, 948, 949f, 950, 951t
 Vitamin D₃ analogs, for psoriasis, 1374, 1374t
- Vitamin D deficiency
 classic manifestations of, 949
 definition, 948–949
 measurement, 948–949
 screening for, 949
- Vitamin D-resistant rickets, 950
- Vitamin E (α-tocopherol), 1047–1051, 1051b
 action, 1047
 deficiency, 1046b, 1051
 pharmacokinetics, 1050t
 preparations and administration of, 1050t
 recommended intakes, 1048t–1049t
- Vitamin E (α-tocopherol) (*Continued*)
 sources of, 1050–1051
 therapeutic uses, 1047–1050
 toxicity, 1051
- Vitamin K (phytonadione), 1051–1052
 action of, 1051
 deficiency, 1046b, 1051–1052
 pharmacokinetics, 1050t
 preparations and administration of, 1050t
 recommended intakes, 1048t–1049t
 sources of, 1051
 therapeutic uses, 1051
 toxicity, 1052
- Vitamin K antagonist
 adverse effects, 633
 dietary sources, 635
 dosage, 635
 drug interactions, 633–634, 634t
 vs. heparin, 635, 635t
 history, 632
 mechanism of action, 632
 monitoring treatment, 632–633, 633t
 pharmacokinetics, 632
 therapeutic uses, 632
 vitamin K₁, 635
 warnings and contraindications, 634–635
- Vitrasert. *See* Ganciclovir
- Vivax malaria, 1275–1276, 1275t
- Vivitrol. *See* Naltrexone
- Vogelxo, 812
- Volatile liquids, anesthetics, 301, 302t
- Volatile nitrites, 473
- Voltaren XR. *See* Diclofenac
- Volume contraction, 488
- Volume expansion, 488–489
- Vorapaxar, 641–642
- Voriconazole (Vfend), 1177t
- Vorinostat (Zolinza), 1339t–1340t, 1344
- Votrient. *See* Pazopanib
- Vraylar. *See* Cariprazine
- Vulvovaginal candidiasis, 1180–1181
- Vytorin. *See* Simvastatin/ezetimibe
- Vyvanse. *See* Lisdexamfetamine
- W**
- Waist circumference (WC)
 and health risk, 1059
 measurement of, 1059
- Warfarin, 732, 1170
 adverse effects, 633
 antifungal drugs, 1179t
 dietary sources, 635
 dosage, 635
 drug interactions, 633–634, 634t
 vs. heparin, 635, 635t
 history, 632
 interaction with
 acetaminophen, 902–903
 aspirin, 896
 celecoxib, 901
 mechanism of action, 632
 monitoring treatment, 632–633, 633t
 nursing implications, 646–647
 pharmacokinetics, 632
 therapeutic uses, 632
 vitamin K₁, 635
 warnings and contraindications, 634–635
- Warts
 agents used to remove, 1382–1384
 common, 1384
 venereal
 patient-applied drugs, 1383–1384
 prevention of, 1383t
 provider-applied drugs for, 1382–1383
 treatment of, 1383t
- Water retention, in heart failure, 552
- Water-soluble vitamins, 1052–1056
- Weight control, for ASCVD, 595
- Weight gain
 with clozapine, 365
 with fluoxetine, 377
 pathophysiology of, 1060
- Weight loss
 amphetamines for, 424
 with atomoxetine, 431
 in hypertension, 534
 minimize risks for, 433
- Weight-loss drugs, 1061–1066
 across life span, 1064t
 combination products, 1062t, 1065–1066
 glucagon-like peptide-1 agonist, 1062–1064, 1062t–1063t
 history of, 1066
 lipase inhibitor, 1061–1062, 1062t–1063t
 note regarding, 1066
 orlistat, 1061–1062, 1062t, 1062b
 phentermine/topiramate, 1062t–1063t, 1065
 sympathomimetic amines, 1062t–1063t, 1064–1065
- Weight-loss therapy
 benefits of, 1061
 goal of, 1060
 modalities for, 1061
 bariatric surgery, 1061
 behavioral modification, 1061
 caloric restriction, 1061
 drug therapy, 1061
 exercise, 1061
- Welchol. *See* Colesevelam
- Wellbutrin. *See* Bupropion
- Wet beriberi, 1054
- Whipworm infestation, 1268
- Whole-bowel irrigation, 1396–1397
- Whooping cough, 857
- Withdrawal syndrome, 435
 with fluoxetine, 377
- Women, osteoporosis in, 954, 962
- Wong-Baker FACES pain rating scale, 331f, 571f
- World Anti-Doping Agency, 813
- World Health Organization (WHO)
 analgesic ladder from, 331–332, 332f, 573f, 574
 on migraine attacks, 344
- World Heart Federation, 596
- Wuchereriosis, 1269
- X**
- Xalatan. *See* Latanoprost
- Xalkori. *See* Crizotinib
- Xanax. *See* Alprazolam
- Xanax XR. *See* Alprazolam
- Xanthine oxidase inhibitors, 940–941
- Xarelto. *See* Rivaroxaban
- Xatral. *See* Alfuzosin
- XDR-TB. *See* Extensively drug-resistant tuberculosis
- Xeloda. *See* Capecitabine
- Xenical. *See* Orlistat
- Xerostomia, 141
 clonidine and, 200
- Xgeva, 960
- Xifaxan. *See* Rifaximin
- Xolair. *See* Omalizumab
- Xolegel. *See* Ketoconazole
- Xylocaine. *See* Lidocaine
- Xyzal. *See* Levocetirizine
- Y**
- Yersinia pestis* (pneumonic plague), 1403
- Yervoy. *See* Ipilimumab

- Z**
- Zafirlukast (Accolate), 975–976
 adverse effects of, 976
 mechanism of action, 976
 pharmacokinetics of, 976t
 preparations and dosage, 976t
- Zaleplon (Sonata), 406, 413
- Zanamivir (Relenza)
 actions and uses, 1206
 adverse effects and interactions, 1206
 pharmacokinetics, 1205t
 preparation, dosage, and considerations for, 1206t
- Zanosar. *See* Streptozocin
- Zegerid. *See* Omeprazole
- Zelboraf. *See* Vemurafenib
- Zeldox. *See* Ziprasidone
- Zemlara. *See* Paricalcitol
- Zemuron. *See* Rocuronium
- Zent. *See* Stavudine
- Zestril. *See* Lisinopril
- Ziagen. *See* Abacavir
- Zidovudine (Retrovir, AZT), 1220–1221
 actions and use, 1220
 adverse effects
 hematologic toxicity, 1220
 lactic acidosis with hepatomegaly, 1220
 myopathy, 1220
 drug interactions, 1220–1221
 pharmacokinetics, 1219t
- Zidovudine (Retrovir, AZT) (*Continued*)
 preparation, dosage, and administration, 1219t
- Zileuton (Zyflo, Zyflo CR), 975
 adverse effects of, 975
 mechanism of action, 975
 pharmacokinetics of, 975, 976t
 preparations, and dosage, 975, 976t
- Zinecard. *See* Dexrazoxane
- Zingiber officinale. *See* Ginger root
- Zioptan. *See* Tafluprost
- Ziprasidone (Geodon, Zeldox), 358t–359t, 363t
- Zipsor. *See* Diclofenac
- Zirgan. *See* Ganciclovir
- Zithranol. *See* Anthralin
- Zithranol-RR. *See* Anthralin
- Zithromax. *See* Azithromycin
- Zocor. *See* Simvastatin
- Zofran. *See* Ondansetron
- Zofran ODT. *See* Ondansetron
- Zoladex. *See* Goserelin
- Zoledronate (Reclast, Zometa, Aclasta), 956–957, 1327, 1332
 adverse effects of, 957
 for breast cancer, 1328t–1329t
 drug interactions, 957
 mechanism of action, 956–957
 therapeutic uses, 956
 in women with breast cancer, 1332
- Zoledronic acid, 336t, 572t
- Zollinger-Ellison syndrome, 1008, 1013
- Zolmitriptan (Zomig, Zomig ZMT), 345t
- Zoloft. *See* Sertraline
- Zolpidem (Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist), 405–406, 413
 characteristics of, 405–406
 formulations for, 405–406
 side-effect, 406
- Zolpimist. *See* Oral spray; Zolpidem
- Zomacton, 744t. *See also* Somatropin (human growth hormone)
- Zometa. *See* Zoledronate
- Zomig. *See* Zolmitriptan
- Zomig ZMT. *See* Zolmitriptan
- Zonatuss. *See* Benzonatate
- Zonisamide (Zonegran), 277–278
- Zortress. *See* Everolimus
- Zorvolex. *See* Diclofenac
- Zovirax. *See* Acyclovir
- Zuplenz. *See* Ondansetron
- Zyban. *See* Bupropion
- Zyclara. *See* Imiquimod
- Zyloprim. *See* Allopurinol
- Zyprexa. *See* Olanzapine
- Zyrtec. *See* Cetirizine
- Zytiga. *See* Abiraterone